KINDAI UNIVERSITY


*A space between the first name and last name, please enter

HOSONO Makoto

Profile

FacultyDepartment of Medicine / Graduate School of Medical Sciences / Atomic Energy Research Institute
PositionProfessor
Degree
Commentator Guidehttps://www.kindai.ac.jp/meikan/2127-hosono-makoto.html
URL
Mail
Last Updated :2020/11/25

Education and Career

Education

  •   1979 04  - 1985 03 , Kyoto University Faculty of Medicine
  •   1989 04  - 1993 03 , Kyoto University Graduate School of Medicine, Internal Medicine System

Academic & Professional Experience

  •   2005 10 ,  - 現在, Professor, Department of Radiology, Kindai University Faculty of Medicine
  •   2003 04 ,  - 2005 09 , Associate Professor, Department of Radiology, Kindai University Faculty of Medicine
  •   1995 10 ,  - 2003 04 , Lecturer, Department of Radiology, Saitama Medical University
  •   1994 10 ,  - 1995 09 , Research Fellow, INSERM U211, Nantes University, French Government Research Fellowship
  •   1993 10 ,  - 1994 09 , Humboldt Foundation Research Fellow, Bonn University Department of Nuclear Medicine, Humboldt Foundation Research Fellowship
  •   1993 04 ,  - 1993 09 , Fellow, Department of Radiology and Nuclear Medicine, Kyoto University Hospital
  •   1986 04 ,  - 1989 03 , Fellow, Department of Radiology, Kitano Hospital (Osaka)
  •   1985 04 ,  - 1986 03 , Resident, Department of Radiology and Nuclear Medicine, Kyoto University Hospital

Research Activities

Research Areas

  • Life sciences, Radiology

Research Interests

  • Radiological Protection, tumor targeting, Molecular Imaging, Targeted Molecular Therapy, Nuclear Oncology

Published Papers

  • A case of cardiac amyloidosis incidentally detected by bone scintigraphy, Tanaka H, Hosono M, Kanagaki M, Shimizu M, Matsubara N, Kawabata K, Miyamoto T, Itoi K, AOJNMB, AOJNMB, 9(1), 1 - 5, Jan. 2022 , Refereed
  • Developing diagnostic reference levels in Japan, Kanda R, Akahane M, Koba Y, Chang W, Akahane K, Okuda Y, Hosono M, Japanese Journal of Radiology, Japanese Journal of Radiology, in press, Nov. 2020 , Refereed
  • The 2020 national diagnostic reference levels for nuclear medicine in Japan, Koichiro Abe, Makoto Hosono, Takayuki Igarashi, Takashi Iimori, Masanobu Ishiguro, Teruo Ito, Tomomasa Nagahata, Hiroyuki Tsushima, Hiroshi Watanabe, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 34(11), 799 - 806, Oct. 24 2020 , Refereed
    Summary:The diagnostic reference levels (DRLs) are one of several effective tools for optimizing nuclear medicine examinations and reducing patient exposure. With the advances in imaging technology and alterations of examination protocols, the DRLs must be reviewed periodically. The first DRLs in Japan were established in 2015, and since 5 years have passed, it is time to review and revise the DRLs. We conducted a survey to investigate the administered activities of radiopharmaceuticals and the radiation doses of computed tomography (CT) in hybrid CT accompanied by single photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. We distributed a Web-based survey to 915 nuclear medicine facilities throughout Japan and survey responses were provided by 256 nuclear medicine facilities (response rate 28%). We asked for the facility's median actual administered activity and median radiation dose of hybrid CT when SPECT/CT or PET/CT was performed for patients with standard habitus in the standard protocol of the facility for each nuclear medicine examination. We determined the new DRLs based on the 75th percentile referring to the 2015 DRLs, drug package inserts, and updated guidelines. The 2020 DRLs are almost the same as the 2015 DRLs, but for the relatively long-lived radionuclides, the DRLs are set low due to the changes in the Japanese delivery system. There are no items set higher than the previous values. Although the DRLs determined this time are roughly equivalent to the DRLs used in the US, overall they tend to be higher than the European DRLs. The DRLs of the radiation dose of CT in hybrid CT vary widely depending on each imaging site and the purpose of the examination.
  • Role of J-RIME from view-point of revision of Japan DRLs2020, Hosono M, Kanda R, Chang W, Koba Y, Akahane K, Okuda Y, Innervision, Innervision, 35(10), 4 - 4, Oct. 2020
  • Outline of revision of nuclear medicine DRLs and points of utilization, Hosono M, Abe K, Iimori T, Igarashi T, Ishiguro M, Ito T, Tsushima H, Nagahata T, Watanabe H, Innervision, Innervision, 35(10), 22 - 24, Oct. 2020
  • Time trend of the radiation exposure dose in e ndoscopic retrograde cholangiopancreatography over an 8-year period: a single-center retrospective study, Hayashi S, Nishida T, Osugi N, Yamaoka S, Sugimoto A, Mukai K, Nakamatsu Dai, Matsumoto K, Yamamoto M, Fukui K, Takenaka M, Hosono M, Inada M, American J Gastroenterology, American J Gastroenterology, in press, Aug. 2020 , Refereed
  • Post-marketing surveillance (PMS) study for safety and effectiveness of radium-223 in Japanese patients with CRPC and bone metastases in real-world settings: exploratory analysis on treatment completion of six cycles on radium-223 and discontinuation, Matsumori N, Kakei Y, Hosono M, Kinuya M, Takahashi S, Okayama Y, Sunaya T, Horio T, Uemura H, Shinryo to Shinyaku (Med Cons New-Remed), Shinryo to Shinyaku (Med Cons New-Remed), 57(7), 705 - 717, Jul. 2020 , Refereed
  • The nationwide survey on;avoidance of targeted;radionuclide therapy in;patients with limited activities of daily living;those undergoing hemodialysis, MORI H, INAKI A, KAYANO D, WAKABAYASHI H, HOSONO M Tatsuya, HIGASHI T, ORIUCHI N, ABE K, UCHIYAMA M, KINUYA S, Kakuigaku, Kakuigaku, 57(1), 39 - 46, May 2020 , Refereed
  • Safety and effectiveness of radium-223 in Japansese patients with CRPC and bone metastases in real world-settings: the results of post-marketing surveillance (PMS), Takahashi S, Uemura H, Matsumori N, Kinuya S, Hosono M, Okayama Y, Sunaya T, Horio T, Kakehi Y, Jpn J Urol Surg, Jpn J Urol Surg, 33(4), 435 - 449, Apr. 2020 , Refereed
  • A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study, Nobuaki Matsubara, Go Kimura, Hiroji Uemura, Hirotsugu Uemura, Motonobu Nakamura, Satoshi Nagamori, Atsushi Mizokami, Hiroaki Kikukawa, Makoto Hosono, Seigo Kinuya, Heiko Krissel, Jonathan Siegel, Yoshiyuki Kakehi, International Journal of Clinical Oncology, International Journal of Clinical Oncology, 25(4), 720 - 731, Apr. 2020 , Refereed
    Summary:BACKGROUND: ERA 223 compared concurrent abiraterone acetate/prednisolone (AAP) plus radium-223 with AAP plus placebo in men with chemotherapy-naïve asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. We report data from a subgroup of Japanese patients in ERA 223. METHODS: Patients were randomized to radium-223 (55 kBq/kg) or placebo once every 4 weeks (max. 6 cycles), and also received oral abiraterone acetate 1000 mg once daily plus prednisone/prednisolone 5 mg twice daily during and after radium-223/placebo treatment, until a symptomatic skeletal event (SSE). The primary endpoint was SSE-free survival (SSE-FS); overall survival (OS) was a secondary endpoint. RESULTS: Of 806 patients randomized in ERA 223, 114 patients (57 per arm) were enrolled in Japan. SSE-FS was not improved significantly in the radium-223 arm [25.5 months, 95% CI 20.6-not estimated (NE)] compared with the placebo arm (28.7 months, 95% CI 19.7-NE) (HR = 0.907, 95% CI 0.501-1.642). OS and other secondary endpoints were not improved significantly in the radium-223 arm. The incidence of fracture was 23% and 11% in the radium-223 and placebo arms, respectively. The incidence of death was 32% and 36%, respectively. CONCLUSIONS: In the Japanese ERA 223 subgroup, concurrent treatment with AAP and radium-223 did not significantly improve SSE-FS and increased the incidence of fracture, similar to outcomes achieved in the overall population, while an increased incidence of death was not evident. The combination of radium-223 with AAP is not recommended in Japanese patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. CLINICAL TRIAL REGISTRATION: Clinical trial registration no: NCT02043678.
  • Trends in Medical Exposure, HOSONO Makoto, Journal of Kyoto Prefectural University of Medicine, Journal of Kyoto Prefectural University of Medicine, 129(2), 153 - 157, Feb. 2020 , Refereed
  • Evolution of PET in Japan from Viewpoint of 16-years' Surveys, Makoto Hosono, Kengo Ito, Isotope News, Isotope News, (767), 16 - 19, Feb. 2020
  • Current status of radiation exposure to crystalline lens in ERCP (endoscopic retrograde cholangiopancreatography), Mamoru Takenaka, Makoto Hosono, Atsushi Nakai, Shunsuke Omoto, Kosuke Minaga, Ken Kamata, Kentaro Yamao, Shiro Hayashi, Tsutomu Nishida, Masatoshi Kudo, Journal of Japanese Society of Gastroenterology, Journal of Japanese Society of Gastroenterology, 116(12), 1053 - 1055, Dec. 2019 , Refereed
  • Prospects of personalized medicine through theranostics, HATAZAWA Jun, HOSONO Makoto, Japanese Journal of Clinical Radiology, Japanese Journal of Clinical Radiology, 64(13), 1495 - 1495, Dec. 2019
  • Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials, Hosono M, Ikebuchi H, Kinuya S, Yanagida S, Nakamura Y, Yamada T, Sakaguchi K, Sugano H, Kojima K, Hatazawa J, Ann Nucl Med, Ann Nucl Med, 33(11), 787 - 505, Nov. 2019 , Refereed
  • A sight-visit report on the radiation safety managements in the University of Gothenburg, NAGATSU K, UKON N, YAMADA T, HOSONO M, Japanese Journal of Radiation Safety Management, Japanese Journal of Radiation Safety Management, 18(2), 36 - 40, Nov. 2019 , Refereed
  • Radiation protection in therapy with radiopharmaceuticals, HOSONO Makoto, International Journal of Radiation Biology, International Journal of Radiation Biology, 95(10), 1427 - 1430, Oct. 2019 , Refereed
  • Radiological protection in therapy with radiopharmaceuticals, Yonekura Y, Mattsson S, Flux G, Bolch WE, Dauer LT, Fisher DR, Lassmann M, Palm S, Hosono M, Doruff M, Divgi C, Zanzonico P, Ann ICRP, Ann ICRP, 48(1), 5 - 95, Oct. 2019 , Refereed
  • Quantitative measurement of 219Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with 223RaCl2, Ooe K, Watabe T, Kamiya T, Yoshimura T, Hosono M, Shinohara A, Hatazawa J, EJNMMI Physics, EJNMMI Physics, 6(13), 1 - 11, Jul. 2019 , Refereed
  • EXAMINATION OF ACTUAL RADIATION EXPOSURE DOSE OF THE PATIENTS WHO PERFORMED EUS-GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD), Takenaka Mamoru, Hayashi Shiro, Nishida Tsutomu, Hosono Makoto, Yoshikawa Tomoe, Ishikawa Rei, Okamoto Ayana, Yamazaki Tomohiro, Nakai Atsushi, Omoto Shunsuke, Minaga Kosuke, Kamata Ken, Yamao Kentaro, Kudo Masatoshi, GASTROINTESTINAL ENDOSCOPY, GASTROINTESTINAL ENDOSCOPY, 89(6), AB444 - AB445, Jun. 2019 , Refereed
  • Involvement of costal cartilage in relapsing polychondritis detected by 18F-FDG PET/CT, Fukumoto G, Hosono M, Kanagaki M, Ichinose M, Nishisaka K, Japanese Archive of Cases Conference of Clinical Nuclear Medicine, Japanese Archive of Cases Conference of Clinical Nuclear Medicine, 1, 23 - 27, Jun. 2019 , Refereed
  • Perspectives for concepts of individualized radionuclide therapy, molecular radiotherapy, and theranostic approaches, HOSONO Makoto, Nuclear Medicine and Molecular Imaging, Nuclear Medicine and Molecular Imaging, 53(3), 167 - 171, Jun. 2019 , Refereed
  • Rapid progression of metastatic pulmonary calcification diagnosed by 99mTc-MDP scintigraphy, Fukumoto G, Hosono M, Kanagaki M, Otani T, Ikegaki S, Japanese Archive of Cases Conference of Clinical Nuclear Medicine, Japanese Archive of Cases Conference of Clinical Nuclear Medicine, 1, 17 - 22, May 2019 , Refereed
  • Projects for revision of DRLs in nuclear medicine and prospects, HOSONO Makoto, Innervision, Innervision, 34(3), 32 - 33, Mar. 2019
  • Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation, Hosono M, Ikebuchi H, Nakamura Y, Yanagida S, Kinuya S, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 33(3), 211 - 221, Mar. 2019 , Refereed
  • Significance and application of diagnostic reference level in ICRP recommendation (Explanation of Pub.135), HOSONO Makoto, Radiation Effects Association, Radiation Effects Association, 10(97), 21 - 22, Oct. 2018
  • Proposal of Criteria for Release of Patients and Use of the Normal Ward in 64Cu-ATSM Internal Radiotherapy, Yukie Yoshii, Mitsuyoshi Yoshimoto, Tatsuya Higashi, Makoto Hosono, Kakuigaku, Kakuigaku, 55(1), 77 - 87, Jul. 2018 , Refereed
  • Impact to Z-score Mapping of Hyperacute Stroke Images by Computed Tomography in Adaptive Statistical Iterative Reconstruction, Watanabe Shota, Sakaguchi Kenta, Hosono Makoto, Ishii Kazunari, Murakami Takamichi, Ichikawa Katsuhiro, Japanese Journal of Radiological Technology, Japanese Journal of Radiological Technology, 74(4), 375 - 381, Apr. 2018 , Refereed
  • Resistance to ibritumomab, HOSONO Makoto, CHATAL Jean-François, Resistance to Targeted Anti-Cancer Therapeutics, Resistance to Targeted Anti-Cancer Therapeutics, 1 - 158, Apr. 2018 , Refereed
  • 孤立性内臓動脈解離のCT所見, 福井秀行, 松木充, 任誠雲, 甲斐田勇人, 柳生行伸, 小塚健倫, 細川知紗, 熊野正士, 柏木伸夫, 鶴崎正勝, 今岡いずみ, 細野眞, 石井一成, 村上卓道, Japanese Journal of Radiology, Japanese Journal of Radiology, 36(Supplement), 34, Feb. 25 2018
  • 神経核内封入体病の1例, 沼本勲男, 松木充, 福井秀行, 若林雄一, 日高正二郎, 渡口真史, 藤谷哲也, 山川美帆, 兵頭朋子, 山田穣, 任誠雲, 甲斐田勇人, 柳生行伸, 柏木伸夫, 細川知紗, 小塚健倫, 鶴崎正勝, 今岡いずみ, 細野眞, 石井一成, 村上卓道, Japanese Journal of Radiology, Japanese Journal of Radiology, 36(Suppl.), 27 - 27, Feb. 2018 , Refereed
  • 前立腺癌における骨のマネージメント 前立腺癌骨転移に対するRa‐223の基礎, 細野眞, 細野眞, 泌尿器外科, 泌尿器外科, 30(10), 1521‐1526, Oct. 15 2017
  • Basics of radium-223 for treatment of prostate cancer with bone metastasis, HOSONO Makoto, hinyoki-geka, hinyoki-geka, 30(10), 1521 - 1526, Oct. 2017
  • Features of Alpha Targeted Therapy and History of Development for Ra-223, HOSONO Makoto, Pharma Medica, Pharma Medica, 35(9), 96 - 101, Sep. 20 2017
  • Ra‐223の臨床応用について, 細野眞, 日本医学放射線学会秋季臨床大会抄録集, 日本医学放射線学会秋季臨床大会抄録集, 53回, S435 - S436, Aug. 2017 , Refereed
  • 興味深いFDG‐PET/CT所見を示した小児の後腹膜腫瘍の1例, 大西康之, 細野眞, 金柿光憲, 福本元気, 尾谷知亮, 松原菜穂子, 木村弘之, 核医学症例検討会症例集, 核医学症例検討会症例集, 38(2), 41, Aug. 2017
  • Q.Freezeが有用であった肺腺がん肝転移の1例, 藤井康司, 白髭賢也, 竹中達明, 細野眞, 核医学症例検討会症例集, 核医学症例検討会症例集, 38(2), 31‐32, Aug. 2017
  • PET検診の総括から未来へ はじめに, HOSONO Makoto, 62, 619 - 612, May 2017 , Refereed
  • CRPC治療におけるRa-223の位置付け, 赤座 英之, 酒井 英樹, 米田 俊之, 細野 眞, 和久本 芳彰, 泌尿器外科, 泌尿器外科, 30(4), 409 - 416, Apr. 2017
  • アルファ線核種の臨床利用における法令と指針, 細野眞, 日本放射線技術学会総会学術大会予稿集, 日本放射線技術学会総会学術大会予稿集, 73rd, 112, Mar. 21 2017
  • 4D‐CTを用いた呼吸同期撮像法の有用性, 藤井康司, 白髭賢也, 竹中達明, 細野眞, 日本放射線技術学会総会学術大会予稿集, 日本放射線技術学会総会学術大会予稿集, 73rd, 302, Mar. 21 2017
  • 前立腺小線源療法後1年以内死亡の3例, 横川正樹, 中松清志, 稲田正浩, 福田浩平, 建部仁志, 石川一樹, 立花和泉, 門前一, 金森修一, 西村恭昌, 細野眞, Japanese Journal of Radiology, Japanese Journal of Radiology, 35(Suppl.), 51 - 51, Feb. 2017
  • アイソトープ治療の現状と展望 アルファ核種の利用, 細野 眞, Japanese Journal of Radiology, Japanese Journal of Radiology, 35(Suppl.), 45 - 45, Feb. 2017
  • 医療被ばくの正当化と最適化に向けて Part II 医療被ばく管理と放射線防護の現状と将来展望, 細野眞, Innervision, Innervision, 31(12), 2‐4, Nov. 25 2016
  • 【医療被ばくの正当化と最適化に向けてPart II】 診断参考レベル(DRL)に対する活動と課題 核医学検査の診断参考レベル(DRL)に対する活動と課題, 細野 眞, INNERVISION, INNERVISION, 31(12), 12 - 14, Nov. 2016
    Summary:医療放射線に関連した学会・団体が、医療被ばく研究情報ネットワーク(Japan Network for Research and Information on Medical Exposure:J-RIME)の枠組みにて協働して診断参考レベルの設定に取り組み、2015年6月7日に「診断参考レベル2015(Japan DRLs 2015)」(以下、DRLs2015)を公表した。これに含まれる6つのモダリティの1つに核医学検査がある。核医学検査の診断参考レベルは、全国のすべての核医学診療施設を対象にして調査を実施し、その集計結果に基づいて「実投与量」として設定したものである。また、小児の核医学検査における放射性薬剤の適正投与量の設定も重要な課題であった。これについては、診断参考レベルとは別の概念に基づいて検討され、「小児核医学検査適正施行のコンセンサスガイドライン」に示された。したがって、現在、成人の適正投与量についてはDRLs2015、小児の適正投与量については「小児核医学検査適正施行のコンセンサスガイドライン」に規定されている仕組みとなっており、この2つの適正投与量とその内容を十分に理解して核医学検査を実施することが要である。これらの適正投与量が公表(2013〜2015年)された後、関連した学会・団体は学術集会、機関誌、Webサイトなどを通じてその普及に努めている。(著者抄録)
  • 医療被ばくの正当化と最適化に向けて Part II II 診断参考レベル(DRL)に対する活動と課題 3.核医学検査の診断参考レベル(DRL)に対する活動と課題, 細野眞, Innervision, Innervision, 31(12), 26 - 27, Nov. 2016
  • 分子標的RIがん治療の新展開 国内のRI治療の問題点と解決のための提言, 東 達也, 池渕 秀治, 内山 眞幸, 織内 昇, 絹谷 清剛, 細野 眞, 日本癌治療学会学術集会抄録集, 日本癌治療学会学術集会抄録集, 54回, S18 - 2, Oct. 2016
  • Theranostics:イメージングと治療の融合, 細野眞, 核医学技術, 核医学技術, 36, 386, Sep. 30 2016
  • 肺血流MAAシンチグラフィにおいて投与時の体位によりシャント率が変化した1例, 渡邊翔太, 坂口健太, 黒川敏昭, 小西達郎, 吉田修平, 又野嘉枝子, 細野眞, 核医学症例検討会症例集, 核医学症例検討会症例集, 37(1), 3‐4, Aug. 2016
  • 診断参考レベル(DRLs)の国内導入, 細野眞, 近畿大学医学雑誌, 近畿大学医学雑誌, 41(1-2), 3‐7, Jun. 23 2016
  • [Long-term results of coronary artery bypass grafting using radial artery graft]., Hosono M, Shibata T, Nihon rinsho. Japanese journal of clinical medicine, Nihon rinsho. Japanese journal of clinical medicine, 74 Suppl 4 Pt 1, 482 - 6, Jun. 20 2016 , Refereed
  • Pretherapeutic FDG heterogeneity in tumors can predict local control in oropharyngeal cancer patients undergoing intensity-modulated radiation therapy, Hanaoka Kohei, Hosono Makoto, Tatebe Hitoshi, Ishikawa Kazuki, Monzen Hajime, Ishii Kazunari, Nishimura Yasumasa, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 57, May 01 2016 , Refereed
  • Texture analysis for FMISO PET/CT in oncology patients receiving extra-beam radiation therapy, Hosono Makoto, Tachibana Izumi, Nishimura Yasumasa, Hanaoka Kohei, Sakaguchi Kenta, Ishikawa Kazuki, Nakamatsu Kiyoshi, Kanamori Shuichi, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 57, May 01 2016 , Refereed
  • アイソトープ治療の現状と展望, 細野眞, FB News, FB News, (473), 1 - 3, May 01 2016
  • Myocardial changes on FDG-PET/CT after radiation therapy for esophageal cancer, 稲田正浩, 西村恭昌, 石川一樹, 花岡宏平, 坂口健太, 細野眞, 臨床放射線, 臨床放射線, 61(5), 657 - 666, May 2016
  • 診断参考レベルの国内導入, 細野眞, 日本診療放射線技師会誌, 日本診療放射線技師会誌, 63(4), 403‐405, Apr. 01 2016
  • 医療における放射線防護と関連法令整備に関する研究 水晶体線量の評価手法に関する研究, 坂口健太, 赤羽正章, 薬師寺優子, 高原尚美, 花岡宏平, 細野眞, 医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書, 医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書, 162‐166, 2016
  • 医療における放射線防護と関連法令整備に関する研究 放射性医薬品(放射性塩化ラジウム(223RaCl2)注射液)を投与された患者の退出基準について, 細野眞, 池渕秀治, 上田いづみ, 北岡麻美, 坂口健太, 中村伸貴, 中村吉秀, 花岡宏平, 柳田幸子, 山田崇裕, 医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書, 医療における放射線防護と関連法令整備に関する研究 平成27年度 総括・分担研究報告書, 9‐30, 2016
  • Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition, Ishii K, Hosokawa C, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, Hosono M, Yamazoe Y, Murakami T, Nuclear Medicine In Clinic, Nuclear Medicine In Clinic, 49(6), 89 - 90, 2016 , Refereed
  • Radioisotope Therapy of Japan: Future Perspective and Recommendations., Higashi T, Ikebuchi S, Uchiyama M, Oriuchi N, Kinuya S, Hosono M, Kaku igaku. The Japanese journal of nuclear medicine, Kaku igaku. The Japanese journal of nuclear medicine, 53(1), 27 - 43, 2016 , Refereed
  • 医療における放射線防護と関連法令整備に関する研究 がんの骨転移及び原発性骨腫瘍等の治療に用いられる放射性ラジウム‐223の有効性及び投与された患者の管理区域からの退出などの放射線防護対策について, 細野眞, 宇佐美公男, 坂口健太, 花岡宏平, 上田いづみ, 池渕秀治, 中村吉秀, 中村伸貴, 山田崇裕, 柳田幸子, 北岡麻美, 医療における放射線防護と関連法令整備に関する研究 平成26年度 総括・分担研究報告書, 医療における放射線防護と関連法令整備に関する研究 平成26年度 総括・分担研究報告書, 1‐3,5‐38, 2015
  • 医療放射線防護に関する研究 国際動向に関する研究,核医学領域における放射線防護に関する研究 核医学診療施設における濃度限度等の評価に関する検討について, 細野眞, 池渕秀治, 中村吉秀, 中村伸貴, 山田崇裕, 柳田幸子, 北岡麻美, 宇佐美公男, 坂口健太, 花岡宏平, 上田いづみ, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, HOSONO,25-76, 2014
  • 医療放射線防護に関する研究 災害等による事故の場合の措置や事故防止に関する検討 放射線診療部門での災害への備えに関する検討, 細野眞, 山口一郎, 小高喜久雄, 佐藤幸光, 奥山康男, 平出博一, 遠山尚紀, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, YAMAGUCHI,15-30, 2014
  • 医療放射線防護に関する研究 災害等による事故の場合の措置や事故防止に関する検討 CT装置の放射線事前安全の合理的評価法開発, 細野眞, 山口一郎, 小川泰良, 笹沼和智, 庄司友和, 中野拓郎, 能登公也, 平出博一, 藤淵俊王, 渡邉浩, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, 医療放射線防護に関する研究 平成25年度 総括・分担研究報告書, YAMAGUCHI,1-13, 2014
  • A newly designed radioimmunoconjugate releasing a hippurate-like radiometal chelate for enhanced target/non-target radioactivity, Arano Y, Matsushima H, Tagawa M, Inoue T, Koizumi M, Hosono M, Sakahara H, Endo K, Konishi J, Yokoyama A, Nucl Med Biol, Nucl Med Biol, 21, 63 - 69, 2014 , Refereed
  • Measurements for a Contamination Control of a ^<223>Ra Medicament, HOHARA Sin-ya, HOSONO Makoto, INAGAKI Masayo, IM Sung-Woon, MORIMOTO Hideo, HANAOKA Kohei, SAKAGUCHI Kenta, YAMANISHI Hirokuni, ITOH Tetsuo, RADIOISOTOPES, RADIOISOTOPES, 62(9), 659 - 665, Sep. 15 2013
    Summary:In recent years, attention has been focused on radionuclide therapy with &alpha; emission nuclides. Research and clinical tests of pharmaceuticals including <sup>223</sup>Ra, which has short half-life and a number of &alpha; & &beta; decays with its decay family, started in Japan in this year. Despite the fact that research on pharmaceuticals including <sup>223</sup>Ra is continuing, methods and knowledge of <sup>223</sup>Ra radiation controls have not been researched.<br>Contamination controls of radioactive pharmaceuticals in clinical sites are very important because of radiation protection, and research on <sup>223</sup>Ra-contamination controls should be performed as soon as possible before any medical application becomes licensed.<br>In this work, we performed demonstration experiments of <sup>223</sup>Ra-contamination with commonly-used survey meters. The results of experiments show that a Geiger-Muller type survey meter(TGS-133:Hitachi Aloka Medical) is effective to find <sup>223</sup>Ra-contamination, but an NaI(Tl) scintillation type survey meter(TCS-161:Hitachi Aloka Medical) should be used carefully due to the measurement limit in a <sup>223</sup>Ra-contamination survey.
  • 医療放射線防護に関する厚生労働省班研究の概要, 細野 眞, 山口 一郎, 高橋 健夫, 赤羽 正章, 成田 雄一郎, 池渕 秀治, 中村 吉秀, 柳田 幸子, 中村 伸貴, 山田 崇裕, 日本医学放射線学会学術集会抄録集, 日本医学放射線学会学術集会抄録集, 72回, S162 - S162, Feb. 2013
  • 医療放射線防護に関する研究 国際動向に関する研究,核医学領域における放射線防護に関する研究 塩化ラジウム(Ra‐223)注射液の使用に当たって実施する放射線管理のための遮へい計算並びに空気中及び排気・排水中の放射能濃度の計算方法について, 細野眞, 宇佐美公男, 花岡宏平, 上田いづみ, 池渕秀治, 中村吉秀, 中村伸貴, 山田崇裕, 柳田幸子, 北岡麻美, 医療放射線防護に関する研究 平成24年度 総括・分担研究報告書, 医療放射線防護に関する研究 平成24年度 総括・分担研究報告書, 38 - 63, 2013
  • 111In‐ゼバリンSPECT/CTで腫瘍活性残存を検出できた非ホジキンリンパ腫の一例, 米矢吉宏, 細野眞, 山田穣, 松木充, 花岡宏平, 坂口健太, 任誠雲, 柳生行伸, 石井一成, 辰巳陽一, 松村到, 土屋典生, 核医学, 核医学, 49(4), 439, Nov. 30 2012
  • Guidelines for clinical use of FDG PET, PET/CT 2012, 細野 眞, 佐賀 恒夫, 伊藤 健吾, 汲田 伸一郎, 佐々木 雅之, 千田 道雄, 畑澤 順, 渡邉 浩, 伊藤 浩, 金谷 信一, 木村 裕一, 佐治 英郎, 陣之内 正史, 福喜多 博義, 村上 康二, 絹谷 清剛, 山崎 純一, 内山 眞幸, 宇野 公一, 加藤 克彦, 川野 剛, 日下部 きよ子, 窪田 和雄, 戸川 貴史, 本田 憲業, 丸野 廣大, 吉村 真奈, 宍戸 文男, 井上 登美夫, 福田 寛, 中村 佳代子, Jpn J Nucl Med (Kaku Igaku), Jpn J Nucl Med (Kaku Igaku), 49(4), 391 - 401, Nov. 30 2012
  • Gamut of FDG-PET, 御前 隆, 石津 浩一, 石守 崇好, 工藤 崇, 中本 裕士, 東 達也, 細野 眞, 核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine, 核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine, 49(4), 357 - 389, Nov. 30 2012
  • Recognition of complete response by long-term observation after treatment with 90Y-Ibritumomab tiuxetan for relapsed follicular lymphoma, Acta Med Kinki Univ, Acta Med Kinki Univ, 36(2), 87 - 89, Sep. 2012
  • Recognition of complete response by long-term observation after treatment with 90Y-Ibritumomab tiuxetan for relapsed follicular lymphoma, Tatsumi Y, Rai S, Shimada T, Yamaguchi K, Morita Y, Kawanishi K, Miyatake J, Ashida T, Hosono M, Matsumura I, Acta Med Kinki Univ, Acta Med Kinki Univ, 36(2), 87 - 89, Sep. 2012 , Refereed
  • 内用療法の環境整備, 細野眞, 核医学, 核医学, 49(3), 164, Aug. 31 2012
  • 認知症における脳FDG‐PET早期撮像の可能性について, 兵頭朋子, 石井一成, 坂口健太, 花岡宏平, 宇佐美公男, 島元健次, 山添譲, 山田穣, 松木充, 細野眞, 村上卓道, 核医学, 核医学, 49(3), 294, Aug. 31 2012
  • SPECT/CTを用いたバセドウ病のヨウ素131治療計画, 細野眞, 花岡宏平, 米矢吉宏, 土屋典生, 坂口健太, 高田裕史, 森元英夫, 宇佐美公男, 石井一成, 核医学症例検討会症例集, 核医学症例検討会症例集, 33(1), 15-16, Aug. 2012
  • 医療放射線の安全確保と有効利用に関する厚生労働省班研究の概要, 細野眞, 岡野友宏, 山口一郎, 高橋健夫, 赤羽正章, 雫石一也, 池渕秀治, 柳田幸子, 米矢吉宏, 土屋典生, 日本医学放射線学会総会抄録集, 日本医学放射線学会総会抄録集, 71st, S150, Feb. 29 2012
  • 131I甲状腺内用療法におけるSPECT/CTを用いた甲状腺重量測定について, 花岡宏平, 大塚正和, 吉田修平, 井上亮, 石井一成, 村上卓道, 細野眞, 日本放射線技術学会総会学術大会予稿集, 日本放射線技術学会総会学術大会予稿集, 68th, 185-186, Feb. 29 2012
  • 脳FDG集積低下を示す大きな腫瘍代謝症例の分析, 細野眞, 花岡宏平, 米矢吉宏, 土屋典生, 宇佐美公男, 高田裕史, 坂口健太, 森元英夫, IM Sung‐Woon, 石井一成, 辰巳陽一, 下野太郎, 核医学症例検討会症例集, 核医学症例検討会症例集, 32(2), 41-42, Feb. 2012
  • 医療放射線の安全確保と有効利用に関する研究 医療現場における医療放射線の安全管理体制に関する指針等についての調査研究, 細野眞, 山口一郎, 藤田真紀, 清堂峰明, 医療放射線の安全確保と有効利用に関する研究 平成22-23年度 総合研究報告書, 医療放射線の安全確保と有効利用に関する研究 平成22-23年度 総合研究報告書, YAMAGUCHI,1-19, 2012
  • 医療放射線の安全確保と有効利用に関する研究 医療現場における医療放射線の安全管理体制に関する指針等についての調査研究, 細野眞, 山口一郎, 藤田真紀, 清堂峰明, 医療放射線の安全確保と有効利用に関する研究 平成23年度 総括・分担研究報告書, 医療放射線の安全確保と有効利用に関する研究 平成23年度 総括・分担研究報告書, YAMAGUCHI,1-9, 2012
  • 〈Case Reports〉Recognition of complete response by long-term observation after treatment with ^<90>Y-Ibritumomab tiuxetan for relapsed follicular lymphoma, Tatsumi Yoichi, Rai Shinya, Shimada Takahiro, Yamaguchi Terufumi, Morita Yasuhiro, Kawanishi Kazunobu, Miyatake Junichi, shida Takashi, Maeda Yasuhiro, Hosono Makoto, Matsumura Itaru, Acta Medica Kinki University, Acta Medica Kinki University, 36(2), 87 - 89, Dec. 01 2011
    Summary:[Abstract] Monoclonal antibodies have markedly changed the treatment possibilities for patients with indolent B-cell lymphoma. ^<90>Y-Ibritumomab tiuxetan (Zevalin) is the first radioimmunotherapy (RIT) agent approved for the treatment of relapsed and refractory indolent lymphoma patients. In most cases, the maximum clinical response were observed two to three months after RIT. Treatment with ^<90>Y-ibritumomab tiuxetan may have potential late effects in some cases of relapsed follicular lymphomas, and we must be careful to start the next treatment after RIT.
  • Report on the 44th Annual Meeting of Japan Health Physics Society, HOSONO Makoto, 保健物理 : hoken buturi, 保健物理 : hoken buturi, 46(4), 288 - 291, Dec. 01 2011
  • 18F‐FDG PET/CTにてsuperscanを呈した腎癌骨転移の1例, 兵頭朋子, 石井一成, 細野眞, 阪本祐一, 米矢吉宏, 柳生行伸, 土屋典生, 熊野正士, 足利竜一朗, 中村一郎, 植村天受, 村上卓道, 核医学, 核医学, 48(4), 471 - 471, Nov. 2011
  • 核医学治療の有効性と環境整備および今後の展望, 細野眞, 核医学, 核医学, 48(3), 245, Sep. 30 2011
  • 高精度放射線治療におけるPET/CTの臨床的有効性に関する検討, 大久保充, 小泉潔, 徳植公一, 西村恭昌, 細野眞, 核医学, 核医学, 48(3), 238, Sep. 30 2011
  • [Evaluation of patient dose from diagnostic X-ray using glass badges]., Usami K, Sakaguchi K, Ootsuka M, Nagamoto K, Inoue R, Fukuda K, Kano Y, Yoshida K, Hosono M, Nihon Hoshasen Gijutsu Gakkai zasshi, Nihon Hoshasen Gijutsu Gakkai zasshi, 67(7), 785 - 792, Jul. 20 2011 , Refereed
    Summary:Radiography is used in medical practices based on the principles of justification and optimization. Patients’ exposure doses should be kept as low as still allows for image quality that does not disturb the diagnostic processes. To optimize diagnostic radiological procedures, the international commission on radiological protection (ICRP) advocated the establishment of diagnosis reference levels (DRLs) in the new basic recommendation (Publication 103) in 2007 by stating that “The DRL should be expressed as a readily measurable patient-dose-related quantity for the specified procedure.” In th...
  • 医療放射線の安全確保と有効利用に関する研究「医療放射線の安全確保のための立ち入り検査のあり方に関する研究」, 細野眞, 山口一郎, 小高喜久雄, 矢野和秀, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 68 - 90, 2011
  • 医療放射線の安全確保と有効利用に関する研究 診療用放射性同位元素使用室への入退出時における患者のスリッパ等の履き替えの必要性に関する検討, 細野眞, 山口一郎, 金谷信一, 小高喜久雄, 渡邉浩, 池渕秀治, 中村伸貴, 柳田幸子, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 107 - 114, 2011
  • 医療放射線の安全確保と有効利用に関する研究「エックス線診療室等のしゃへい評価法に関する研究」, 細野眞, 山口一郎, 小高喜久雄, 渡邉浩, 堀越亜希子, 池渕秀治, 柳田幸子, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 医療放射線の安全確保と有効利用に関する研究 平成22年度 総括・分担研究報告書, 91 - 106, 2011
  • Report on the 44th Annual Meeting of Japan Health Physics Society, HOSONO Makoto, Jpn. J. Health Phys., Jpn. J. Health Phys., 46(4), 288 - 291, 2011
  • The radiation exposure dose of fluoroscopy-guided gastrointestinal procedures: A single-center retrospective study, Hayashi S, Nishida T, Endoscopy International Open, Endoscopy International Open, in press, Sep. 2010 , Refereed
  • 診断参考レベルの国内導入に向けて, 細野眞, 宇佐美公男, 岡野友宏, 米矢吉宏, 土屋典生, 赤羽正章, 成田浩人, 大場久照, 山口一郎, 並木宣雄, 日本医学放射線学会総会抄録集, 日本医学放射線学会総会抄録集, 69th, S146, Feb. 28 2010
  • Radiation treatment planning using positron emission and computed tomography (PET/CT) for lung and pharyngeal cancers: A multiple thresholds method for FDG activity., Int J Radiat Oncol Biol Phys, Int J Radiat Oncol Biol Phys, 77, 350 - 356, 2010
  • 医療放射線の安全確保に関する研究 放射線治療装置に係る職員研修マニュアル作成に関する調査研究, 細野眞, 大場久照, 笈田将皇, 藤淵俊王, 西部茂美, 早川登志雄, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, KADAI6,31-122, 2010
  • 医療放射線の安全確保に関する研究 エックス線診療施設の遮へい評価法に関する調査研究, 細野眞, 大場久照, 三田創吾, 浅沼治, 山口一郎, 小高喜久雄, 池渕秀治, 中村伸貴, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, KADAI6,1-29, 2010
  • 医療放射線の安全確保に関する研究「医療機関で行う死亡時画像病理診断(Ai=Autopsy imaging)における放射線防護のためのルール整備に関する研究」, 細野眞, 山口一郎, 金谷信一, 小高喜久雄, 櫻井公一, 池渕秀治, 中村吉秀, 中村伸貴, 柳田幸子, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, KADAI4,1-17, 2010
  • 医療放射線の安全確保に関する研究 Positron Emission Mammography(陽電子放出乳房撮影装置)の有用性と使用場所の放射線防護に関する検討, 井上登美夫, 細野眞, 雫石一也, 山口一郎, 池渕秀治, 中村伸貴, 柳田幸子, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, KADAI1,77-84, 2010
  • 医療放射線の安全確保に関する研究「診断参考レベルの導入に向けたリスクコミュニケーションのあり方に関する研究」, 細野眞, 山口一郎, 金谷信一, 西澤真理子, 小高喜久雄, 諸澄邦彦, 櫻井公一, 池渕秀治, 中村吉秀, 中村伸貴, 柳田幸子, 医療放射線の安全確保に関する研究 平成19-21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成19-21年度 総括・分担研究報告書, 23 - 38, 2010
  • 医療放射線の安全確保に関する研究「診療用高エネルギー放射線発生装置の運転に伴い発生する放射化物の適正な管理に関する研究」, 細野眞, 山口一郎, 小高喜久雄, 藤淵俊王, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成21年度 総括・分担研究報告書, KADAI4,31-96, 2010
  • Worldwide trends in radiation protection in medicine, HOSONO M, Jpn. J. Radiol. Technol., Jpn. J. Radiol. Technol., 54(13), 1772 - 1778, Dec. 2009
  • 悪性リンパ腫に対するRI標識抗体療法の基礎と臨床 2.放射免疫療法の歴史と将来展望, 細野眞, 辰巳陽一, 金丸昭久, 山添譲, 血液フロンティア, 血液フロンティア, 19(12), 1905 - 1911, Nov. 30 2009
  • Measurement of regional cerebral blood flow associated with cilostazol therapy in vascular dementia, Hanada Kazushi, Hosono Makoto, Hitomi Yoshie, Tsuchiya Norio, Komeya Yoshihiro, Tsujii Noa, Kitahata Daisuke, Takahashi Eriko, Murakami Takumi, Shirakawa Osamu, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 50, May 2009 , Refereed
  • 肺癌・咽頭癌におけるPET/CTシミュレーション;転移リンパ節の評価, 大久保充, 中松清志, 柴田徹, 金森修一, 西川龍之, 小池竜太, 立花和泉, 奥村雅彦, 西村恭昌, 細野眞, 日本医学放射線学会総会抄録集, 日本医学放射線学会総会抄録集, 68th, S226, Feb. 28 2009
  • [Research on the shielding evaluation method for medical X-ray imaging facilities]., Ohba H, Fujibuchi T, Mita S, Horikoshi A, Iwanaga T, Ikebuchi H, Hosono M, Nihon Hoshasen Gijutsu Gakkai zasshi, Nihon Hoshasen Gijutsu Gakkai zasshi, 65(1), 57 - 63, Jan. 20 2009 , Refereed
    Summary:The purpose of this study was to verify the shielding evaluation method for medical X-ray imaging facilities in Report No. 147 of the National Council on Radiation Protection and Measurements (NCRP). We investigated the concept of radiation protection and the major revised point in Report No. 147. The goal of radiation protection in Report No. 147 was compared with that in Japan. Using the data of the Imaging Performance Assessment of CT scanners (ImPACT) 2006 and the latest pre-installation manuals of several manufactures for different computed tomography (CT) scanner models, we verified t...
  • 医療放射線の安全確保に関する研究 放射線診療機器の使用に係る職員研修の実施に関する検討およびエックス線診療施設の遮へい計算法に関する検討 放射線治療装置に係る職員研修マニュアル作成に関する調査研究, 細野眞, 大場久照, 笈田将皇, 藤淵俊王, 西部茂美, 早川登志雄, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 199 - 257, 2009
  • 医療放射線の安全確保に関する研究 放射線診療全般で患者が受ける放射線の量の把握・放射線診療の説明のあり方に関する検討 医療での放射線リスクの説明のあり方に関する研究, 細野眞, 山口一郎, 金谷信一, 西澤真理子, 小高喜久雄, 諸澄邦彦, 櫻井公一, 池渕秀治, 中村吉秀, 中村伸貴, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 124 - 168, 2009
  • 医療放射線の安全確保に関する研究 放射線診療全般で患者が受ける放射線の量の把握・放射線診療の説明のあり方に関する検討 放射性医薬品(医療機器)を投与された患者の退出基準のあり方に関する研究, 細野眞, 山口一郎, 金谷信一, 小高喜久雄, 諸澄邦彦, 櫻井公一, 池渕秀治, 中村吉秀, 中村伸貴, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 169 - 178, 2009
  • 医療放射線の安全確保に関する研究 放射線診療全般で患者が受ける放射線の量の把握・放射線診療の説明のあり方に関する検討 医療で用いたI‐131の汚染物を減衰待ち保管により10半減期後に清掃工場に搬入する場合の清掃作業者や公衆への放射線曝露量の推計, 細野眞, 山口一郎, 金谷信一, 小高喜久雄, 諸澄邦彦, 櫻井公一, 池渕秀治, 中村吉秀, 中村伸貴, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成20年度 総括・分担研究報告書, 179 - 188, 2009
  • OOKP(歯根部利用人工角膜)手術後のCT像, 桑原 雅知, 下野 太郎, 勝部 敬, 藤谷 哲也, 松久保 祐子, 足利 竜一朗, 細野 眞, 村上 卓道, 福田 昌彦, 濱田 傑, 日本医学放射線学会秋季臨床大会抄録集, 日本医学放射線学会秋季臨床大会抄録集, 44回, S500 - S500, Sep. 2008
  • PET/CTシミュレーションにおけるGTV描出のためのファントム実験, 大久保充, 中松清志, 柴田徹, 金森修一, 小池竜太, 廣井啓二, 奥村雅彦, 西村恭昌, 花岡宏平, 宇佐美公男, 細野眞, Radiat Med, Radiat Med, 26, 46, Apr. 25 2008
  • PET/CTシミュレーションにおけるPET描出体積と肉眼的腫瘍体積との比較, 大久保充, 中松清志, 柴田徹, 金森修一, 小池竜太, 廣井啓二, 西村恭昌, 奥村雅彦, 細野眞, Radiat Med, Radiat Med, 26, 52, Apr. 25 2008
  • Recent advances in unsealed radionuclide therapy, 細野 眞, 月刊新医療, 月刊新医療, 35(3), 56 - 59, Mar. 2008
  • PET/CTの放射線治療計画への応用:動体ファントムによる検討, 大久保充, 中松清志, 柴田徹, 金森修一, 小池竜太, 廣井啓二, 西川龍之, 奥村雅彦, 西村恭昌, 花岡宏平, 細野眞, 核医学, 核医学, 45(1), 54 - 55, Feb. 28 2008
  • PET/CTシミュレーションにおけるFDG活性閾値設定の検討, 大久保充, 中松清志, 柴田徹, 金森修一, 西川龍之, 小池竜太, 廣井啓二, 奥村雅彦, 西村恭昌, 細野眞, 日本医学放射線学会総会抄録集, 日本医学放射線学会総会抄録集, 67th, S258, Feb. 28 2008
  • Clinical Usefulness of [^<18>F] FDG-PET for Diagnosis of Bone and Soft Tissue Tumors : An Analysis Based on Multi-center Questionnaire Survey, KATO Katsuhiko, HOSONO Makoto, ITO Kengo, OKADA Masahiro, KOMEYA Yoshihiro, IM Sung-WOON, TSUCHIDA Norio, TORIZUKA Kanji, RADIOISOTOPES, RADIOISOTOPES, 57(1), 13 - 23, Jan. 15 2008
    Summary:The usefulness of [<SUP>18</SUP>F] FDG-PET for the diagnosis of bone and soft tissue tumors was evaluated using 75 cases(20 kinds of diseases)which were collected from7institutions in Japan by sending out questionnaires. The data of the study patients, who had osteosarcoma, Ewing′s sarcoma(including primitive neuroectodermal tumor), liposarcoma, leiomyosarcoma, Hemangiosarcoma, synovial sarcoma, rhabdomyosarcoma, giant cell tumor, schwannoma, malignant fibrous histiocystoma, chondrosarcoma, alveolar soft part sarcoma, epithelioid sarcoma, endometrial stromal sarcoma, hibernoma, fibrosarcoma, multiple osteochondroma, sacral chordoma, Langerhans cell histiocytosis, and neurofibromatosis, respectively, were analyzed. From the analytical results it was concluded that the usefulness of [<SUP>18</SUP>F] FDG-PET is high for the diagnosis of these tumors.
  • 医療放射線の安全確保に関する研究 放射線機器の使用に係る職員研修の実施に関する研究 X線診療室の遮へい評価法に関する基礎的研究, 細野眞, 大場久照, 藤淵俊王, 三田創吾, 中村吉秀, 岩永哲雄, 堀越亜希子, 医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書, 486 - 549, 2008
  • 医療放射線の安全確保に関する研究 放射線診療全般で患者が受ける放射線の量の把握・放射線診療の説明のあり方に関する研究, 細野眞, 山口一郎, 金谷信一, 西澤真理子, 中沢敦, 迫義知, 池渕秀治, 中村伸貴, 医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書, 医療放射線の安全確保に関する研究 平成19年度 総括・分担研究報告書, 406 - 448, 2008
  • Clinical usefulness of <18F> FDG-PET for diagnosis of bone and soft tissue tumors: an analysis based on multi-center questionnaire survey, 加藤 克彦, 細野 眞, 伊藤 健吾, Radioisotopes, Radioisotopes, 57(1), 15 - 25, Jan. 2008
  • [Advancement of the imaging for hepatic malignancies]., Kumano S, Okada M, Imaoka I, Shimono T, Hosono M, Murakami T, Gan to kagaku ryoho. Cancer & chemotherapy, Gan to kagaku ryoho. Cancer & chemotherapy, 34, 1357 - 1360, Sep. 2007 , Refereed
  • 近畿大学病院における造影CT検査副作用への対応について, 土屋典生, 下野太郎, 足利竜一朗, 岡田真広, 柳生行伸, 米矢吉宏, 任誠雲, 葉輝明, 細野眞, 大久保充, 廣井啓二, 小池竜太, 中松清志, 金森修一, 柴田徹, 西村泰昌, Radiat Med, Radiat Med, 25, 79, Apr. 25 2007
  • 動体ファントムを用いたPET抽出体積の検討, 大久保充, 中松清志, 金森修一, 小池竜太, 廣井啓二, 柴田徹, 西村恭昌, 奥村雅彦, 花岡宏平, 細野眞, 日本医学放射線学会学術集会抄録集, 日本医学放射線学会学術集会抄録集, 66th, S332, Feb. 28 2007
  • Contrast enhanced MDCT, 22(5), 106 - 109, 2007
  • 肺癌に対するPET/CTシミュレーションにおけるFDG活性閾値設定法の検討, 大久保充, 中松清志, 柴田徹, 金森修一, 小池竜太, 廣井啓二, 西村恭昌, 奥村雅彦, 細野眞, 日本放射線腫よう学会誌, 日本放射線腫よう学会誌, 18(Supplement 1), 147, Oct. 25 2006
  • 泌尿器科領域におけるFDG-PETの有用性, 田中 基幹, 清水 信貴, 森 康範, 南 高文, 林 泰司, 辻 秀憲, 松本 成史, 能勢 和宏, 野澤 昌弘, 石井 徳味, 細野 眞, 植村 天受, 日本癌治療学会誌, 日本癌治療学会誌, 41(2), 481 - 481, Sep. 2006
  • 国際放射線防護委員会新勧告における放射線荷重係数等の検討, 細野真, 米矢吉宏, 油野民雄, 日下部きよ子, 草間経二, 山口一郎, 小林一三, 渡辺浩, 並木宣雄, 藤村洋子, 堀越亜希子, 核医学, 核医学, 42(3), 293, Sep. 20 2005
  • Radiotherapy and ND-YAG laser for locally advanced non-small cell lung cancer with malignant airwary stenosis and dyspnea, NISHIMURA Keiichiro, TAKAHASHI Takeo, OSADA Hisato, MURATA Osamu, HONDO Mikito, HOSONO Makoto, HONDA Norinari, The Journal of JASTRO, The Journal of JASTRO, 17(2), 97 - 101, Jun. 25 2005
  • Aggressive multiple lung metastases from intracranial atypical meningioma, Jpn J Tomogrraphy, Jpn J Tomogrraphy, 32(1), 24 - 27, Jan. 2005
  • RADIOTHERAPY AND ND-YAG LASER FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER WITH MALIGNANT AIRWAY STENOSIS AND DYSPNEA, NISHIMURA Keiichiro, TAKAHASHI Takeo, OSADA Hisato, MURATA Osamu, HONDO Mikito, HOSONO Makoto, HONDA Norinari, The Journal of JASTRO, The Journal of JASTRO, 17(2), 97 - 101, 2005
    Summary:Locally advanced non-small cell lung cancer is often inoperable. It is difficult to choose the optimal therapy for locally advanced lung carcinoma with malignant airway obstruction. We applied Neodymiumyttrium-aluminum garnet (Nd-YAG) laser therapy combined with external beam radiotherapy. Seven patients were treated with Nd-YAG laser and 60 Gy and more of conventional radiotherapy. All patients had malignant airway obstructions and severe dyspnea at the beginning of Nd-YAG laser therapy. These patients received good to excellent palliation and were able to have normal daily lifes after the treatments. The Nd-YAG laser combined with external radiotherapy may be one of the most useful treatment for locally advanced lung cancer with malignant airway stenosis to improve quality of life.
  • [Drawing up the guidelines for ventilation, draining and disposal of radioactive medical waste]., Koizumi M, Endo K, Yokoyama K, Narita Y, Kinoshita F, Hosono M, Kusakabe K, Kosaka N, Mori Y, Kosuda S, Kaku igaku. The Japanese journal of nuclear medicine, Kaku igaku. The Japanese journal of nuclear medicine, 41, 48 - 50, Feb. 2004 , Refereed
  • 放射性核種の免除レベルとクリアランスレベルの算出に関する考察, 細野 眞, 西村 恭昌, 粟井 和夫, 井上 正昭, 下野 太郎, 金森 修一, 柳生 行伸, 中松 清志, 花田 一志, 小池 竜太, 米矢 吉宏, 核医学, 核医学, 40(4), 507 - 508, Nov. 2003
  • Optimal Injection Protocol In Hepatic Dynamic CT Using MDCT, 23(9), 1017 - 1025, Sep. 2003
  • Adult embryonal rhabdomyosarcoma in axilla, Radiation Medicine, Radiation Medicine, 21(3), 135 - 137, Mar. 2003
  • Effective radiotherapy and an abscopal effect for bone metastases of an unknown origin, Jpn J Tomogrraphy, Jpn J Tomogrraphy, 30, 96 - 99, Feb. 2003
  • EVALUATION OF QOL IN CANCER PATIENTS TREATED WITH RADIATION THERAPY, TAKAHASHI Takeo, MACHIDA Kikuo, HONDA Norinari, HOSONO Makoto, MURATA Osamu, OSADA Hisato, OMICHI Masahide, The Journal of JASTRO, The Journal of JASTRO, 14(4), 233 - 238, Dec. 25 2002
  • Interobserver variation in diagnosis of dementia by brain perfusion SPECT, Radiation Medicine, Radiation Medicine, 20, 281 - 289, May 2002
  • Current topics of nuclear medicine in lung cancer, 本田 憲業, 町田 喜久雄, 細野 眞, 月刊新医療, 月刊新医療, 29(5), 112 - 115, May 2002
  • Measurement of decreased cerebellar blood flow of Machado-Joseph Disease by brain perfusion SPECT, Jpn J Tomography, Jpn J Tomography, 28, 94 - 98, Mar. 2002
  • Increased uptake of Tc-99m MDP in pulmonary osseous chondrosarcoma in a patient with Carney’s syndrome, Jpn J Tomography, Jpn J Tomography, 29, 29 - 32, Jan. 2002
  • Evaluation of QOL in cancer patients treated with radiation therapy., TAKAHASHI Takeo, MACHIDA Kikuo, HONDA Norinari, HOSONO Makoto, MURATA Osamu, OSADA Hisato, OMICHI Masahide, J Jpn Soc Ther Radiol Oncol, J Jpn Soc Ther Radiol Oncol, 14(4), 233 - 238, 2002
    Summary:Introduction: Evaluation of QOL in cancer patients is an important theme. However, we do not have an established method to assess QOL in cancer patients during radiotherapy in Japan. We evaluated both the changes of QOL and the factors affecting QOL in radiotherapy patients.<BR>Materials and Methods: Three hundred and fifty-five cancer patients, who filled in a questionnaire at the beginning, middle, and end of radiotherapy between 1998 and 2001, were studied. Weused"The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD)" devisedby Kurihara et al, the Ministry of Health and Welfare. The QOL Questionnaire had five categories: physical activity, physical condition, mental state, social interaction, and face scale. The total score, sum of the score of five categories, were established synthetically (maximum score is 110).<BR>Results: The mean of total QOL scores were 75.8, 77.6, and 78.2 at the beginning, middle, and end of radiotherapy respectively. Patients with symptoms related to cancer had apparent improvement of QOL score. Patients receiving chemotherapy had a decreased QOL score at the end of radiotherapy. The score of physical condition was reduced improvement.<BR>Conclusions: It was suggested that radiotherapy could be performed without losing QOL of cancer patients, including older patients. However, patients receiving chemotherapy and those with head and neck cancer may lose their QOL, therfore, we should treat such patients carefully.
  • Clinical Application of 133-Xe Ventilation Scintigraphy, HONDA Norinari, MACHIDA Kikuo, HOSONO Makoto, 日本醫學放射線學會雜誌, 日本醫學放射線學會雜誌, 60(5), 237 - 242, Apr. 25 2000
  • Clinical Application of 133-Xe Ventilation Scintigraphy, Honda Norinari, Machida Kikuo, Hosono Makoto, 日本医学放射線学会雑誌, 日本医学放射線学会雑誌, 60(5), 237 - 242, Apr. 25 2000
  • Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure, M. Hosono, Folia Pharmacologica Japonica, Folia Pharmacologica Japonica, 114(2), 83 - 88, 1999
    Summary:Colforsin daropate hydrochloride (COL) is a water-soluble forskolin derivative for the treatment of acute heart failure. COL, like forskolin, stimulated adenylate cyclase (AC) directly and produced pharmacologic activities accompanied by the increase in cellular cAMP. COL was different from forskolin in watersolubility, duration of action, BBB permeability, oral activity and AC-subtype selectivity. COL was a inodilator with positive inotropic and vasodilator effects and was effective on a β-receptor desensitized-heart model in Which the effects of β-agonists and PDE inhibitors were attenuated. COL improved cardiac function in some heart failure models. In the clinical studies, COL improved hemodynamics, subjective and objective symptoms of heart failure patients, and was also effective in the catecholamine-resistant heart failure patients. COL is a first clinically available adenylate cyclase activator. Further information from the post-marketing-surveillance will provide information that will enable more adequate usage of this drug.
  • Nuclear Oncology with Monoclonal Antibodies and Peptides, HOSONO Makoto, 核医学, 核医学, 35(8), 681 - 687, Oct. 20 1998
  • Nuclear Medicine in Europe, HOSONO Makoto, Radioisotopes, Radioisotopes, 47(6), 531 - 532, Jun. 1998
  • Nuclear medicine in Europe. Mainl on France., 細野 眞, RADIOISOTOPES, RADIOISOTOPES, 47(6), 531 - 532, 1998
  • Nuclear oncology with monoclonal antibodies and peptides, Makoto Hosono, Kakuigaku, Kakuigaku, 35(8), 685 - 687, 1998
    Summary:Imaging and therapy using radiolabeled monoclonal antibodies have proved useful in many clinical studies. However, immunogenicity of mouse antibodies to human and insufficient tumor-to-normal tissue ratios remained to be solved. Chimerization and humanization by genetic engineering, and multistep targeting techniques have enabled lower immunogenicity and higher tumor-to-normal tissue contrast. Peptides like somatostatin-analogs have been reportedly useful in imaging tumors, which are either somatostatin receptor positive or negative. Elevated normal tissue accumulation of radiolabeled peptides is a drawback in aiming internal radiation therapy.
  • Initial studies on Tc-99m- and Re-188-somatostatin analogues: stannous-mediated direct-labeling and biodistribution in normal mice, Haberberger T, Zamora P, Hosono M, Hosono MN, Bender H, Guhlke S, Knapp FFR, Biersask HJ, Technetium and Rhenium chemistry and nuclear medicine, Technetium and Rhenium chemistry and nuclear medicine, 1994 , Refereed
  • Effect of drugs on malignant cells studied by 1H MRS., 伊島理枝子, 赤坂一之, 中井敏晴, 遠藤啓吾, 細野真, 佐賀恒夫, 阪原晴海, 小西淳二, NMR討論会講演要旨集, NMR討論会講演要旨集, 30th, 341 - 342, Oct. 1991
  • Fundamental and clinical studies of the measurement of serum CA 19-9 concentrations in patients with pancreatic and gastrointestinal cancer using (Ball CA 19-9 kits)., HOSONO MAKOTO, ENDO KEIGO, NAKAJIMA KOTOKO, NAKAI TOSHIHARU, SAGA TSUNEO, SAKAHARA HARUMI, KONISHI JUNJI, MANABE TADAO, TOBE RYUKICHI, 月刊医学と薬学, 月刊医学と薬学, 25(1), 117 - 123, Jan. 1991
  • Antigenic nature in a care who showed remarkably high serum CA 125 and normal CA 130 levels., 23(6), 1287 - 1292, Jun. 1990
  • Basic and clinical studies on ELSA CA 72-4 kit for measurement of serum CA 72-4 concentrations: Usefulness in patients with gastrointestinal cancer., NAKAI TOSHIHARU, ENDO KEIGO, NAKAJIMA KOTOKO, HATTORI NORIKO, HOSONO MAKOTO, SAGA TSUNEO, WATANABE YUJI, SAKAHARA HARUMI, TOBE RYUKICHI, 核医学, 核医学, 27(5), 505 - 511, May 1990
  • Basic and clinical studies on SPan-1 RIABEAD kit: Usefulness in patients wiith pancreatic and biliary tract cancer., 26(12), 1559 - 1565, Dec. 1989
  • Transcatheter Arterial Embolization for Osseous Metastasis of Hepatocellular Carcinoma, Nagata Yasushi, Nakano Yoshihisa, Takahashi Masaji, Abe Mitsuyuki, Saga Tsuneo, Okajima Kaoru, Hosono Makoto, Kohno Shigene, 日本医学放射線学会雑誌, 日本医学放射線学会雑誌, 48(4), 417 - 422, Apr. 25 1988
  • Multicentre prospective observational study protocol for radiation exposure from gastrointestinal fluoroscopic procedures (REX-GI study)., Tsutomu Nishida, Shiro Hayashi, Mamoru Takenaka, Makoto Hosono, Hirofumi Kogure, Kenkei Hasatani, Shinjiro Yamaguchi, Hirotsugu Maruyama, Hisashi Doyama, Hideyuki Ihara, Toshiyuki Yoshio, Koji Nagaike, Takuya Yamada, Takayuki Yakushijin, Tadayuki Takagi, Hidetaka Tsumura, Akira Kurita, Satoshi Asai, Yukiko Ito, Toshio Kuwai, Yasuki Hori, Iruru Maetani, Kenji Ikezawa, Takuji Iwashita, Kengo Matsumoto, Masami Inada, BMJ open, BMJ open, 10(2), e033604 - 8, Feb. 26 2020 , Refereed
    Summary:INTRODUCTION: Recently, the use of various endoscopic procedures under X-ray fluoroscopic guidance, such as endoscopic retrograde cholangiopancreatography (ERCP), interventional endoscopic ultrasonography (EUS), enteral endoscopy and stenting, has been rapidly increasing because of the minimally invasive nature of these procedures compared with that of surgical intervention. With the spread of CT and fluoroscopic interventions, including endoscopic procedures under X-ray guidance, high levels of radiation exposure (RE) from medical imaging have led to major concerns throughout society. However, information about RE related to these image-guided procedures in gastrointestinal endoscopy is scarce, and the RE reference levels have not been established. The aim of this study is to prospectively collect the actual RE dose and to help establish diagnostic reference levels (DRLs) in the field of gastroenterology in Japan. METHODS AND ANALYSIS: This is a multicentre, prospective observational study that is being conducted to collect the actual RE from treatments and diagnostic procedures, including ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement. We will measure the total fluoroscopy time (min), the total dose-area product (Gycm2) and air-kerma (mGy) of those procedures. Because we are collecting the actual RE data and identifying the influential factors through a prospective, nationwide design, this study will provide guidance regarding the DRLs of ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement. ETHICS AND DISSEMINATION: Approval was obtained from the Institutional Review Board of Toyonaka Municipal Hospital (25 April 2019). The need for informed consent will be waived via the opt-out method of each hospital website. TRIAL REGISTRATION NUMBER: The UMIN Clinical Trials Registry, UMIN000036525.
  • Evaluation and Optimization of a New PET Reconstruction Algorithm, Bayesian Penalized Likelihood Reconstruction, for Lung Cancer Assessment According to Lesion Size., Tomoaki Otani, Makoto Hosono, Mitsunori Kanagaki, Yasuyuki Onishi, Naoko Matsubara, Kazuna Kawabata, Hiroyuki Kimura, AJR. American journal of roentgenology, AJR. American journal of roentgenology, 213(2), W50-W56 - W56, Aug. 2019 , Refereed
    Summary:OBJECTIVE. The purpose of this study was to characterize the Bayesian penalized likelihood (BPL) reconstruction algorithm in comparison with an ordered subset expectation maximization (OSEM) reconstruction algorithm and to determine its optimal penalization factor (expressed as a beta value) for clinical use. MATERIALS AND METHODS. FDG PET/CT scans of 46 patients with lung cancer were reconstructed using OSEM and BPL with beta values of 200, 300, 400, 500, and 1000. The liver signal-to-noise ratio, mean standardized uptake value (SUVmean) of the liver, and maximum standardized uptake value (SUVmax) and SUVmean of the cancers were measured. Tumors were categorized into three size groups, and the percentage difference in the tumor SUVmax between OSEM and BPL with a beta value of 200 as well as the percentage difference in the SUVmax between BPL with a beta value of 200 and BPL with a beta value of 1000 were calculated. Image quality was assessed by visual scoring. RESULTS. BPL showed a significantly higher liver signal-to-noise ratio than OSEM, except for BPL with a beta value of 200. The liver SUVmean showed no statistical difference among all algorithms. The SUVmax and SUVmean of tumors decreased as the beta value increased. BPL with a beta value of 200 produced a significantly higher tumor SUVmax than did OSEM (p < 0.01), and BPL with a beta value of 400, 500, or 1000 produced a significantly lower tumor SUVmax than did OSEM (p < 0.01). Visual analysis showed the highest and lowest scores for BPL with beta values of 500 and 200, respectively. In the small size group, the percentage difference in the SUVmax between OSEM and BPL with a beta value of 200 and the percentage difference in the SUVmax between BPL with a beta value of 200 and BPL with a beta value of 1000 were significantly larger than that in the other size groups (p < 0.01). CONCLUSION. The BPL algorithm improves image quality without compromising image quantification. A beta value of 500 appeared to be optimal in this study. Smaller tumors were more influenced by BPL.
  • Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases., Hirotsugu Uemura, Hiroji Uemura, Satsohi Nagamori, Yoshiaki Wakumoto, Go Kimura, Hiroaki Kikukawa, Akira Yokomizo, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Takashi Akagawa, Nobuaki Matsubara, International journal of clinical oncology, International journal of clinical oncology, 24(5), 557 - 566, May 2019 , Refereed
    Summary:BACKGROUND: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC. METHODS: Patients with symptomatic mCRPC, ≥ 2 bone metastases and no known visceral metastases received up to 6 injections of radium-223 (55 kBq/kg), one every 4 weeks. Adverse events (AEs) considered to be related to radium-223 were reported until 3 years after the first injection. Pre-specified conditions, such as acute myelogenous leukemia, myelodysplastic syndrome, aplastic anemia, primary bone cancer, or other primary malignancies, were reported regardless of causality. RESULTS: Of the 49 patients enrolled in the study, 44 (89.8%) entered the survival follow-up period and 33 (67.3%) died. Throughout the entire study, there were no reports of second primary malignancy or other pre-specified conditions. Eight patients (16.3%) experienced post-treatment drug-related AEs, which were all hematological (anemia and decreased lymphocyte, platelet, and white blood cell counts). No serious post-treatment drug-related AEs were reported. Updated median OS was 19.3 months (95% CI: 14.2, 28.5). CONCLUSIONS: In Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC.
  • Radiation exposure during image-guided endoscopic procedures: The next quality indicator for endoscopic retrograde cholangiopancreatography, Shiro Hayashi, Shiro Hayashi, Tsutomu Nishida, Mamoru Takenaka, Makoto Hosono, World Journal of Clinical Cases, World Journal of Clinical Cases, 6(16), 1087 - 1093, Dec. 01 2018 , Refereed
    Summary:© The Author(s) 2018. Endoscopic retrograde cholangiopancreatography (ERCP) is one of the most frequently used image-guided procedures in gastrointestinal endoscopy. Post-ERCP pancreatitis is an important concern, and prophylaxis, cannulation and other related technical procedures have been well documented by endoscopists. In addition, medical radiation exposure is of great concern in the general population because of its rapidly increasing frequency and its potential carcinogenic effects. International organizations and radiological societies have established diagnostic reference levels, which guide proper radiation use and serve as global standards for all procedures that use ionizing radiation. However, data on gastrointestinal fluoroscopic procedures are still lacking because the demand for these procedures has recently increased. In this review, we present the current status of quality indicators for ERCP and the methods for measuring radiation exposure in the clinical setting as the next quality indicator for ERCP. To reduce radiation exposure, knowledge of its adverse effects and the procedures for proper measurement and protection are essential. Additionally, further studies on the factors that affect radiation exposure, exposure management and diagnostic reference levels are necessary. Then, we can discuss how to manage medical radiation use in these complex fluoroscopic procedures. This knowledge will help us to protect not only patients but also endoscopists and medical staff in the fluoroscopy unit.
  • 骨転移を有する去勢抵抗性前立腺癌患者を対象とした塩化ラジウム-223の使用成績調査(中間解析結果), 絹谷 清剛, 筧 善行, 舛森 直哉, 高橋 俊二, 細野 眞, 平野 和史, 松葉 康浩, 砂谷 敏行, 植村 天受, 核医学, 核医学, 55(Suppl.), S189 - S189, Nov. 2018 , Refereed
  • FDG PET/CTによる食道癌術前化学療法の予後解析, 甲斐田 勇人, 白石 治, 岩間 密, 加藤 寛章, 木村 豊, 花岡 宏平, 山田 穣, 北島 一宏, 細野 眞, 安田 卓司, 石井 一成, 核医学, 核医学, 55(Suppl.), S200 - S200, Nov. 2018 , Refereed
  • 短寿命α核種等のRI利用における合理的な放射線安全管理のあり方に関する研究, 細野 眞, 織内 昇, 右近 直之, 永津 弘太郎, 伊藤 哲夫, 山西 弘城, 松田 外志朗, 山田 崇裕, 蜂須賀 暁子, 中村 吉秀, 核医学, 核医学, 55(Suppl.), S215 - S215, Nov. 2018 , Refereed
  • 放射性同位元素内用療法の現状と発展 国内の核医学治療の現状と将来, 細野 眞, 日本癌治療学会学術集会抄録集, 日本癌治療学会学術集会抄録集, 56回, PD18 - 1, Oct. 2018 , Refereed
  • Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.), Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura, Nobutaka Nakamura, Takahiro Yamada, Sachiko Yanagida, Asami Kitaoka, Kiyotaka Kojima, Hiroyasu Sugano, Seigo Kinuya, Tomio Inoue, Jun Hatazawa, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 32(3), 217 - 235, Apr. 01 2018 , Refereed
    Summary:Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.
  • Tips to avoid complications related to direct cannulation of the axillary artery, Takashi Murakami, Mitsuharu Hosono, Toshihiko Shibata, Asian Cardiovascular and Thoracic Annals, Asian Cardiovascular and Thoracic Annals, 26(3), 250 - 251, Mar. 01 2018 , Refereed
  • Tumor Hypoxia Detected by 18F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT)., Izumi Tachibana, Yasumasa Nishimura, Kohei Hanaoka, Masahiro Inada, Kohei Fukuda, Hitoshi Tatebe, Kazuki Ishikawa, Kiyoshi Nakamatsu, Shuichi Kanamori, Makoto Hosono, Anticancer research, Anticancer research, 38(3), 1775 - 1781, Mar. 2018 , Refereed
    Summary:BACKGROUND/AIM: 18F-misonidazole positron emission tomography (FMISO PET)/computed tomography (CT) obtained before and during radiotherapy (RT) was analyzed as to whether it could predict clinical outcome. PATIENTS AND METHODS: Twenty-two patients were included. FMISO PET/ CT was performed twice before RT and at a dose of approximately 20 Gy/10 fractions. FMISO maximum standardized uptake values (SUVmax), the tumor-to-muscle ratios (T/M), and hypoxic volume (HV) in gross target volumes were measured. RESULTS: Of the 22 tumors, 18 had hypoxic areas (SUVmax ≥1.60) before RT. SUVmax, T/M, and HV on the first PET/CT were significantly correlated with initial tumor response, although the values during RT were not related to the response. The overall survival and loco-regional control rates of patients below cut-off values were significantly better than those above the cut-off values. CONCLUSION: Tumor hypoxia detected by FMISO PET/CT before RT may predict clinical outcome.
  • Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer., Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura, International journal of clinical oncology, International journal of clinical oncology, 23(1), 173 - 180, Feb. 2018 , Refereed
    Summary:BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles. The primary endpoint was the percent change in total alkaline phosphatase (ALP) from baseline at 12 weeks. Secondary endpoints included the percent ALP change from baseline to end of treatment (EOT), ALP response rates, percent change in prostate-specific antigen (PSA) from baseline to 12 weeks and EOT, PSA response rates, overall survival (OS), and time to symptomatic skeletal events (SSEs). Adverse events were monitored throughout the study period. RESULTS: Of the 49 Japanese patients (median age 74 years), 28 completed all infusions. Mean percent change in total ALP and PSA from baseline to 12 weeks was -19.3 and +97.4%, respectively. One-year OS and SSE-free rate at the end of active follow-up were 78 and 89%, respectively. The ALP response rate was 31%, while the PSA response rate was 6%. Grade 3/4 treatment-emergent adverse events observed in ≥10% of patients included decreased lymphocyte count (14%), anemia (14%), anorexia (10%), and bone pain (10%). CONCLUSIONS: Radium-223 is effective and well tolerated in Japanese patients with CRPC and bone metastases. Results were comparable with the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01929655.
  • Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases., Hiroji Uemura, Hirotsugu Uemura, Nobuaki Matsubara, Seigo Kinuya, Makoto Hosono, Yoko Yajima, Toshihiko Doi, International journal of clinical oncology, International journal of clinical oncology, 22(5), 954 - 963, Oct. 2017 , Refereed
    Summary:BACKGROUND: Radiation therapy with radium-223 dichloride improves overall survival, reduces symptomatic skeletal events in Caucasian patients with castration-resistant prostate cancer (CRPC) and bone metastases, and is well tolerated. We report here the results of the first efficacy and safety study of radium-223 dichloride in a Japanese population. METHODS: In this open-label, uncontrolled, non-randomized, phase I trial, radium-223 dichloride was given to Japanese patients with CRPC and ≥2 bone metastases in 4-week cycles. The patients were divided into three cohorts, with cohort 1 and the expansion cohort receiving injections of radium-223 dichloride [55 kBq/kg body weight (BW)] every 4 weeks (Q4W) for up to six injections, and cohort 2 receiving an initial single radium-223 dichloride injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W. Safety was determined via adverse event (AE) reporting, and biochemical bone markers were assessed for treatment efficacy. RESULTS: In total 19 patients received at least one dose of radium-223 dichloride and 18 patients experienced at least one treatment-emergent AE (TEAE) of which the most common were anemia, thrombocytopenia, and lymphocytopenia. Serious AEs were reported in three patients but none were drug-related. In the patients of cohort 1 + expansion cohort (55 kBq/kg BW Q4W treatment; n = 16), prostate-specific antigen levels remained stable or slightly increased while the bone alkaline phosphatase (ALP) level significantly decreased. The response rates of bone ALP (≥30 and ≥50% reductions) were 81.8 and 36.4% at week 12, and 81.3 and 50.0% at the end of treatment. CONCLUSIONS: Radium-223 dichloride was well tolerated in these Japanese patients and, at a dose of 55 kBq/kg BW, efficacy on biomarkers was as expected. The outcomes in Japanese patients were consistent with those reported in other non-Japanese populations. TRIAL REGISTRATION: ClinicalTrials.gov record NCT01565746.
  • A new shielding calculation method for X-ray computed tomography regarding scattered radiation, Hiroshi Watanabe, Kimiya Noto, Tomokazu Shohji, Yasuyoshi Ogawa, Toshioh Fujibuchi, Ichiro Yamaguchi, Hitoshi Hiraki, Tetsuo Kida, Kazutoshi Sasanuma, Yasushi Katsunuma, Takurou Nakano, Genki Horitsugi, Makoto Hosono, Radiological Physics and Technology, Radiological Physics and Technology, 10(2), 213 - 226, Jun. 01 2017 , Refereed
    Summary:The goal of this study is to develop a more appropriate shielding calculation method for computed tomography (CT) in comparison with the Japanese conventional (JC) method and the National Council on Radiation Protection and Measurements (NCRP)-dose length product (DLP) method. Scattered dose distributions were measured in a CT room with 18 scanners (16 scanners in the case of the JC method) for one week during routine clinical use. The radiation doses were calculated for the same period using the JC and NCRP-DLP methods. The mean (NCRP-DLP-calculated dose)/(measured dose) ratios in each direction ranged from 1.7 ± 0.6 to 55 ± 24 (mean ± standard deviation). The NCRP-DLP method underestimated the dose at 3.4% in fewer shielding directions without the gantry and a subject, and the minimum (NCRP-DLP-calculated dose)/(measured dose) ratio was 0.6. The reduction factors were 0.036 ± 0.014 and 0.24 ± 0.061 for the gantry and couch directions, respectively. The (JC-calculated dose)/(measured dose) ratios ranged from 11 ± 8.7 to 404 ± 340. The air kerma scatter factor κ is expected to be twice as high as that calculated with the NCRP-DLP method and the reduction factors are expected to be 0.1 and 0.4 for the gantry and couch directions, respectively. We, therefore, propose a more appropriate method, the Japanese-DLP method, which resolves the issues of possible underestimation of the scattered radiation and overestimation of the reduction factors in the gantry and couch directions.
  • Influence of acquisition orbit on phase analysis of gated single photon emission computed tomography myocardial perfusion imaging for assessment of left ventricular mechanical dyssynchrony, Tomofumi Misaka, Makoto Hosono, Takashi Kudo, Takamichi Ito, Tsutomu Syomura, Masanobu Uemura, Kaoru Okajima, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 31(3), 235 - 244, Apr. 2017 , Refereed
    Summary:Objective The association between left ventricular (LV) dyssynchrony parameters, given by phase analysis of gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), and acquisition orbits is unclear. The aim of this study was to assess the dependence of LV dyssynchrony parameters on acquisition orbits. Methods Ninety-nine patients who underwent Tl-201-gated SPECT MPI were categorized into minor hypoperfusion or major hypoperfusion groups. Forty-four patients who underwent Tc-99m-tetrofosmin-gated SPECT MPI were categorized into minor hypoperfusion or major hypoperfusion groups. The major hypoperfusion group with Tl-201 was divided into inferior or non-inferior wall hypoperfusion subgroups, and anteroseptal or non-anteroseptal wall hypoperfusion subgroups. Gated SPECT MPI data over a 360A degrees acquisition orbit (360A degrees images) and a 180A degrees acquisition orbit (180A degrees images) were reconstructed, and histogram bandwidth (HBW) and phase standard deviation (PSD) were compared. Results Between 360A degrees and 180A degrees images with Tl-201, there were significant differences in HBW and PSD both globally (HBW 34.8 +/- 16.6 vs. 29.1 +/- 10.2; PSD 8.8 +/- 4.9 vs. 7.0 +/- 2.3, p < 0.05 for both) and in the inferior wall (HBW 29.5 +/- 15.5 vs. 23.3 +/- 9.0; PSD 7.6 +/- 4.6 vs. 5.6 +/- 2.4, p < 0.001 for both) in the major hypoperfusion group, and also in the inferior wall in all subgroups of the major hypoperfusion group. In contrast, no segment had any significant differences in HBW or PSD between 360A degrees and 180A degrees images with Tc-99m. Conclusion Differences in acquisition orbit had a significant influence on HBW and PSD with Tl-201-gated SPECT MPI in the inferior wall in patients with major hypoperfusion myocardium.
  • Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers, Tomohiro Matsuura, Yasumasa Nishimura, Kiyoshi Nakamatsu, Shuichi Kanamori, Kazuki Ishikawa, Izumi Tachibana, Makoto Hosono, Toru Shibata, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22(1), 52 - 58, Feb. 2017 , Refereed
    Summary:Background Clinical results of computed tomography (CT) simulations and [F-18]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT simulations were compared retrospectively. Materials and methods Between 2006 and 2011, [F-18]FDG PET/CT simulation was performed on 68 consecutive patients with pharyngeal cancers (PET/CT group). As an historical control, conventional CT simulation was performed on 56 consecutive patients with pharyngeal cancer between 2000 and 2006 (CT group). In the PET/CT group, the primary sites were nasopharynx (NPC), oropharynx (OPC), and hypopharynx (HPC) in 35, 20, and 13 patients, respectively; in the CT group, the primary sites were NPC, OPC, and HPC in 21, 17, and 18 patients, respectively. All but five patients in the PET/CT group were treated with intensity modulated radiation therapy (IMRT). Results In the PET/CT group, TNM and clinical stages changed in 11 (16 %) and eight (12 %) patients, respectively. Although the 5-year overall survival (OS) rates for the PET/CT and the CT groups were 80 and 64 %,respectively (p = 0.0420), this result may be attributable to the background difference between the two groups. Similarly, the 5-year locoregional control rates of the two groups were 82 and 70 %, respectively (p = 0.0501). Notably, marginal recurrences around the planning target volume (PTV) were only noted in four CT group patients. Conclusion PET/CT simulation was useful for delineating an accurate clinical target volume (CTV) of pharyngeal cancer, and its clinical results were satisfactory.
  • Estimation of activity of administered 18F-fluorodeoxyglucose by measurement of the dose equivalent rate on the right temporal region of the head., Kenta Sakaguchi, Makoto Hosono, Tomomi Imamura, Naomi Takahara, Misa Hayashi, Yuko Yakushiji, Kazunari Ishii, Tatsuro Uto, Takamichi Murakami, EJNMMI physics, EJNMMI physics, 3(1), 28 - 28, Dec. 2016 , Refereed
    Summary:BACKGROUND: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is now a routine procedure for the management of cancer patients. Intravenous administration of FDG is sometimes halted due to troubles. In such cases, estimations of the FDG dosage injected prior to halting administration may be helpful. We have established a method of estimating the activity of FDG to patients on the basis of the dose equivalent rate on the surface of the right temporal region of the head. The correlation of actual administered dosage with independent variables, such as the dose equivalent rate on the right temporal region of the head, age, sex, and body weight, was analyzed using multiple regression analysis to obtain linear, quadratic, and cubic regression equations. RESULTS: When entering independent variables, the cubic regression equation could be used to estimate an administered dosage with an accuracy of ±10 % for 62 % of all patients and ±20 % for 90 % of all patients. CONCLUSIONS: We conclude that this method is useful for estimating the administered dosage from the dose equivalent rate on the temporal region of the head.
  • Report of a nationwide survey on actual administered radioactivities of radiopharmaceuticals for diagnostic reference levels in Japan, Hiroshi Watanabe, Kazunari Ishii, Makoto Hosono, Etsuko Imabayashi, Koichiro Abe, Masayuki Inubushi, Kazuko Ohno, Yasuhiro Magata, Kinya Ono, Kei Kikuchi, Kei Wagatsuma, Tadashi Takase, Kyoko Saito, Yasuyuki Takahashi, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 30(6), 435 - 444, Jul. 2016 , Refereed
    Summary:The optimization of medical exposure is one of the major issues regarding radiation protection in the world, and The International Committee of Radiological Protection and the International Atomic Energy Agency recommend establishing diagnostic reference levels (DRLs) as tools for dose optimization. Therefore, the development of DRLs based on the latest survey has been required for nuclear medicine-related societies and organizations. This prompted us to conduct a nationwide survey on the actual administered radioactivity to adults for the purpose of developing DRLs in nuclear medicine. A nationwide survey was conducted from November 25, 2014 to January 16, 2015. The questionnaire was sent to all of the 1249 nuclear medicine facilities in Japan, and the responses were collected on a website using an answered form. Responses were obtained from 516 facilities, for a response rate of 41 %. 75th percentile of Tc-99m-MDP and Tc-99m-HMDP: bone scintigraphy, Tc-99m-HM-PAO, Tc-99m-ECD and I-123-IMP: cerebral blood flow scintigraphy, Tc-99m-Tetrofosmin, Tc-99m-MIBI and Tl-201-Cl; myocardial perfusion scintigraphy and F-18-FDG: oncology PET (in-house-produced or delivery) in representative diagnostic nuclear medicine scans were 932, 937, 763, 775, 200, 831, 818, 180, 235 and 252, respectively. More than 90 % of the facilities were within the range of 50 % from the median of these survey results in representative diagnostic nuclear medicine facilities in Japan. Responses of the administered radioactivities recommended by the package insert, texts and guidelines such as 740 MBq (Tc-99m-MDP and Tc-99m-HMDP: bone scintigraphy), 740 MBq (Tc-99m-ECD and Tc-99m-HM-PAO: cerebral blood flow scintigraphy) and 740 MBq (Tc-99m-Tetrofosmin and Tc-99m-MIBI: myocardial perfusion scintigraphy), etc. were numerous. The administered activity of many radiopharmaceuticals of bone scintigraphy (Tc-99m-MDP and Tc-99m-HMDP), cerebral blood flow scintigraphy (Tc-99m-HM-PAO) and myocardial perfusion scintigraphy (Tc-99m-Tetrofosmin and Tc-99m-MIBI), etc. were within the range of the EU DRLs and almost none of the administered radioactivity in Japan exceeded the upper limit of SNMMI standard administered radioactivity. This survey indicated that the administered radioactivity in diagnostic nuclear medicine in Japan had been in the convergence zone and nuclear medicine facilities in Japan show a strong tendency to adhere to the texts and guidelines. Furthermore, the administered radioactivities in Japan were within the range of variation of the EU and the SNMMI administered radioactivities.
  • Performance of C-11-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images, Chisa Hosokawa, Kazunari Ishii, Yuichi Kimura, Tomoko Hyodo, Makoto Hosono, Kenta Sakaguchi, Kimio Usami, Kenji Shimamoto, Yuzuru Yamazoe, Takamichi Murakami, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 56(12), 1910 - 1915, Dec. 2015 , Refereed
    Summary:The goal of this study was to clarify whether binding potential (BP) images using C-11-Pittsburgh compound B (C-11-PiB) and dynamic PET can reliably detect cortical amyloid deposits for patients whose C-11-PiB PET static images are ambiguous and whether visual ratings are affected by white matter retention. Methods: Static and BP images were constructed for 85 consecutive patients with cognitive impairment after C-11-PiB dynamic PET. Cortical uptake was visually assessed as positive, negative, or equivocal for both types of images. Quantitatively, the standardized uptake value ratio (SUVR) from the static image, the nondisplaceable BP from the dynamic image for mean gray matter uptake, and the ratio of gray matter uptake to white matter retention were compared among C-11-PiB-positive, C-11-PiB-equivocal, and C-11-PiB-negative groups. Results: Forty-three scans were visually assessed as C-11-PiB-positive in both the static and the BP images. Ten scans were C-11-PiB-equivocal in the static images. In 8 of them, the BP images were C-11-PiB-positive, whereas the other 2 were C-11-PiB-equivocal. Thirty-two scans were assessed as C-11-PiB-negative in the static images. In the BP images, 4 were C-11-PiB-positive and 2 were C-11-PiB-equivocal. The mean gray matter uptake of C-11-PiB in SUVR and nondisplaceable BP, respectively, showed statistically significant differences among the C-11-PiB-positive, C-11-PiB-equivocal, and C-11-PiB-negative groups. The ratio of gray matter uptake to white matter retention was lower in the BP images than static images from the C-11-PiB-negative and C-11-PiB-equivocal groups, whereas it was higher in the C-11-PiB-positive group. Conclusion: C-11-PiB PET BP images can clarify visual interpretation of clinical static C-11-PiB-equivocal images by reducing the interference of nonspecific white matter retention. We conclude that C-11-PiB-equivocal PET findings on static images reflect cortical amyloid deposits, which can be verified using BP images. Furthermore, quantitative assessments, such as SUVR and nondisplaceable BP, are of no use for correctly rating equivocal visual findings.
  • Feasibility of heterogeneity analysis for intratumoral hypoxia on FMISO PET/CT in radiation therapy, Makoto Hosono, Izumi Tachibana, Yasumasa Nishumura, Kohei Hanaoka, Shuichi Kanamori, Kiyoshi Nakamatsu, Kazuki Ishikawa, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 56(3), May 2015 , Refereed
  • Radiation exposure of nursing staff in PET practices in correlation to performance status of patients, Makoto Hosono, Naomi Takahara, Yuuko Yakushiji, Kenta Sakaguchi, Kazunari Ishii, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 56(3), May 2015 , Refereed
  • Heterogeneity of intratumoral In-111-ibritumomab tiuxetan and F-18-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma, Kohei Hanaoka, Makoto Hosono, Yoichi Tatsumi, Kazunari Ishii, Sung-Woon Im, Norio Tsuchiya, Kenta Sakaguchi, Itaru Matsumura, EJNMMI RESEARCH, EJNMMI RESEARCH, 5, 10, Mar. 2015 , Refereed
    Summary:Background: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of In-111-ibritumomab tiuxetan (Zevalin (R)) and tumor accumulation of F-18-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin's lymphoma patients receiving Y-90-ibritumomab tiuxetan (Zevalin (R)) therapy. Methods: Sixteen patients with histologically confirmed non-Hodgkin's B-cell lymphoma who underwent Y-90-ibritumomab tiuxetan therapy along with In-111-ibritumomab tiuxetan single-photon emission computerized tomography (SPECT)/CT and FDG positron emission tomography (PET)/CT were enrolled in this retrospective study. On pretherapeutic FDG PET/CT images, the maximum standardized uptake value (SUVmax) was measured. On SPECT/CT images, a percentage of the injected dose per gram (%ID/g) and SUVmax of In-111-ibritumomab tiuxetan were measured at 48 h after its administration. The skewness and kurtosis of the voxel distribution were calculated to evaluate the intratumoral heterogeneity of tumor accumulation. As another intratumoral heterogeneity index, cumulative SUV-volume histograms describing the percentage of the total tumor volume above the percentage thresholds of pretherapeutic FDG and In-111-ibritumomab tiuxetan SUVmax (area under the curve of the cumulative SUV histograms (AUC-CSH)) were calculated. All lesions (n = 42) were classified into responders and non-responders lesion-by-lesion on pre- and post-therapeutic CT images. Results: A positive correlation was observed between the FDG SUVmax and accumulation of In-111-ibritumomab tiuxetan in lesions. A significant difference in pretherapeutic FDG SUVmax was observed between responders and non-responders, while no significant difference in In-111-ibritumomab tiuxetan SUVmax was observed between the two groups. In contrast, voxel distribution of FDG demonstrated no significant differences in the three heterogeneity indices between responders and non-responders, while In-111-ibritumomab tiuxetan demonstrated skewness of 0.58 +/- 0.16 and 0.73 +/- 0.24 (p < 0.05), kurtosis of 2.39 +/- 0.32 and 2.78 +/- 0.53 (p < 0.02), and AUC-CSH of 0.37 +/- 0.04 and 0.34 +/- 0.05 (p < 0.05) for responders and non-responders. Conclusions: Pretherapeutic FDG accumulation was predictive of the tumor response in Y-90-ibritumomab tiuxetan therapy. The heterogeneity of the intratumoral distribution rather than the absolute level of In-111-ibritumomab tiuxetan was correlated with the tumor response.
  • Investigation of C-11-PiB equivocal PET findings, Chisa Hosokawa, Kazunari Ishii, Tomoko Hyodo, Kenta Sakaguchi, Kimio Usami, Kenji Shimamoto, Yuzuru Yamazoe, Makoto Hosono, Kazushi Hanada, Masami Ueda, Kazuma Saigo, Takamichi Murakami, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 29(2), 164 - 169, Feb. 2015 , Refereed
    Summary:We have encountered occasional equivocal findings when assessing cerebral cortical amyloid retention with C-11-Pittsburgh compound B (PiB) PET. We investigated the diagnostic significance of equivocal PiB PET findings. This retrospective study included 101 consecutive patients complaining of cognitive disorders (30 Alzheimer's disease, 25 mild cognitive impairment, 8 Lewy body disease, 7 frontotemporal lobar degeneration, 31 others) who underwent both C-11-PiB PET and F-18-fluorodeoxy-d-glucose (FDG) PET. We visually classified PiB-positive, PiB-equivocal or PiB-negative ratings according to cortical uptake. For quantitative assessments of PiB PET, standard uptake values referred to cerebellar cortex (SUVR) were calculated in regional template volume of interests (frontal, temporoparietal, precuneus/posterior cingulate cortex, cerebral white matter and cerebellar cortex). The results of visual assessment were compared with the regional and mean cortical SUVRs and cortical-to-white matter ratio of PiB uptake, as well as clinical and FDG PET findings. Among the 101 scans, 41 were PiB negative, 11 were PiB equivocal, and 49 were rated PiB positive in the visual assessments. The mean cortical SUVR and cortical-to-white matter ratio were 0.97 +/- A 0.07 and 0.57 +/- A 0.21 in PiB-negative, 1.51 +/- A 0.17 and 0.75 +/- A 0.06 in PiB equivocal and 2.10 +/- A 0.33 and 0.97 +/- A 0.11 in PiB-positive group, respectively. Nine of 11 subjects with PiB-equivocal findings had cognitive impairments and FDG distribution compatible with Alzheimer's disease or dementia with Lewy bodies. We considered equivocal visual findings on PiB PET equivalent to PiB-positive with slight cortical uptake. In addition, slight cortical amyloid deposits were considered to cause cerebral metabolic abnormality and cognitive impairment. Although mean cortical SUVR was more sensitive than visual assessment because of low cortical-to-white matter contrast due to non-specific accumulation in white matter, it is important not to overlook small amounts of cortical uptake of PiB in visual inspection for exact diagnosis.
  • Applicability of self-activation of an NaI scintillator for measurement of photo-neutrons around a high-energy X-ray radiotherapy machine, Genichiro Wakabayashi, Akihiro Nohtomi, Eriko Yahiro, Toshioh Fujibuchi, Junichi Fukunaga, Yoshiyuki Umezu, Yasuhiko Nakamura, Katsumasa Nakamura, Makoto Hosono, Tetsuo Itoh, Radiological Physics and Technology, Radiological Physics and Technology, 8(1), 125 - 134, 2015 , Refereed
    Summary:The applicability of the activation of an NaI scintillator for neutron monitoring at a clinical linac was investigated experimentally. Thermal neutron fluence rates are derived by measurement of the I-128 activity generated in an NaI scintillator irradiated by neutrons β-rays from I-128 are detected efficiently by the NaI scintillator. In order to verify the validity of this method for neutron measurement, we irradiated an NaI scintillator at a research reactor, and the neutron fluence rate was estimated. The method was then applied to neutron measurement at a 10-MV linac (Varian Clinac 21EX), and the neutron fluence rate was estimated at the isocenter and at 30 cm from the isocenter. When the scintillator was irradiated directly by high-energy X-rays, the production of I-126 was observed due to photo-nuclear reactions, in addition to the generation of I-128 and Na-24. From the results obtained by these measurements, it was found that the neutron measurement by activation of an NaI scintillator has a great advantage in estimates of a low neutron fluence rate by use of a quick measurement following a short-time irradiation. Also, the future application of this method to quasi real-time monitoring of neutrons during patient treatments at a radiotherapy facility is discussed, as well as the method of evaluation of the neutron dose.
  • Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition, Kazunari Ishii, Chisa Hosokawa, Tomoko Hyodo, Kenta Sakaguchi, Kimio Usami, Kenji Shimamoto, Makoto Hosono, Yuzuru Yamazoe, Takamichi Murakami, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 29(1), 78 - 83, Jan. 2015 , Refereed
    Summary:There is evidence that some cases of patients with dementia with Lewy bodies (DLB) can demonstrate Alzheimer disease (AD) like reduced glucose metabolism without amyloid deposition. The aim of this study was to clarify whether regional hypometabolism is related to amyloid deposits in the DLB brain and measure the degree of regional hypometabolism. Ten consecutive subjects with DLB and 10 AD patients who underwent both Pittsburgh compound B (PiB)-PET and F-18-fluoro-2-deoxyglucose (FDG)-PET were included in this study. Regional standardized uptake value ratio (SUVR)s normalised to cerebellar cortices were calculated in the FDG- and PiB-PET images. All AD patients and five DLB patients showed amyloid deposits (PiB positive). In the DLB group the parietotemporal and occipital metabolism were significantly lower than those in the AD group but there was no difference between the posterior cingulate hypometabolism between DLB and AD groups. There were no differences in regional glucose metabolism between PiB positive and negative DLB patients. In the DLB brain, it is suggested that decreased regional glucose metabolism is unrelated to amyloid deposits, although the hypometabolic area overlaps with the AD hypometabolic area and the degree of parietotemporal and occipital hypometabolism in DLB brain is much larger than that in AD brain.
  • Clinical practice guideline for dedicated breast PET, Makoto Hosono, Tsuneo Saga, Kengo Ito, Shinichiro Kumita, Masayuki Sasaki, Michio Senda, Jun Hatazawa, Hiroshi Watanabe, Hiroshi Ito, Shinichi Kanaya, Yuichi Kimura, Hideo Saji, Seishi Jinnouchi, Hiroyoshi Fukukita, Koji Murakami, Seigo Kinuya, Junichi Yamazaki, Mayuki Uchiyama, Koichi Uno, Katsuhiko Kato, Tsuyoshi Kawano, Kazuo Kubota, Takashi Togawa, Norinari Honda, Hirotaka Maruno, Mana Yoshimura, Masami Kawamoto, Yukihiko Ozawa, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 28(6), 597 - 602, Jul. 2014 , Refereed
  • Heterogeneity of intratumoral In-111-Zevalin and FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell lymphoma, Makoto Hosono, Kohei Hanaoka, Kazunari Ishii, Kenta Sakaguchi, Sung-Woon Im, Norio Tsuchiya, Yoshihiro Komeya, Yoichi Tatsumi, Itaru Matsumura, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 55, May 2014 , Refereed
  • Comparison between SUV and BP images acquired using 11C-PIB PET: Questionable PIB accumulation in SUV images, Chisa Hosokawa, Kazunari Ishii, Yuichi Kimura, Kenta Sakaguchi, Makoto Hosono, Takamichi Murakami, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 55, May 2014 , Refereed
  • A prospective clinical trial of tumor hypoxia imaging with 18f-fluoromisonidazole positron emission tomography and computed tomography (f-miso pet/ct) before and during radiation therapy, Izumi Tachibana, Yasumasa Nishimura, Toru Shibata, Shuichi Kanamori, Kiyoshi Nakamatsu, Ryuta Koike, Tatsuyuki Nishikawa, Kazuki Ishikawa, Masaya Tamura, Makoto Hosono, Journal of Radiation Research, Journal of Radiation Research, 54(6), 1078 - 1084, Nov. 2013 , Refereed
    Summary:To visualize intratumoral hypoxic areas and their reoxygenation before and during fractionated radiation therapy (RT), 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISOPET/CT) were performed. A total of 10 patients, consisting of four with head and neck cancers, four with gastrointestinal cancers, one with lung cancer, and one with uterine cancer, were included. F-MISO PET/CT was performed twice, before RT and during fractionated RT of approximately 20 Gy/10 fractions, for eight of the 10 patients. F-MISO maximum standardized uptake values (SUVmax) of normal muscles and tumors were measured. The tumor-to-muscle (T/M) ratios of F-MISO SUVmax were also calculated. Mean SUVmax ± standard deviation (SD) of normal muscles was 1.25 ± 0.17, and SUVmax above the mean + 2 SD (=1.60 SUV) was regarded as a hypoxic area. Nine of the 10 tumors had an F-MISO SUVmax of =1.60. All eight tumors examined twice showed a decrease in the SUVmax, T/M ratio, or percentage of hypoxic volume (F-MISO =1.60) at approximately 20 Gy, indicating reoxygenation. In conclusion, accumulation of F-MISO of =1.60 SUV was regarded as an intratumoral hypoxic area in our F-MISO PET/CT system. Most human tumors (90%) in this small series had hypoxic areas before RT, although hypoxic volume was minimal (0.0-0.3%) for four of the 10 tumors. In addition, reoxygenation was observed in most tumors at two weeks of fractionated RT. © The Author 2013. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Therapeutic Radiology and Oncology.
  • Dynamic sequence respiratory gated perfusion pulmonary SPECT without external tracking device, Kenta Sakaguchi, Makoto Hosono, Masakazu Otsuka, Kohei Hanaoka, Kimio Usami, Tatsuro Uto, Kazunari Ishii, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 27(1), 65 - 73, Jan. 2013 , Refereed
    Summary:The purpose of this study was to develop and evaluate a new method for respiratory gated pulmonary perfusion SPECT (RGPS) based on dynamic acquisition without using an external tracking device (ETD) or list-mode data acquisition. In the phantom study, our method used a dynamic sequence technique, which was specified by sequences of 50-ms acquisition during 30 s per view of SPECT instead of using an ETD. For this purpose, we created a computer program that identified respiratory phases by calculating the center of activity (COA) in each dynamic frame image. We compared RGPS using the dynamic sequence acquisition (RGPS-DS) and RGPS using ETD (RGPS-ETD) in phantom studies employing a cylinder phantom filled with technetium-99m solution attached to an instrument providing a simple harmonic motion. In the patient study, RGPS-DS was applied to data collected from 3 patients during a routine study of Tc-MAA pulmonary perfusion SPECT. In the phantom study, the calculation of COA indicated a good agreement between RGPS-DS and RGPS-ETD. With an oscillatory phantom movement amplitude of 30 mm, the amplitudes determined by RGPS-DS and RGPS-ETD (28.36 and 27.58 mm, respectively) were identical on considering a pixel size of 4.66 mm for reconstructed SPECT images. In the patient study, applicability of our method to patient data was demonstrated. We have showed the feasibility of our method to obtain RGPS without ETD, and conclude that RGPS-DS may be an innovative and efficient technique in respiratory gated pulmonary perfusion SPECT. Further studies with a larger number of patients should demonstrate the accuracy of our method.
  • The iliac wing sign: An indicator of the presence of bone and/or soft-tissue injury of the pelvis and hips, Takahide Kakigi, Makoto Hosono, Taro Shimono, Taizo Hiraoka, Kazumasa Nishimura, EUROPEAN JOURNAL OF RADIOLOGY, EUROPEAN JOURNAL OF RADIOLOGY, 81(9), 2348 - 2352, Sep. 2012 , Refereed
    Summary:Purpose: To prospectively evaluate the feasibility of using the "iliac wing sign (IWS)" as an indicator of bone and/or soft-tissue injury of the pelvis and hips on magnetic resonance (MR) imaging. IWS means edema of the iliacus muscle attachment entering the iliac wing that is visualized as a linear high signal intensity on fat-suppressed T2-weighted MR images. Methods: Consecutive 106 patients who complained of hip pain were enrolled in this study. We evaluated the correlation between IWS and bone and/or soft-tissue injury of the pelvis and hips using Fisher's exact test. Further, performance parameters of sensitivity, specificity, accuracy, the positive predictive value (PPV), and negative predictive value (NPV) of IWS were calculated. Results: Thirty-eight of the 106 (36%) patients had bone and/or soft-tissue injury. Twenty-seven of these 38 (71%) patients with injury showed a positive IWS, while only 11 of 68 (16%) patients without injury showed a positive IWS (p < .0001). IWS, thus, yielded a sensitivity of 71%, specificity of 84%, accuracy of 79%, positive predictive value (PPV) of 71%, and negative predictive value (NPV) of 84%. Conclusion: In cases with a positive IWS, the careful interpretation of MR images is needed because injury presence is highly likely, as suggested by the relatively high sensitivity and PPV. IWS absence may mean a low probability of injury because of the high specificity and NPV. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
  • Impact of CT attenuation correction by SPECT/CT in brain perfusion images, Kazunari Ishii, Kohei Hanaoka, Masahiro Okada, Seishi Kumano, Yoshihiro Komeya, Norio Tsuchiya, Makoto Hosono, Takamichi Murakami, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 26(3), 241 - 247, Apr. 2012 , Refereed
    Summary:The aim of this study was to elucidate the regional differences between brain perfusion single photon emission computed tomography (SPECT) images reconstructed with a uniform attenuation correction using Chang's method (AC-Chang) and a non-uniform attenuation correction with CT using SPECT/CT (AC-CT). SPECT images of a phantom with and without head holder were obtained, and reconstructed images of AC-Chang and AC-CT were compared. Twenty-eight consecutive patients with brain disease examined by SPECT/CT brain perfusion imaging were selected, and images were reconstructed with AC-Chang and AC-CT. The AC-Chang and AC-CT reconstructed images were then compared by voxel-based analysis using three-dimensional stereotactic surface projections. Counts in the frontal area of the AC-Chang phantom image with head holder were higher than those in the posterior area. Counts in the frontal area of the AC-Chang clinical images were significantly higher than those in the AC-CT images, while the counts in the margin of the frontal lobe and posterior margin of the parietal, occipital cortices and cerebellum of the AC-Chang images were significantly lower. Relative frontal perfusion was 5.0% higher and relative cerebellar perfusion was 4.6% lower in the AC-Chang images relative to the AC-CT images, on average. We demonstrated the frontal dominant hyper-perfusion and parieto-occipital and cerebellar hypo-perfusion in brain SPECT images reconstructed with AC-Chang compared to those reconstructed with AC-CT. We suggest that to obtain an accurate attenuation-corrected brain perfusion SPECT image, attenuation correction by Chang's method is inadequate.
  • Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma, Kohei Hanaoka, Makoto Hosono, Kimio Usami, Yoichi Tatsumi, Yuzuru Yamazoe, Yoshihiro Komeya, Norio Tsuchiya, Kazunari Ishii, Mitsugu Sumita, NUCLEAR MEDICINE COMMUNICATIONS, NUCLEAR MEDICINE COMMUNICATIONS, 32(8), 678 - 683, Aug. 2011 , Refereed
    Summary:Purpose To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin's lymphoma. Methods A total of 127 patients with confirmed non-Hodgkin's lymphoma who underwent FDG PET within 60 days from the last administration of G-CSF were retrospectively reviewed. Thirty age-matched and sex-matched healthy controls were also included to evaluate physiological FDG uptake. PET/CT examinations were retrospectively reviewed, and maximum standardized uptake value (SUV(max)) was measured by placing volumetric regions of interest over each thoracic and lumbar vertebra on PET images referring to CT images. Bone marrow SUV was defined as the mean SUV(max) of the vertebra. The correlation between the interval after G-CSF and the bone marrow SUV was plotted and analyzed with polynomial approximation. Results In controls, physiological bone marrow SUV of the spine was determined. In patients with lymphoma, bone marrow SUV decreased over time and reached a plateau at about 14 days after G-CSF administration, and this was higher by 5% than the plateau at 10 days. SUV declined to the 'physiological range', that is, mean+ 1 standard deviation of patients, at about 7 days. Conclusion For a PET/CT study, an interval of 10 days after G-CSF administration is recommended to minimize the influence of G-CSF on the bone marrow when evaluating treatment response in patients with non-Hodgkin's lymphoma. Nucl Med Commun 32:678-683 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
  • Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions, Kohei Hanaoka, Makoto Hosono, Taro Shimono, Kimio Usami, Yoshihiro Komeya, Norio Tsuchiya, Yuzuru Yamazoe, Kazunari Ishii, Youichi Tatsumi, Mitsugu Sumita, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 24(10), 707 - 711, Dec. 2010 , Refereed
    Summary:Faint brain [(18)F]fluoro-2-deoxyglucose (FDG) uptake has sporadically been reported in patients with FDG-avid large or diffusely extended tumors. The purpose of this study was to investigate whether there is a correlation between massive tumor uptake and decreased brain uptake on FDG positron emission tomography/computed tomography (PET/CT). Sixty-five patients with histologically confirmed non-Hodgkin's lymphoma who underwent FDG-PET/CT were enrolled. Thirty control subjects were also included to evaluate normal brain FDG uptake. PET/CT examinations were retrospectively reviewed. The volumetric regions of interest were placed over lesions by referring to CT and PET/CT fusion images to measure mean standardized uptake value (SUVavg). The products of SUVavg and tumor volume were calculated as total glycolytic volume (TGV). The maximum SUV (SUVmax) and SUVavg were measured in the cerebrum and cerebellum. The values of TGV and brain FDG uptake were plotted and analyzed with a linear regression method. In the lymphoma patients, there were statistically significant negative correlations between TGV and brain SUVs. Demonstrating a significant negative correlation between TGV and brain uptake validated the phenomenon of decreased brain FDG uptake. Diversion of FDG from the brain to the lymphoma tissue may occur during the FDG accumulation process. Recognition of this phenomenon prevents unnecessary further neurological examinations in such cases.
  • FDG PET/CT versus CT, MR Imaging, and Ga-67 Scintigraphy in the Posttherapy Evaluation of Malignant Lymphoma, Masahiro Okada, Norihide Sato, Kazunari Ishii, Kaname Matsumura, Makoto Hosono, Takamichi Murakami, RADIOGRAPHICS, RADIOGRAPHICS, 30(4), 939 - 960, Jul. 2010 , Refereed
    Summary:Malignant lymphoma is the most common form of hematologic cancer, yet because of advanced methods of assessment, the traditional histology-based classification of lymphoma is insufficient for understanding lymphoma imaging. Still, radiologists should be familiar with the imaging findings in lymphoma. Integrated positron emission tomography (PET) computed tomography (CT) allows improved diagnostic accuracy, and uptake of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help predict response during treatment. The sensitivity and specificity of FDG PET are superior to those of gallium 67 scintigraphy in all but indolent lymphoma. Both magnetic resonance (MR) imaging and CT allow excellent assessment of bone texture, but FDG PET is superior in demonstrating bone marrow metabolic activity. Thus, FDG PET is important in both the primary diagnosis and the evaluation of therapy in lymphoma. It may be difficult to determine whether residual abnormalities seen after the completion of chemotherapy radiation therapy represent residual tumor or fibrotic tissue, but PET/CT may allow more accurate diagnosis than MR imaging or CT, thereby helping identify patients who require more intensive treatment. Some diagnostic pitfalls are encountered at FDG PET. However, anatomic CT helps localize and define disease and avoid these potential pitfalls. (c) RSNA, 2010 . radiographics.rsna.org
  • RADIATION TREATMENT PLANNING USING POSITRON EMISSION AND COMPUTED TOMOGRAPHY FOR LUNG AND PHARYNGEAL CANCERS: A MULTIPLE-THRESHOLD METHOD FOR [F-18]FLUORO-2-DEOXYGLUCOSE ACTIVITY, Mitsuru Okubo, Yasumasa Nishimura, Kiyoshi Nakamatsu, Masahiko Okumura, Toru Shibata, Shuichi Kanamori, Kouhei Hanaoka, Makoto Hosono, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(2), 350 - 356, Jun. 2010 , Refereed
    Summary:Purpose: Clinical applicability of a multiple-threshold method for [F-18]fluoro-2-deoxyglucose (FDG) activity in radiation treatment planning was evaluated. Methods and Materials: A total of 32 patients who underwent positron emission and computed tomography (PET/CT) simulation were included; 18 patients had lung cancer, and 14 patients had pharyngeal cancer. For tumors of cm <= 2 to 5 cm, and >5 cm, thresholds were defined as 2.5 standardized uptake value (SUV), 35%, and 20% of the maximum FDG activity, respectively. The cervical and mediastinal lymph nodes with the shortest axial diameter of >= 10 mm were considered to be metastatic on CT (LNCT). The retropharyngeal lymph nodes with the shortest axial diameter >= 5 of mm on CT and MRI were also defined as metastatic. Lymph nodes showing maximum FDG activity greater than the adopted thresholds for radiation therapy planning were designated LNPET-RTP, and lymph nodes with a maximum FDG activity of >= 2.5 SUV were regarded as malignant and were designated LNPET-2.5 SUV. Results: The sizes of gross tumor volumes on PET (GTVPET) with the adopted thresholds in the axial plane were visually well fitted to those of GTV on CT (GTVCT). However, the volumes of GTVPET were larger than those of GTVCT, with significant differences (p < 0.0001) for lung cancer, due to respiratory motion. For lung cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 29, 28, and 34, respectively. For pharyngeal cancer, the numbers of LNCT, LNPET-RTP, and LNPET-2.5 SUV were 14, 9, and 15, respectively. Conclusions: Our multiple thresholds were applicable for delineating the primary target on PET/CT simulation. However, these thresholds were inaccurate for depicting malignant lymph nodes. (C) 2010 Elsevier Inc.
  • Fourth ventricular mixed germ cell tumor demonstrating adipose tissue in a young adult, Akihiro Kuriu, Taro Shimono, Masatomo Kuwabara, Ryuichiro Ashikaga, Makoto Hosono, Takamichi Murakami, JAPANESE JOURNAL OF RADIOLOGY, JAPANESE JOURNAL OF RADIOLOGY, 28(2), 166 - 168, Feb. 2010 , Refereed
    Summary:We report a case of fourth ventricular mixed germ cell tumor (GCT) in a 20-year-old man. Neuroradiological investigations revealed a fourth ventricular hemorrhagic tumor with adipose tissue. We suspected mixed GCT because adipose tissue was seen preoperatively, but mixed GCT occurring after childhood in this location has not previously been reported. We describe herein the imaging findings for mixed GCT and discuss the differential diagnoses of fourth ventricular tumors with adipose tissue.
  • Quality of portal verification radiography using EC-L film in electron beam therapy, Mieko Kawai, T. Tada, M. Hosono, Y. Takada, K. Ishii, T. Nagahata, T. Sahara, Y. Inoue, British Journal of Radiology, British Journal of Radiology, 82(978), 447 - 451, Jun. 2009 , Refereed
    Summary:The quality of the portal verification radiographs produced using the enhanced-contrast localisation (EC-L) Fast cassette-EC-L film (F-EC) combination and the EC-L Oncology cassette-EC-L film (O-EC) combination was investigated fundamentally and clinically. A computerised radiography (CR) system was used for comparison. In the clinic, portal verification radiographs produced for 22 patients with breast cancer were evaluated. The characteristic curves showed that the relative speed was 0.92 for the O-EC combination when the speed of the F-EC combination was defined to be 1, and that the average gradients were 4.76 and 4.35 for the F-EC combination and the O-EC combination, respectively. The smallest visible volumes of Burger's phantom were 50.3 mm3, 60.8 mm3 and 199.5 mm3 for the F-EC combination, the O-EC combination and the CR system, respectively, at an energy of 9 MeV, and 68.4 mm3, 74.2 mm3 and 195 mm3, respectively, at an energy of 12 MeV. In the clinic, both combinations at an energy of 6 MeV and the O-EC combination at 9 MeV showed very poor quality owing to underdensity. However the F-EC combination at an energy of 12 MeV and the O-EC combination at an energy of 15 MeV demonstrated a higher quality. When bremsstrahlung dose passing through the body is sufficient, the quality of portal verification radiography using EC-L film is appropriate for clinical use. © 2009 The British Institute of Radiology.
  • Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions, Masahiro Okada, Taro Shimono, Yoshihiro Komeya, Rina Ando, Yuki Kagawa, Takashi Katsube, Masatomo Kuwabara, Yukinobu Yagyu, Seishi Kumano, Izumi Imaoka, Norio Tsuchiya, Ryuichiro Ashikaga, Makoto Hosono, Takamichi Murakami, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 23(4), 349 - 354, Jun. 2009 , Refereed
    Summary:To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUV(max)), tumor/liver (T/L) SUV(max) ratio, and CT attenuation value (Hounsfield Units; HU) of unenhanced CT obtained from FDG-PET/CT data. We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 +/- A 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 +/- A 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening). All patients underwent PET/CT at 1 h post FDG injection. Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy. An adrenal mass that remained unchanged for over 1 year was the standard used to diagnose adrenal benign lesions. Values of FDG uptake and CT attenuation were measured by placing volumetric regions of interest over PET/CT images. Adrenal uptake of SUV(max) a parts per thousand yen 2.5 was considered to indicate a malignant lesion; SUV(max) < 2.5 was considered to indicate a benign lesion. In further analysis, 1.8 was employed as the threshold for the T/L SUV(max) ratio. Unenhanced CT obtained from PET/CT data was considered positive for adrenal malignant lesions based on a CT attenuation value a parts per thousand yen 10 HU; lesions with a value < 10 HU were considered adrenal benign lesions. Mann-Whitney's U test was used for statistical analyses. SUV(max) in adrenal malignant lesions (7.4 +/- A 3.5) was higher than that in adrenal benign lesions (2.1 +/- A 0.5, p < 0.05). The CT attenuation value of adrenal malignant lesions (27.6 +/- A 11.9 HU) was higher than that of adrenal benign lesions (10.1 +/- A 12.3 HU, p < 0.05). In differentiating between adrenal benign and malignant lesions, a CT threshold of 10 HU corresponded to a sensitivity of 57%, specificity of 94%, accuracy of 74%, positive predictive value of 92% and negative predictive value of 65%. An SUV(max) cut-off value of 2.5 corresponded to a sensitivity of 89%, specificity of 94%, accuracy of 91%, positive predictive value of 94% and negative predictive value of 88%. The T/L SUV(max) ratio was 1.0 +/- A 0.2 for adrenal benign lesions and 4.5 +/- A 3.0 for adrenal malignant lesions. And T/L SUV(max) ratio cut-off value of 1.8 corresponded to a sensitivity of 85%, specificity of 100%, accuracy of 91%, positive predictive value of 100% and negative predictive value of 83%. FDG-PET/CT with additional SUV(max) analysis improves the diagnostic accuracy of adrenal lesions in cancer patients.
  • Ring-shaped lateral ventricular nodules: an incidental finding on brain magnetic resonance imaging, Taro Shimono, Makoto Hosono, Ryuichiro Ashikaga, Seishi Kumano, Izumi Imaoka, Yukinobu Yagyu, Masahiro Okada, Masatomo Kuwabara, Takamichi Murakami, NEURORADIOLOGY, NEURORADIOLOGY, 51(3), 145 - 150, Mar. 2009 , Refereed
    Summary:We have occasionally seen ring-shaped lateral ventricular nodules < 1 cm in diameter during routine brain magnetic resonance imaging (MRI). We investigated retrospectively clinical and MRI findings of the nodules. Review of radiological records was performed for 39,607 patients who underwent brain MRI between January 2001 and April 2008. Nodules were assessed for number, location, shape, and signal intensity, which was determined based on the range of signal intensity from gray to white matter on T1- and T2-weighted imaging. Fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging (DWI), contrast enhancement characteristics, and serial MRI changes of nodules were assessed when available. Nine of 39,607 patients (0.023%) showed the nodules. No symptoms associated with the nodules. Among the nine patients, 11 nodules were identified (one nodule in seven patients (77.8%) and two nodules in two patients (22.2%)). Location was limited to the roof of the body for six nodules (54.5%) and the frontal horn for five patients (45.5%). All nodules (100%) were round and isointense on T1- and T2-weighted imaging. On FLAIR imaging of eight nodules, six (75%) were hyperintense, and two (25%) were isointense. On DWI of seven nodules, all nodules (100%) were isointense. None of seven nodules (0%) examined using postcontrast MRI showed enhancement. None of eight nodules (0%) examined using serial MRI (range, 4-60 months) showed changes in morphology over time. These nodules were incidentally encountered and shared similar MRI features. Although pathological confirmation was lacking in our cases, these nodules may be of nonaggressive nature.
  • Demonstration of Cerebellar Atrophy in Neuroacanthocytosis of 2 Siblings, T. Katsube, T. Shimono, R. Ashikaga, M. Hosono, H. Kitagaki, T. Murakami, AMERICAN JOURNAL OF NEURORADIOLOGY, AMERICAN JOURNAL OF NEURORADIOLOGY, 30(2), 386 - 388, Feb. 2009
    Summary:Neuroacanthocytosis is a rare hereditary disorder characterized by involuntary choreiform movements and erythrocytic acanthocytosis in the peripheral blood. Clinical manifestations of this disorder resemble those of Huntington disease (HID). Neuroimaging features of neuroacanthocytosis are atrophy and signal intensity change of the striata on MR imaging, as in HID. We report herein the cases of 2 siblings with neuroacanthocytosis showing cerebellar atrophy as well as atrophy and signal intensity changes of striata.
  • Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer, Masahiro Okada, Takamichi Murakami, Seishi Kumano, Masatomo Kuwabara, Taro Shimono, Makoto Hosono, Hitoshi Shiozaki, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 23(1), 73 - 80, Jan. 2009 , Refereed
    Summary:To assess whether integrated fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can improve the diagnostic accuracy of metastatic regional lymph nodes (LNs) in esophageal cancer compared with contrast enhanced CT (CECT). We examined 180 consecutive patients with esophageal cancer by integrated PET/CT between April 2006 and March 2007. Eighteen patients (M:F 14:4) underwent radical esophagectomy after evaluations by PET/CT and CECT of 5-7-mm-thick slices 70-80 s after injection. Regional LNs of esophageal cancer were retrospectively reviewed on CECT images by two blinded evaluators on the basis of the following cutoff sizes: 7 mm for all regional LNs (Protocol A), 10 mm for paratracheal LNs (Protocol B), and 7 mm for others. In addition, the maximum standardized uptake value (SUVmax) on PET/CT was evaluated for positive uptake by LNs. Of 210 LNs excised at surgery, 25 were positive and 185 were negative for metastasis at pathology. The PET/CT images identified 15 true-positive and 184 truenegative LNs, whereas CECT identified 15 true positives and 176 true negatives in Protocol A, and 14 true positives and 180 true negative in Protocol B. The sensitivity, specificity, accuracy, positive, and negative predictive values of PET/CT were respectively 60.0%, 99.5%, 94.8%, 93.8%, and 94.8%, whereas those of CECT were 60.0%, 95.1%, 91.0%, 62.5%, and 94.6% (Protocol A) and 56.0%, 97.3%, 92.4%, 73.7%, and 94.2% (Protocol B). A comparison of the two CECT protocols revealed fewer false-positive LNs in Protocol B, but slightly lower sensitivity in Protocol B than in Protocol A. Substantial numbers of false-positive LNs were determined by CECT in the paratracheal regions (6 of 9, 66.7%) and CECT revealed central necrosis in 4 of 15 (26.7%) true-positive LNs > 1.8 cm. The mean SUVmax on PET/CT was 2.9 (range 1.7-5.5) in true-positive LNs. The smallest LN metastasis detectable by PET/CT was 6 mm. Integrated PET/CT improves the PPV of regional LNs when compared with CECT.
  • Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system, Mitsuru Okubo, Yasumasa Nishimura, Kiyoshi Nakamatsu, Masahiko Okumura, Toru Shibata, Shuichi Kanamori, Kouhei Hanaoka, Makoto Hosono, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 22(7), 579 - 586, Aug. 2008 , Refereed
    Summary:Objective To determine an appropriate threshold value for delineation of the target in positron emission tomography (PET) and to investigate whether PET can delineate an internal target volume (ITV), a series of phantom studies were performed. Methods An ellipse phantom (background) was filled with 1028 Bq/ml of [(18)F] fluoro-2-deoxyglucose ((18)FDG), and six spheres of 10 mm, 13 mm, 17 mm, 22 mm, 28 mm, and 37 mm in diameter inside it were filled with (18)FDG activity to achieve source-to-background (S/B) ratios of 10, 15, and 20. In static phantom experiments, an appropriate threshold value was determined so that the size of PET delineation fits to an actual sphere. In moving phantom experiments with total translations of 10 mm, 20 mm, and 30 mm and a period of oscillation of 4s, the maximum size of PET delineation with the appropriate threshold value was measured in both the axial and sagittal planes. Results In the static phantom experiments, the measured maximum (18)FDG activities of spheres of less than 22 mm were lower than 80% of the injected (18)FDG activity, and those for the larger spheres ranged from 90% to 110%. Appropriate threshold values determined for the spheres of 22 mm or more ranged from 30% to 40% of the maximum (18)FDG activity, independent of the S/B ratio. Therefore, we adopted an appropriate threshold value as 35% of the measured maximum (18)FDG activity. In moving phantom experiments, the maximum (18)FDG activity of spheres decreased significantly, dependent on the movement distance. Although the sizes of PET delineation with 35% threshold value tended to be slightly smaller (< 3 mm) than the actual spheres in the axial plane, the longest sizes in the sagittal plane were larger than the actual spheres. Conclusions When a threshold value of 35% of the measured maximum (18)FDG activity was adopted, the sizes of PET delineation were almost the same for static and moving phantom spheres of 22 mm or more in the axial plane. In addition, PET images have the potential to provide an individualized ITV.
  • "Prominent ear sign" on diffusion-weighted magnetic resonance imaging in relapsing polychondritis, Masatomo Kuwabara, Taro Shimono, Mami Toyomasu, Mitsuaki Shioyama, Yoshiyuki Mitsui, Eiji Yoshinaga, Akira Kawada, Makoto Hosono, Takamichi Murakami, Susumu Kusunoki, RADIATION MEDICINE, RADIATION MEDICINE, 26(7), 438 - 441, Aug. 2008 , Refereed
    Summary:Relapsing polychondritis is a rare autoimmune disease characterized by recurrent inflammation of cartilage in multiple sites of the body, including the auricles. Central nervous system involvement appears rare. We encountered a case of relapsing polychondritis with encephalitis that could be diagnosed by the unique appearance of the auricle with signal hyperintensity on diffusion-weighted magnetic resonance imaging.
  • Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas, Teruaki Yoh, Makoto Hosono, Yoshihiro Komeya, Sung-Woon Im, Ryuichiro Ashikaga, Taro Shimono, Norio Tsuchiya, Masahiro Okada, Kazushi Hanada, Yukinobu Yagyu, Yasumasa Nishimura, Takamichi Murakami, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 22(6), 513 - 519, Jul. 2008 , Refereed
    Summary:Objective The objective of our study was to evaluate diagnostic ability and features of quantitative indices of three modalities: uptake rate on norcholesterol scintigraphy, computed tomography (CT) attenuation value, and fat suppression on chemical-shift magnetic resonance imaging (MRI) for characterizing adrenal adenomas. Methods Image findings of norcholesterol scintigraphy, CT, and MRI were reviewed for 78 patients with functioning (n = 48) or nonfunctioning (n = 30) adrenal masses. The norcholesterol uptake rate, attenuation value on unenhanced CT, and suppression on in-phase to opposed-phase MRI were measured for adrenal masses. Results The norcholesterol uptake rate, CT attenuation value, and MR suppression index showed the sensitivity of 60%, 82%, and 100%, respectively, for functioning adenomas of < 2.0 cm, and 96%, 79%, and 67%, respectively, for those of >= 2.0 cm. A statistically significant correlation was observed between size and norcholesterol uptake, and between CT attenuation value and MR suppression index. Regarding norcholesterol uptake, the adenoma-to-contralateral gland ratio was significantly higher in cortisol releasing than in aldosterone-releasing adenomas. Conclusions The norcholesterol uptake rate was reliable for characterization of adenomas among adrenal masses of >= 2.0 cm. CT attenuation value and MR suppression index were well correlated with each other, and were useful regardless of mass size.
  • Comparison between one-route and two-route injection for liver and aortic enhancement using MDCT, Masahiro Okada, Takamichi Murakami, Seishi Kumano, Izumi Imaoka, Taro Shimono, Ryuichiro Ashikaga, Makoto Hosono, AMERICAN JOURNAL OF ROENTGENOLOGY, AMERICAN JOURNAL OF ROENTGENOLOGY, 190(6), W323 - W326, Jun. 2008 , Refereed
    Summary:OBJECTIVE. The purpose of our study was to evaluate whether simultaneous injection into cubital veins bilaterally at one half of the standard injection rate achieves similar hepatic and aortic enhancement on MDCT as the conventional injection rate into a single cubital vein. MATERIALS AND METHODS. Thirty-two patients underwent multiphase MDCT because they were suspected of having a hepatic tumor. Patients were assigned to one of the following two groups: group A, 100 mL of 370 mg I/mL of contrast medium injected into a unilateral cubital vein (one-route) via a 20-gauge cannula at a rate of 4 mL/s; or group B, 50 mL of contrast medium injected into the cubital veins bilaterally (two-route) via 24-gauge cannulas at 2 mL/s. Peak contrast enhancement of the liver and abdominal aorta for groups A and B was measured using regions of interest and compared; arrival time of the contrast media was also compared using a bolus-tracking system. Analysis was performed using Wilcoxon's signed rank test. RESULTS. Peak aortic enhancement of groups A and B was 367 +/- 67 H and 361 +/- 113 H (p = 0.61, not significant), respectively, and peak hepatic enhancement of groups A and B was 56 +/- 11 H and 56 +/- 16 H (p = 0.88, not significant), respectively. Mean arrival time to the aorta of group B (19.4 +/- 3.4 seconds) was significantly later compared with that of group A (15.5 +/- 3.5 seconds) (p = 0.005). CONCLUSION. The slower two-route injection produced the same aortic and hepatic enhancement as the faster one-route method with faster injection, but the arrival time of the contrast medium was later using the two-route method.
  • Discordance of motion artifacts on magnetic resonance imaging in Creutzfeldt-Jakob disease: comparison of diffusion-weighted and conventional imaging sequences, Taro Shimono, Takahiro Tsuboyama, Masatomo Kuwabara, Sung-woon Im, Yukinobu Yagyu, Izumi Imaoka, Ryuichiro Ashikaga, Makoto Hosono, Takamichi Murakami, RADIATION MEDICINE, RADIATION MEDICINE, 26(3), 151 - 155, Apr. 2008 , Refereed
    Summary:Purpose. Motion artifact is problematic in the diagnosis of Creutzfeldt-Jakob disease (CJD) because of dementia. The purpose was to compare the occurrence of this artifact between a diffusion-weighted (DW) magnetic resonance ( MR) imaging sequence and conventional sequences. Materials and methods. Ten MR examinations comprising T2- weighted, T1- weighted, DW, and fl uidattenuated inversion recovery imaging in seven CJD patients were retrospectively evaluated. The occurrence of motion artifacts on each sequence were assessed, and the examination was classifi ed into four groups as follows: group A, motion artifact not revealed on DW imaging but revealed on one or more other sequences; group B, revealed on DW imaging and one or more other sequences; group C, not revealed on any sequences; and group D, revealed on DW imaging but not on any other sequences. Results. The 10 MR examinations were classifi ed as eight group A ( 80%), one B ( 10%), one C ( 10%), and zero D ( 0%). Conclusion. Motion artifacts are likely to occur in any conventional imaging sequences in CJD, but the fastimaging ability of DW imaging can reduce this artifact. The combination of an absence of motion artifact on DW imaging and the presence on conventional sequences may be one of the frequent fi ndings of CJD.
  • Regional cerebral blood flow in the assessment of major depression and Alzheimer's disease in the early elderly, K Hanada, M Hosono, T Kudo, Y Hitomi, Y Yagyu, E Kirime, Y Komeya, N Tsujii, K Hitomi, Y Nishimura, NUCLEAR MEDICINE COMMUNICATIONS, NUCLEAR MEDICINE COMMUNICATIONS, 27(6), 535 - 541, Jun. 2006 , Refereed
    Summary:Background Alzheimer's disease and major depression are representative diseases that present forgetfulness and a depressive mood. It is often difficult to make a differential diagnosis between the two in the initial phase. Aim To evaluate the differential diagnosis method using regional cerebral blood flow patterns with a three-dimensional stereotactic surface projection technique. Methods Twenty early-elderly patients with mild and moderate forgetfulness were studied. Among them, 10 were diagnosed as having major depression (the MD group) and the other 10 as having Alzheimer's disease (the AD group). All patients underwent cerebral perfusion single photon emission computed tomography (SPECT) with [I-123] iodoamphetamine. A z-score was calculated for each pixel of the cerebral surface. Twenty-one circular regions of interest (ROIs) were placed on the z-score map. The significance of the statistical difference in ROI values between the two groups was determined by using the two-sided Mann-Whitney U-test. Results The z-scores for the lateral parietal, lateral temporal, bilateral precuneus and bilateral posterior cingulate gyrus were significantly reduced in the AD group compared with those in the MD group. The z-scores for the lateral frontal, left thalamus and bilateral medial frontal regions were significantly lower in the MD group than in the AD group. Conclusion Our study demonstrated a difference in regional cerebral blood flow patterns between the early elderly with Alzheimer's disease and those with major depression. All patients were classified into the appropriate categories using discriminant analysis and z-scores of frontal and parietal regions. Brain perfusion SPECT was a useful tool for the differential diagnosis between Alzheimer's disease and major depression.
  • Influence of different pneumoperitoneal pressures on tumor cell distribution in rats, H Nakada, H Ishida, D Hashimoto, T Mori, M Hosono, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 19(4), 563 - 568, Apr. 2005
    Summary:Background: The effect of different pneumoperitoneal pressures on tumor cell distribution was investigated. Methods: Donryu rats were allocated to receive carbon dioxide pneumoperitoneum at 5, 10, or 15 mmHg for 60 min or to serve as a control. During the procedure, each rat was inoculated with radiolabeled ascites hepatoma cells via the portal vein (experiment 1) or femoral vein (experiment 2). In both experiments, the rats were killed 30, 60, 90, or 120 min after tumor cell inoculation, and the liver and lungs were extirpated for radioactivity count (n = 5 or 6 for each time point in each group). Results: In experiment 1, the percentage of injected dose (% ID) for the liver was greater than for the other three groups 120 min after tumor cell inoculation. There were no significant differences in the %IDs of the lungs at any time point among the groups. In experiment 2, there were no significant differences in the %IDs of the liver and lungs at any time point among the groups. Conclusions: These results Suggest that an elevated insufflation pressure facilitates the location of intraportally injected tumor cells in the liver, and that pulmonary location of the tumor cells may not depend on insufflation pressures in this animal model.
  • A new bifunctional chelating agent conjugated with monoclonal antibody and labelled with technetium-99m for targeted scintigraphy: 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecane, AK Mishra, P Panwar, M Hosono, K Chuttani, P Mishra, RK Sharma, JF Chatal, JOURNAL OF DRUG TARGETING, JOURNAL OF DRUG TARGETING, 12(9-10), 559 - 567, Oct. 2004 , Refereed
    Summary:Objective : The purpose of this study was to obtain the convenient, synthetically useful bifunctional chelating agent, 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecane, and to apply it to stable 99m Tc-labelling of monoclonal antibodies (mAbs). Methods : The chelate was synthesised by reaction of nitrobenzyl malonate and triethylenetetramine followed by alkylation by reacting with bromoacetic acid at pH 10. The amino group was converted to isothiocyanato derivative by reacting with thiophosgene at pH 2.0. Conjugation with mAbs [(anti-carcinoembryonic antigen (CEA) and anti-epidermal growth factor receptor (EGFr)] was performed at pH 8.4 using trisodium phosphate solution by incubating at 37degreesC for 1 h and subjected to purification on size exclusion chromatography. Results : When radioimmunoconjugates were labelled with Tc-99m, the specific activity of immunoconjugates was 20-30 mCi/mg of protein and their immunoreactivity exceeded 80%. The stability in serum indicated that the metal remained bound to antibodies. Biodistribution studies in athymic mice grafted with U-87 human glioblastoma multiforme and MDA-MB-468 human breast carcinoma tumours revealed significant localisation of Tc-99m-labelled antibodies in tumours and reduced accumulation in normal organs. Conclusion : This bifunctional chelating agent is promising for immunoscintigraphy because of good tumour-to-normal organ contrast.
  • Extraosseous accumulation of Tc-99m-MDP in lymph node metastases of small cell carcinoma of the esophagus, T Takahashi, K Machida, N Honda, M Hosono, S Oku, H Osada, O Murata, K Nishimura, H Ohno, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 18(2), 157 - 160, Apr. 2004 , Refereed
    Summary:We report a case of esophageal carcinoma that showed extraosseous accumulation of Tc-99m-MDP in lymph node metastases to the cervical and paracardial lymph nodes. There are few cases showing abnormal extraosseous accumulation of Tc-99m-MDP in esophageal cancer lesion. The patient was a 53-year-old man with advanced esophageal cancer. Bone scintigraphy demonstrated extraosseous accumulations in left supraclavicular and paracardial lymph node metastases. The histopathological diagnosis was small cell carcinoma of the esophagus, which is a rare disease with aggressive behavior and poor prognosis. Our patient underwent 2 courses of systemic chemotherapy (CDDP + VP16), but died of rapidly growing systemic metastases 5 months after the initial treatment.
  • Extraosseous accumulation of 99mTc-MDP in lymph node metastases of small cell carcinoma of the esophagus, Takeo Takahashi, Kikuo Machida, Norinari Honda, Makoto Hosono, Shinya Oku, Hisato Osada, Osamu Murata, Keiichiro Nishimura, Hitoshi Ohno, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 18(2), 157 - 160, 2004
    Summary:We report a case of esophageal carcinoma that showed extraosseous accumulation of 99mTc-MDP in lymph node metastases to the cervical and paracardial lymph nodes. There are few cases showing abnormal extraosseous accumulation of 99mTc-MDP in esophageal cancer lesion. The patient was a 53-year-old man with advanced esophageal cancer. Bone scintigraphy demonstrated extraosseous accumulations in left supraclavicular and paracardial lymph node metastases. The histopathological diagnosis was small cell carcinoma of the esophagus, which is a rare disease with aggressive behavior and poor prognosis. Our patient underwent 2 courses of systemic chemotherapy (CDDP + VP16), but died of rapidly growing systemic metastases 5 months after the initial treatment.
  • Three-dimensional stereotactic surface projection of brain perfusion SPECT improves diagnosis of Alzheimer's disease, N Honda, K Machida, T Matsumoto, H Matsuda, E Imabayashi, J Hashimoto, M Hosono, Y Inoue, K Koizumi, S Kosuda, T Momose, Y Mori, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 17(8), 641 - 648, Dec. 2003 , Refereed
    Summary:Objectives: Alzheimer's disease (AD) is diagnosed by either inspection of the brain perfusion SPECT, or three-dimensional stereotactic surface display (3D-SSP). The purpose was to compare diagnostic performances of these methods. Methods: Sixteen nuclear medicine physicians independently interpreted Tc-99m-ECD SPECT in one session and SPECT with 3D-SSP in another session without clinical information for 50 studies of AD patients and 40 studies of healthy volunteers. Probabilities of AD were reported according to a subjective scale from 0% (normal) to 100% (definite AD). Receiver operating characteristics curves were generated to calculate areas under the ROC curves (Az's) for the inspection as well as for an automated diagnosis based on a mean Z value in the bilateral posterior cingulate gyri in a 3D-SSP template. Results: Mean Az for visual interpretation of SPECT alone (0.679 +/- 0.058) was significantly smaller than that for visual interpretation of both SPECT and 3D-SSP (0.778 +/- 0.060). Az for the automated diagnosis (0.883 +/- 0.037) was. significantly greater than that for both modes of visual interpretation. Conclusions: 3D-SSP enhanced performance of the nuclear medicine physicians inspecting SPECT. Performance of the automated diagnosis exceeded that of the physicians inspecting SPECT with and without 3D-SSP.
  • Distribution of intrasplenically injected colon cancer cells following pneumoperitoneum in mice, H Ishida, H Nakada, Takeuchi, I, M Yokoyama, T Okita, D Hashimoto, M Hosono, T Mori, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 17(8), 1278 - 1282, Aug. 2003
    Summary:Background: Few studies have examined tumor cell distribution following laparoscopic surgery for colorectal cancer. We examined the effect of carbon dioxide pneumoperitoneum on the distribution of intrasplenically injected colon cancer cells in mice. Methods: Mice were intrasplenically injected with 2 x 10(4) colon 26 cells labeled with (11I) In-oxine and were randomized to undergo pneumoperitoneum at 10 mmHg for 30 min or to receive no treatment other than anesthesia. Radioactivity of the liver, lungs, and spleen was measured 30, 60, 90, or 150 min following tumor inoculation. Results: The dynamic changes in the hepatic radioactivity were not similar between groups. However, the values were not significantly different at any time point. The radioactivity of lungs was extremely low in both groups throughout the experimental period. Conclusions: Pneumoperitoneum does not appear to cause the accumulation of intraportally spreading tumor cells in the liver, but it may affect the dynamic changes of tumor cells. Also, tumor cell localization in the lungs is negligible in both pneumopentoneum and control groups.
  • Visualization of fatal hepatic necrosis on bone scan, M Hosono, K Machida, N Honda, T Takahashi, N Ohtawa, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(5), 398 - 399, May 2003
  • Spontaneous regression of chest wall malignant lymphoma - Presentation on Ga-67 imaging, K Machida, Y Inoue, N Honda, M Hosono, T Takahashi, A Kashimada, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(5), 405 - 407, May 2003
  • Visualization of fatal hepatic necrosis on bone scan, M Hosono, K Machida, N Honda, T Takahashi, N Ohtawa, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(5), 398 - 399, May 2003 , Refereed
  • Spontaneous regression of chest wall malignant lymphoma - Presentation on Ga-67 imaging, K Machida, Y Inoue, N Honda, M Hosono, T Takahashi, A Kashimada, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(5), 405 - 407, May 2003 , Refereed
  • Adult Embryonal Rhabdomyosarcoma in Axilla, Takeo Takahashi, Kikuo Machida, Norinari Honda, Makoto Hosono, Akio Kashimada, Osamu Murata, Hisato Osada, Keiichiro Nishimura, Radiation Medicine - Medical Imaging and Radiation Oncology, Radiation Medicine - Medical Imaging and Radiation Oncology, 21(3), 135 - 137, May 2003 , Refereed
    Summary:A case of embryonal rhabdomyosarcoma (RMS) arising from an axillary space is described. RMS is one of the most common soft-tissue neoplasms in children, but adult embryonal RMS is rare. The patient was a 55-year-old man with a tumor of the left axillary area. RMS arising from an axillary area is also uncommon. The histological diagnosis was embryonal RMS. He received irradiation combined with chemotherapy (VAC: VCR, act-D, CPA) for the primary and metastatic lesions, obtained complete remission, and has remained disease-free for over four years as of this report.
  • Gallium-67 demonstration of extensive soft-tissue involvement of multiple myeloma, M Hosono, K Machida, Y Inoue, N Honda, T Takahashi, A Kashimada, N Ohtawa, H Ohno, T Yamano, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 17(1), 69 - 72, Feb. 2003 , Refereed
    Summary:A 46-year-old woman with multiple myeloma presented with neurological symptoms in the right upper extremity. After MR imaging of the cervical spine failed to show the cause of her symptoms, Ga-67 scintigraphy demonstrated increased uptake in multiple areas including the right supraclavicular region and bilateral lower extremities. Histology of the specimen obtained from the left thigh proved soft-tissue involvement of myeloma, and extensive extramedullary involvement was diagnosed. Radiotherapy to the right supraclavicular mass relieved her symptoms. Although Ga-67 scintigraphy is generally considered of limited value in multiple myeloma, this modality contributed to the development of an appropriate strategy in this patient with extensive extramedullary involvement.
  • Intense Ga-67 accumulation in pure primary mediastinal seminomas, M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, O Murata, H Osada, N Ohtawa, S Itoyama, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(1), 25 - 28, Jan. 2003
    Summary:The authors examined three patients with pure primary mediastinal seminomas, all of whom had marked Ga-67 uptake on scintigraphy. The unusual presentation of sclerotic bone metastases with remarkable extraosseous soft tissue involvement was observed in one patient. Another had a seminoma associated with a multiloculated thymic cyst, which is a rare lesion.
  • Gallium-67 demonstration of extensive soft-tissue involvement of multiple myeloma, Makoto Hosono, Kikuo Machida, Yusuke Inoue, Norinari Honda, Takeo Takahashi, Akio Kashimada, Nobuyuki Ohtawa, Hitoshi Ohno, Takafumi Yamano, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 17(1), 69 - 72, 2003
    Summary:A 46-year-old woman with multiple myeloma presented with neurological symptoms in the right upper extremity. After MR imaging of the cervical spine failed to show the cause of her symptoms, Ga-67 scintigraphy demonstrated increased uptake in multiple areas including the right supraclavicular region and bilateral lower extremities. Histology of the specimen obtained from the left thigh proved soft-tissue involvement of myeloma, and extensive extramedullary involvement was diagnosed. Radiotherapy to the right supraclavicular mass relieved her symptoms. Although Ga-67 scintigraphy is generally considered of limited value in multiple myeloma, this modality contributed to the development of an appropriate strategy in this patient with extensive extramedullary involvement.
  • Intense Ga-67 accumulation in pure primary mediastinal seminomas, M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, O Murata, H Osada, N Ohtawa, S Itoyama, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 28(1), 25 - 28, Jan. 2003 , Refereed
    Summary:The authors examined three patients with pure primary mediastinal seminomas, all of whom had marked Ga-67 uptake on scintigraphy. The unusual presentation of sclerotic bone metastases with remarkable extraosseous soft tissue involvement was observed in one patient. Another had a seminoma associated with a multiloculated thymic cyst, which is a rare lesion.
  • Quantitative lung perfusion scintigraphy and detection of intrapulmonary shunt in liver cirrhosis, M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, H Osada, O Murata, N Ohtawa, K Nishimura, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 16(8), 577 - 581, Dec. 2002
    Summary:Objective: Frequent association between liver cirrhosis and hypoxemia. has been well documented. It is mostly attributable to intrapulmonary shunt due to dilation of pulmonary vasculature. We performed quantitative lung perfusion scintigraphy to detect an intrapulmonary shunt in cirrhosis patients. Methods: Prior to injection, Tc-99m MAA was applied to thin layer chromatography for quality control. Three cirrhosis patients who had hypoxemia were examined as well as 11 control subjects. After i.v. injection of Tc-99m MAA, whole body anterior and posterior images were taken at 5 min in patients with cirrhosis and at 8 time points up to 60 min in control subjects. Regions of interest were placed at the bilateral lungs and the whole body, and pulmonary accumulation was calculated. Results: All the control subjects demonstrated more than 90% of radioactivity in the lungs until 20 min. In contrast, all the patients showed values less than 80% at 5 min. In the cirrhosis patients with hypoxemia, the presence of intrapulmonary shunt was confirmed on quantitative lung perfusion scan. In control subjects, pulmonary accumulation of Tc-99m MAA dropped as a function of time and became less than 90% after 30 min. Conclusion: The timing of measurements is essential in evaluating intrapulmonary shunt.
  • Quantitative lung perfusion scintigraphy and detection of intrapulmonary shunt in liver cirrhosis, M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, H Osada, O Murata, N Ohtawa, K Nishimura, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 16(8), 577 - 581, Dec. 2002 , Refereed
    Summary:Objective: Frequent association between liver cirrhosis and hypoxemia. has been well documented. It is mostly attributable to intrapulmonary shunt due to dilation of pulmonary vasculature. We performed quantitative lung perfusion scintigraphy to detect an intrapulmonary shunt in cirrhosis patients. Methods: Prior to injection, Tc-99m MAA was applied to thin layer chromatography for quality control. Three cirrhosis patients who had hypoxemia were examined as well as 11 control subjects. After i.v. injection of Tc-99m MAA, whole body anterior and posterior images were taken at 5 min in patients with cirrhosis and at 8 time points up to 60 min in control subjects. Regions of interest were placed at the bilateral lungs and the whole body, and pulmonary accumulation was calculated. Results: All the control subjects demonstrated more than 90% of radioactivity in the lungs until 20 min. In contrast, all the patients showed values less than 80% at 5 min. In the cirrhosis patients with hypoxemia, the presence of intrapulmonary shunt was confirmed on quantitative lung perfusion scan. In control subjects, pulmonary accumulation of Tc-99m MAA dropped as a function of time and became less than 90% after 30 min. Conclusion: The timing of measurements is essential in evaluating intrapulmonary shunt.
  • Interobserver variation in diagnosis of dementia by brain perfusion SPECT, Norinari Honda, Kikuo Machida, Makoto Hosono, Tohru Matsumoto, Hiroshi Matsuda, Motoo Oshima, Kiyoshi Koizumi, Shigeru Kosuda, Toshimitsu Momose, Yutaka Mori, Jun Hashimoto, Yuji Shimizu, Radiation Medicine - Medical Imaging and Radiation Oncology, Radiation Medicine - Medical Imaging and Radiation Oncology, 20(6), 281 - 289, Nov. 2002 , Refereed
    Summary:Brain perfusion SPECT (BP-SPECT) has characteristic patterns of abnormality, enabling the differential diagnosis of dementia. The purpose of this study was to measure interobserver variations in the diagnosis of dementia using BP-SPECT. BP-SPECT images of 57 cases, 19 of Alzheimer's disease (AD), eight of multi-infarct dementia (MID), three of Pick's disease, five of other dementias, and 22 normal controls, were interpreted by ten nuclear medicine physicians with varying levels of experience. Brain MR images of the cases were then interpreted apart from SPECT. The physicians independently rated all of the diagnoses listed beforehand according to a five-point scale, with clinical information provided. Receiver-operating characteristic (ROC) curves and the area under the ROC curve (Az) were calculated. Az varied from 0.48 to 0.87. Mean Az's were significantly larger (p< 0.05) in the diagnosis by SPECT than in that by MRI (0.715 and 0.629 for dementia vs. normal, 0.670 and 0.560 for AD or MID vs. normal, 0. 610 and 0.416 for AD vs. normal, and 0.672 and 0.412 for AD vs. MID, respectively). Considerable interobserver variation was present in BP-SPECT interpretation. BP-SPECT may be more effective for the evaluation of dementia than MRI when the same nuclear medicine physicians interpret both images.
  • Scintigraphic findings of MALT lymphoma of the thyroid, N Honda, K Machida, Y Inoue, M Hosono, T Takahashi, A Kashimada, H Osada, O Murata, M Ohmichi, W Watanabe, T Okada, S Itoyama, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 16(4), 289 - 292, Jun. 2002 , Refereed
    Summary:Mucosa-associated lymphoid tissue (MALT) lymphoma has been established as a distinct entity among non-Hodgkin's lymphomas, and the most common primary site is the stomach. We describe scintigraphic findings in a patient with MALT lymphoma. of the thyroid. A 71-year-old woman with Hashimoto's thyroiditis suffered from rapid cervical swelling, and ultrasonography and CT revealed a thyroid nodule. The nodule showed accumulation of Tc-99m pertechnetate comparable to the surrounding thyroid tissue, mimicking a benign nodule. Both Ga-67 and Tl-201 imaging visualized the lesion as an increased uptake area. After radiotherapy, abnormally increased uptake disappeared on 67Ga images, which predicted a favorable outcome. MALT lymphoma of the thyroid may be visualized as a warm nodule on Tc-99m pertechnetate scintigraphy.
  • Increased insufflation pressure enhances the development of liver metastasis in a mouse laparoscopy model - Possible mechanisms, H Ishida, D Hashimoto, H Nakada, Takeuchi, I, T Hoshino, N Murata, Y Idezuki, M Hosono, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 16(2), 331 - 335, Feb. 2002
    Summary:Background: The effect of different insufflation pressures and durations of CO2 pneumoperitoneum on the growth of liver metastasis was investigated in a mouse model. The possible mechanisms involved in the pressure-related enhancement of liver metastasis were also examined. Methods: Mice inoculated intraportally with colon 26 cells underwent CO, pneumoperitoneum at different pressures (5, 10, or 15 mmHg) for 30 or 60 min, or received no treatment other than tumor cell inoculation (control). The subsequent growth of liver mestastases was examined. Mice injected intraportally with In-111-oxine-labeled colon 26 cells underwent pneumoperitoneum at three different pressures or served as controls. The radioacitivity of the liver was determined to evaluate tumor accumulation in the liver. Mice received pneumoperitoneum at three different pressures or received trocar placement alone. Changes in plasma interleukin-6 levels were determined. Results: The growth of liver metastases on day 14 was influenced by increased insufflation pressures (p<0.05) rather than the prolonged duration of pneumoperitoneum without significant interaction. The 15-mmHg pneumoperitoneum group showed a higher (p<0.05) accumulation of radioactivity in the liver compared with the 5-mmHg pneumoperitoneum group and controls. Pneumoperitoneum groups with 5 and 10 mmHg showed higher (p<0.05) peak levels of IL-6 compared with controls. Conclusions: An elevated insufflation pressure plays an important role in the enhancement of liver metastases, and this pressure-related adverse effect may be partly relevant to facilitating accumulation of tumor cells in the liver.
  • Non-invasive quantitative monitoring of cerebral blood flow in aneurysmal subarachnoid haemorrhage with Tc-99m-ECD, M Hosono, K Machida, T Matsui, N Honda, T Takahashi, S Dei, A Kashimada, Y Shimizu, H Osada, M Ohmichi, T Asano, NUCLEAR MEDICINE COMMUNICATIONS, NUCLEAR MEDICINE COMMUNICATIONS, 23(1), 5 - 11, Jan. 2002
    Summary:The purpose of this prospective study was to detect symptomatic cerebral vasospasm in aneurysmal subarachnoid haemorrhage (SAH) by a non-invasive mean cerebral blood flow (mCBF) quantification using Tc-99m-ethyl cysteinate dimer. Measurement of mCBF without blood sampling and single photon emission tomography (SPECT) were performed at 1 and 7 days after surgery in 35 consecutive SAH patients, of whom 16 were examined at day 30 as well. A decrease in mCBF of more than 10% on day 7 versus day 1 was considered to indicate vasospasm. On visual interpretation of SPECT, a perfusion decrease which appeared newly on day 7 was considered to indicate vasospasm. In total, nine of 35 patients had cerebral vasospasm confirmed by computed tomography (CT) and/or angiography. The mCBF measurement showed a 77.8% (7/9) sensitivity, a 88.5% (23/26) specificity, a 70.0% (7/10) positive predictive value, and a 92.0% (23/25) negative predictive value. SPECT yielded a 33.3% (3/9) sensitivity, a 73.1% (19/26) specificity, a 30.0% (3/10) positive predictive value, and a 76.0% (19/25) negative predictive value. On SPECT, decreased perfusion was observed in most of the patients at clipping sites, which might represent post-operative transient abnormal perfusion and should not be read as vasospasm. In conclusion, thus mCBF measurement is more accurate than visual interpretation of SPECT for detecting vasospasm. ((C) 2002 Lippincott Williams & Wilkins).
  • Oligodendroglioma with cystic component in infant, Makoto Hosono, Kikuo Machida, Toru Matsui, Norinari Honda, Takeo Takahashi, Akio Kashimada, Hisato Osada, Takao Asano, Shinji Itoyama, Computerized Medical Imaging and Graphics, Computerized Medical Imaging and Graphics, 25(4), 361 - 365, Jul. 2001
    Summary:In this report, we examine the case of a 6-year-old girl with a mixed oligodendroglioma demonstrating uncommon neuroradiological images. CT and MR showed an intratemporal mass with multilocular cystic formation and intratumoral massive calcification, suggestive either of astrocytoma, dysembryoplastic neuroepithelial tumor, or ganglioglioma as a presumptive differential diagnosis. The tumor was almost completely removed. Post-operative histological examination revealed a mixed oligodendroglioma with a small component of astrocytoma. The combination of radiotherapy and chemical treatment was supplemented. Copyright © 2001 Elsevier Science Ltd.
  • Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer, MN Hosono, M Hosono, AK Mishra, A Faivre-Chauvet, E Gautherot, J Barbet, FF Knapp, JF Chatal, ANNALS OF NUCLEAR MEDICINE, ANNALS OF NUCLEAR MEDICINE, 14(3), 173 - 179, Jun. 2000 , Refereed
    Summary:We have evaluated the potential of Re-188-labeled monoclonal antibodies (MAbs) modified with 2-iminothiolane (2IT) for targeting small-cell lung cancer (SCLC). Radiolabeled MAbs NK1NBL1 and C218 recognizing neural cell adhesion molecule were injected i.v. into athymic mice inoculated with human SCLC tumors, and the biodistribution was examined. NK1NBL1 localized in the tumors better than C218. Re-188-labeled MAbs cleared from the blood faster than I-125-labeled counterparts, resulting in higher tumor-to-blood ratios. In conclusion, the Re-188-labeled MAbs are attractive candidates for imaging and therapy of SCLC.
  • Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten, M Hosono, MN Hosono, F Kraeber-Bodere, A Devys, P Thedrez, A Faivre-Chauvet, E Gautherot, J Barbet, JF Chatal, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 40(7), 1216 - 1221, Jul. 1999 , Refereed
    Summary:The "affinity enhancement system," a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody. Methods: Antineural cell adhesion molecule/antihistamine bispecific antibody NK1NBL1-679 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NCI-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later I-125-labeled bivalent histamine hapten. I-125-labeled intact NK1NBL1 was injected into other groups of mice. Biodistributions were examined as a function of time. Results: In mice of the two-step targeting, tumor uptake was 2.5 +/- 0.2, 3.2 +/- 0.4, 6.4 +/- 2.0, 7.2 +/- 2.7, 6.1 +/- 2.1 and 2.2 +/- 0.4 %ID/g at 5, 30 min, 5, 24, 48 and 96 h, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 +/- 1.1, 10.8 +/- 13.2 and 4.6 +/- 4.7, respectively, at 5 h, whereas I-125-labeled NK1NBL1 showed a tumor uptake of 5.7 +/- 0.4 %ID/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 +/- 0.1, 1.1 +/- 0.2 and 0.9 +/- 0.1, respectively, at 5 h. These results were confirmed by autoradiographic studies, which demonstrated clear tumor-to-normal tissue contrast. Dosimetry showed that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1. Conclusion: This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer.
  • Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten, M Hosono, MN Hosono, F Kraeber-Bodere, A Devys, P Thedrez, M Fiche, E Gautherot, J Barbet, JF Chatal, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 39(9), 1608 - 1613, Sep. 1998 , Refereed
    Summary:The purpose of this study was to evaluate biodistributions and absorbed doses of anti-carcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA)-indium (anti-DTPA-In) bispecific monoclonal antibody (BsMAb) F6-734 and I-125-labeled DTPA-indium dimer hapten (I-125-di-DTPA-In hapten) in athymic mice xenografted with human medullary thyroid cancer. Methods: Bispecific monoclonal antibodies F6-679 (anti-CEA/antihistamine) and G7A5-734 (antimelanoma/anti-di-DTPA-In) were used as irrelevant BsMAbs. Athymic mice inoculated with TT medullary thyroid cancer cells expressing CEA were administered BsMAbs F6-734, F6-679 or G7A5-734 and then, 48 hr later, I-125-di-DTPA-In hapten. Iodine-125-labeled F6 F(ab')(2) fragment was injected into other groups of mice. Biodistributions were examined at 30 min and 5, 24, 48 and 96 hr after injection of I-125-di-DTPA-In hapten or I-125-labeled F6 F(ab'),. Results: In mice injected with BsMAb F6-734 and I-125-di-DTPA-In hapten, tumor uptake was 9.1% +/- 2.1%, 8.7% +/- 3.5%, 8.0% +/- 2.3%, 5.1% +/- 0.9% and 3.5% +/- 1.5% of the injected dose/g at 30 min and 5, 24, 48 and 96 hr, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 37.0 +/- 12.5, 32.3 +/- 10.9 and 10.4 +/- 2.7 at 24 hr. Iodine-125-F6 F(ab')(2) fragment showed a tumor uptake of 7.39% injected dose/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 1.8 +/- 0.6, 7.3 +/- 2.9 and 3.6 +/- 1.6 at 24 hr. In mice injected with F6-679 or G7A5-734, tumor uptake and tumor-to-normal tissue ratios were much lower than in the mice injected with F6-734. These results were confirmed by autoradiographic studies that demonstrated clear tumor-to-normal tissue contrast. Conclusion: This two-step targeting method seems very potent for the diagnosis and therapy of human medullary thyroid cancer and other CEA-producing tumors because it combines high tumor uptake and low normal tissue background.
  • Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted mice, Masako N. Hosono, Makoto Hosono, Paul O. Zamora, Stefan Guhlke, Thomas Haberberger, Hans Bender, F.F. Russ Knapp, Hans J. Biersack, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 12(2), 83 - 88, 1998 , Refereed
    Summary:In order to evaluate the feasibility of 188Re-labeled antibodies for radioimmunotargeting, monoclonal antibody B72.3, recognizing TAG-72, expressed on the surface membranes of colorectal cancer cells, was directly labeled with 188Re, obtained from a 188W/188Re generator, using stannous tartrate and compared with 125I-labeled B72.3. As a control, a human IgG was also radiolabeled with 188Re and 125I. Prepared antibodies for 188Re labeling could be stored as kits. Biodistribution was determined in nude mice inoculated with human colorectal carcinoma LoVo. Labeling efficiency and immunoreactivity of 188Re-B72.3 were 80.3% and 64.7%, respectively. 188Re-B72.3 localized specifically in the LoVo tumors. Although the absolute tumor accumulation level of 188Re-B72.3 was lower than 125-B72.3, 188Re-B72.3 demonstrated higher tumor-to-blood contrast than the 125I-labeled counterpart, 2.04 ± 0.44 vs. 1.05 ± 0.28 at 96 hours, because of fast clearance from the blood. 188Re-B72.3 seemed efficient for the imaging and therapy of colorectal carcinoma.
  • Three phase Tc-99(m) (V)DMSA scintigraphy in Paget's disease: An indicator of pamidronate effect, H Kobayashi, C Shigeno, H Sakahara, T Yamamoto, M Hosono, R Fujimoto, J Konishi, BRITISH JOURNAL OF RADIOLOGY, BRITISH JOURNAL OF RADIOLOGY, 70(838), 1056 - 1059, Oct. 1997 , Refereed
    Summary:The use of three phase Tc-99(m) (V)DMSA scintigraphy is reported in a patient with Paget's disease of bone before and after intravenous pamidronate therapy. It was a useful modality for estimating the activity of Pagetoid lesions and the therapeutic effect of pamidronate, from a different aspect to bone scintigraphy. Three phase Tc-99(m) (V)DMSA scintigraphy evaluates both the blood flow and the metabolic activity of Pagetoid bone.
  • Septum-like structures in lipoma and liposarcoma: MR imaging and pathologic correlation, M Hosono, H Kobayashi, R Fujimoto, Y Kotoura, T Tsuboyama, Y Matsusue, T Nakamura, T Itoh, J Konishi, SKELETAL RADIOLOGY, SKELETAL RADIOLOGY, 26(3), 150 - 154, Mar. 1997 , Refereed
    Summary:Objective. To-investigate the septum-like structures in predominantly lipomatous tumors, by correlating fat-suppressed MR images with histopathologic findings. Design and patients. The MR findings of three cases of well-differentiated liposarcoma (atypical lipoma), one case of lipoma-like component of dedifferentiated liposarcoma. and nine cases of lipoma were analyzed. T1-, T2-, and fat-suppressed T1- weighted images after Gd-DTPA administration were obtained. Surgical specimens from five patients (four with liposarcoma and one with lipoma) were also scanned with a MR unit, and compared with the pathologic findings. Results and conclusions. Enhancement features of lipoma and liposarcoma were well visualized on fat-suppressed T1-weighted images after Gd-DTPA administration. The septum-like structures of liposarcoma are thick and enhanced considerably, while septa of lipoma are thin and enhanced only slightly. Pathologically, the septum-like structures of Liposarcoma contained muscle fibers and the septa of lipoma represented fibrous capsule, Identification of well-enhanced septa in a predominantly lipomatous tumor helps to differentiate malignant tumors horn lipomas. As the septum-like structures of liposarcoma contain a skeletal muscle component the tumor might need more extensive surgical procedures including resection of adjacent muscles.
  • MRI and scintigraphic features of extraabdominal desmoid tumors, H Kobayashi, Y Kotoura, M Hosono, T Tsuboyama, H Sakahara, K Endo, J Konishi, CLINICAL IMAGING, CLINICAL IMAGING, 21(1), 35 - 39, Jan. 1997
    Summary:To determine whether extraabdominal desmoid can be correctly diagnosed using both magnetic resonance imaging (MRI) and scintigraphy with pentavalent technetium-99m dimercaptosuccinic acid and gallium-67 citrate, MRI (T1- and T2-weighted images) and scintigraphy were performed in 18 patients with 27 histologically proved extraabdominal desmoid tumors. The extraabdominal desmoid tumors were characterized by positive uptake of pentavalent technetium-99m dimercaptosuccinic acid and lack of uptake of gallium-67 citrate on scintigraphy. These tumors were isointense to skeletal muscle on T1-weighted MRIs and hyperintense on T2-weighted images. They also displayed septum-like internal inhomogeneity and surrounding hypointense capsular band. The combination of scintigraphy and MRI is of value in correctly diagnosing extraabdominal desmoid tumors except in the rare case of fibrotic very low-grade sarcoma. (C) Elsevier Science Inc., 1997.
  • Localization of small-cell lung cancer xenografts with iodine-125-, indium-111-, and rhenium-188-somatostatin analogs, M Hosono, MN Hosono, T Haberberger, PO Zamora, S Guhlke, H Bender, FFR Knapp, HJ Biersack, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 87(9), 995 - 1000, Sep. 1996 , Refereed
    Summary:We examined the potential of radiolabeled somatostatin analogs, I-125-Tyr-3-octreotide (I-125-octreotide), In-111-DTPA(diethylenetriaminepentaacetatic acid)-D-Phe-1-octreotide (In-111-octreotide), and Re-188-octreotide for targeting small-cell lung cancer (SCLC) in a mouse model, Tyr-3-octreotide was labeled with I-125 by the chloramine T method, and In-111-octreotide was obtained as a kit, while Re-188 was eluted from a W-188/Re-188 generator, and octreotide was directly labeled with Re-188 by reducing disulfide bonds. The I-125-, In-111- and Re-188-octreotides were injected i.v. into athymic mice bearing NCI-H69 tumors, and the biodistributions were determined at 15 min, and 2, 4, 8, and 24 h. Tumor uptakes were 0.5 +/- 0.2, 0.3 +/- 0.1, 0.3 +/- 0.1 %ID/g, and tumor-to-blood ratios were 1.8, 11.9, 1.2 at 8 h for I-125-, In-111-, and Re-188-octreotides, respectively. Accumulations of In-111-octreotide in normal tissues were lower than those of I-125- and Re-188-octreotides. Re-188-octreotide can be used to localize SCLC lesions as efficiently as radioiodinated octreotide. However, In-111-octreotide was the most suitable agent to obtain high tumor-to-normal tissue contrast for localizing SCLC.
  • Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody, H Sakahara, M Hosono, H Kobayashi, ZS Yao, T Saga, S Yano, K Endo, T Mori, J Konishi, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 87(6), 655 - 661, Jun. 1996 , Refereed
    Summary:The murine monoclonal antibody (mAb) 145-9 recognizes an epitope present on CA125 but different from the epitope defined by the mAb OC125. To evaluate the clinical usefulness of the 145-9 antibody, immunoscintigraphy was performed in ovarian cancer patients and the effect of circulating CA125 on tumor imaging was investigated. Two milligrams (74 MBq) of In-111-labeled 145-9 was injected intravenously into 11 patients with ovarian cancer. Pre-injection serum CA125 concentrations were between 166 U/ml and 7414 U/ml. Tumors were visualized in 10 of 11 patients. In two patients, lymph nodes that were not detected by other imaging modalities but were clinically suspected as metastases were visualized. There was no correlation between serum CA125 level and antibody uptake in the tumors. Immune complexes between the antibody and circulating antigen were observed in sera of all the patients, but the fraction of radioactivity in complex form did not correlate well with serum CA125 levels. The immune complexes survived in the circulation and the circulating radiolabel, including immune complexes, was still bound to solid-phase CA125. The plasma clearance rate and hepatic uptake of the antibody were not significantly affected by circulating CA125. In conclusion, the antibody 145-9 formed complexes with CA125 in vivo but this did not compromise the outcome of antibody imaging. The antibody 145-9 can be used in immunoscintigraphy of ovarian cancer irrespective of serum CA125 level.
  • Periosteal ganglion of the tibia, H Kobayashi, Y Kotoura, M Hosono, T Tsuboyama, H Sakahara, J Konishi, SKELETAL RADIOLOGY, SKELETAL RADIOLOGY, 25(4), 381 - 383, May 1996
    Summary:Radiographic, computed tomographic and scintigraphic findings of a patient with separated, multilocular periosteal ganglion are reported. Multiple periosteal cystic masses with calcification in small parts of the cyst walls were demonstrated in the surface of the left tibia by plain radiograms and CT. The accumulations of technetium-99m hydroxymethylene diphosphonate and pentavalent technetium-99m dimercaptosuccinic acid were shown in the calcification in the periosteum and wall of the cyst. Needle puncture revealed that the masses were filled with jelly-like fluid. The masses were diagnosed as multiple ganglionic cysts at the periosteum of the left tibia.
  • The pharmacodynamics of 6-(3-dimethylaminopropionyl)forskolin and a possible metabolite in beagles, Shunichi Kametani, Shinichi Matsumoto, Takashi Takahira, Makoto Hosono, Yutaka Hashimoto, Hiroo Horinishi, Journal of Pharmaceutical Sciences, Journal of Pharmaceutical Sciences, 85(4), 377 - 380, 1996 , Refereed
    Summary:A specific gas chromatography/mass spectroscopy method with a detection limit of 0.1 ng/mL was developed for the measurement of 6-(3- dimethylaminopropionyl)forskolin (1) in beagle plasma. Using this method, plasma concentrations of 1 in beagles given pharmacologically effective intravenous doses of 1-HCl were determined. The observed maximal plasma concentrations rapidly decreased with time, and half-lives of the α-phases were < 9 min. Pharmacological effects of 1 on the cardiovascular parameters were simultaneously evaluated in one of the studies. Decreases of the pharmacological effects were slower than decreases in plasma concentration of 1. In addition, 6-(3-methylaminopropionyl)forskolin (N-monodemethyl 1), an expected initial metabolite of 1, was prepared and found to be as pharmacologically active as 1 in beagles. These results and others strongly suggest that a metabolite(s) of 1 contributes to the pharmacological effects of 1 in beagles.
  • Effectiveness of NKH477, a novel forskolin derivative, in rat cardiac preparations with desensitized β-adrenoceptors, Osamu Ishizuka, Akira Fujita, Etsuko Kanbe, Mitsue Noguchi, Makoto Hosono, Katsuhiko Sakitama, Folia Pharmacologica Japonica, Folia Pharmacologica Japonica, 108(1), 23 - 30, 1996 , Refereed
    Summary:Effects of prolonged noradrenaline infusion on the density of cardiac β adrenoceptors, phosphodiesterase (PDE) and adenylate cyclase (AC) activities, and the ability of NKH477, 6-(3-dimethylaminopropionyl) forskolin hydrochloride, to increase tension development and heart rate were studied in rat cardiac preparations. Noradrenaline infusion (400 μg/kg/hr, s.c.) for 7 days significantly decreased cardiac β-adrenoceptor density (B(max)), whereas the binding affinity (Kd) of the ligand was unchanged. The basal cardiac PDE activity was increased in treated rats, whereas there was no difference in the basal cardiac AC activity between treated and untreated rats. Significant decreases in basal developed tension and heart rate were observed in the left and right atrial muscles from treated rats, respectively. The positive inotropic and chronotropic potencies of NKH477 were unaffected by noradrenaline infusion, whereas the positive inotropic potencies of isoproterenol and 3-isobutyl-1-methylxanthine were significantly reduced. Thus, NKH477 appears to be superior to β-adrenoceptor agonists or PDE inhibitors as a cardiotonic drug in the treatment of heart failure accompanied by β-adrenoceptor downregulation.
  • RADIOIMMUNODETECTION OF HUMAN LEUKEMIA WITH ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY IN SEVERE COMBINED IMMUNODEFICIENCY MICE, M HOSONO, A TAKAORIKONDO, ZS YAO, H KOBAYASHI, MN HOSONO, H SAKAHARA, K IMADA, M OKUMA, T UCHIYAMA, JJ KONISHI, NUCLEAR MEDICINE AND BIOLOGY, NUCLEAR MEDICINE AND BIOLOGY, 22(7), 869 - 874, Oct. 1995 , Refereed
    Summary:Anti-Tac monoclonal antibody recognizes human interleukin-2 receptor, which is overexpressed in leukemic cells of most adult T-cell leukemia (ATL) patients. To examine the potency of anti-Tac for targeting of ATL, biodistributions of intravenously administered I-125- and In-111-labeled anti-Tac were examined in severe combined immunodeficiency (SCID) mice inoculated with ATL cells. Significant amounts of radiolabeled anti-Tac were found in the spleen and thymus. The trafficking of ATL cells in SCID mice was detected using In-111-oxine-labeled ATL cells. These results were coincident with the histologically confirmed infiltration of ATL cells. The radiolabeled anti-Tac seemed potent for targeting of ATL.
  • 3D-spiral CT of multiple exostoses, H Kobayashi, Y Kotoura, M Hosono, R Fujimoto, T Tsuboyama, H Itoh, J Konishi, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, 19(5), 419 - 422, Sep. 1995 , Refereed
    Summary:We report pre- and post-operative three-dimensional (3D)-spiral CT images in a patient with multiple exostoses, Images of 3D-CT, which were performed using the integrated 3D software of the CT system, showed the exact shapes and locations of the individual tumors around the knee joint in comparison with the surgical findings and resected specimen, 3D-spiral CT images of multiple exostoses would be useful for the planning of surgical procedure. (C) 1996 Elsevier Science Ltd.
  • IMMUNOSCINTIGRAPHY OF COLORECTAL-CANCER USING IN-111-LABELED MONOCLONAL-ANTIBODY TO MUCIN, H SAKAHARA, H ONODERA, M SHIRATO, ZS YAO, G OHSHIO, H KOBAYASHI, M HOSONO, S YANO, H NAKADA, M IMAMURA, YAMASHINA, I, J KONISHI, CANCER IMMUNOLOGY IMMUNOTHERAPY, CANCER IMMUNOLOGY IMMUNOTHERAPY, 41(3), 157 - 161, Sep. 1995 , Refereed
    Summary:A murine monoclonal antibody MLS102 recognizes sialosyl-Tn antigen in mucin and immunohistochemically reacts with more than 80% of colorectal cancer tissues, The purpose of this study was to assess the usefulness of this monoclonal antibody for the immunoscintigraphy of colorectal cancer. Planar and SPECT images were obtained on day 2 or day 3 after injection of 2 mg and 74 MBq In-111-labeled MLS102 antibody into 17 patients with colorectal cancer. Nine of 11 primary tumors and 4 of 6 locally recurrent tumors were detected. Positive images were obtained in all tumors larger than 4.5 x 2.7 cm. Three tumors of less than 2.5 cm and 1 recurrent tumor, which was missed by other imaging modalities, were negative. There were no adverse reactions. Human anti-(mouse Ig) antibody developed in 4 patients. Although improvement of detectability for smaller tumors needs to be pursued, the antibody MLS102 is potentially promising for use in immunoscintigraphy of colorectal cancer.
  • INVOLVEMENT OF MUSCLE BY MALIGNANT-LYMPHOMA - MR AND CT APPEARANCES, M HOSONO, H KOBAYASHI, Y KOTOURA, T TSUBOYAMA, K TSUTSUI, J KONISHI, JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 19(3), 455 - 459, May 1995 , Refereed
    Summary:Objective: The purpose of this study is to investigate the CT and MR findings of muscular involvement by malignant lymphoma and identify the CT acid MR features that may assist in their diagnosis. Materials and Methods: Magnetic resonance imaging was performed on four patients (five lesions) with pathologically proven non-Hodgkin lymphoma using a 1.5 T unit (Cases 1, 2, and 4) and a 0.5 T scanner (Case 3). Computed tomography scans were carried out on three patients (Cases 1, 3, and 4). Results: The lesions that extended along muscle fascicles with preserved fat planes looking like swelling of the muscle were of slightly hyper- to isointensity relative to uninvolved muscles on T1-weighted images, of hyperintensity on T2-weighted images, and of low or isodensity on CT. Microscopically, lymphoma cells were seen clustering among normal and atrophic muscle fibers in a biopsy specimen of one patient. The lesions enhanced relatively homogeneously after Gd-DTPA injection. In three cases, vessels were coursing through the lesion on MRI and in two cases on enhanced CT. Conclusion: Magnetic resonance imaging proved useful to show the extension of involvement of muscular lymphoma compared with CT. The diagnosis of infiltration of muscle by lymphoma is entertained when a lesion of relatively homogeneous intensity and density extends along the muscle fascisles without obliteration of the fat planes and especially when vessels are identified within the lesion.
  • DIAGNOSTIC-VALUE OF TC-99M (V) DMSA FOR CHONDROGENIC TUMORS WITH POSITIVE TC-99M HMDP UPTAKE ON BONE-SCINTIGRAPHY, H KOBAYASHI, Y KOTOURA, M HOSONO, H SAKAHARA, M HOSONO, ZS YAO, T TSUBOYAMA, T YAMAMURO, K ENDO, J KONISHI, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 20(4), 361 - 364, Apr. 1995 , Refereed
    Summary:Technetium-99m (V) DMSA scintigraphy was performed in 17 patients with 37 chondrogenic tumors (13 osteochondromas, 14 enchondromas, and 10 chondrosarcomas) that had previously shown uptake of Tc-99m HMDP. Technetium-99m (V) DMSA showed high uptake by all chondrosarcomas, but low or no uptake always indicated benign chondrogenic tumors. Technetium-99m (V) DMSA scintigraphy may be superior to Tc-99m HMDP scintigraphy for distinguishing benign and malignant chondrogenic tumors, and could also be useful for diagnosing the malignant transformation of chondrogenic tumors.
  • SOLITARY MUSCULAR INVOLVEMENT BY TUBERCULOSIS - CT, MRI, AND SCINTIGRAPHIC FEATURES, H KOBAYASHI, Y KOTOURA, M HOSONO, T TSUBOYAMA, H SAKAHARA, J KONISHI, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, 19(2), 237 - 240, Mar. 1995
    Summary:The authors reported computed tomography (CT), magnetic resonance imaging (MRI) and scintigraphic findings of a patient with solitary muscular tuberculosis in the forearm. All these findings resembled those of other granulomatous inflammatory lesions in the soft tissue such as muscular sarcoidosis.
  • DETECTION OF HOMING, PROLIFERATION, AND INFILTRATION SITES OF ADULT T-CELL LEUKEMIA-CELLS IN SEVERE COMBINED IMMUNODEFICIENCY MICE USING RADIOMETRIC TECHNIQUES, A TAKAORIKONDO, M HOSONO, K IMADA, ZS YAO, H SAKAHARA, H YAMABE, J KONISHI, M OKUMA, T UCHIYAMA, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 86(3), 322 - 328, Mar. 1995 , Refereed
    Summary:To clarify the mechanism of in vivo proliferation of adult T cell leukemia (ATL) cells, we examined the organ distribution of ATL-43T cell line cells derived from original leukemic cells in severe combined immunodeficiency (SCID) mice using radiometric techniques. First, we injected In-111-oxine-labeled ATL-43T cells into SCID and CB17 mice. On day 6, significant accumulation of radioactivity was found in the spleen and thymus of SCID mice (33.3 +/- 9.4 and 10.0 +/- 3.6 % injected dose/g of tissue [%ID/g], respectively) in comparison with that in CB17 mice (19.1 +/- 2.5 and 3.7 +/- 0.9 %ID/g, respectively). Next, we injected radiolabeled anti-Tac monoclonal antibody (MoAb) recognizing human interleukin-2 receptor (IL-2R) alpha chain or isotype-matched control MoAb RPC5 in SCID mice bearing ATL-43T cells 4 weeks after cell inoculation. The amounts of radioactivity found in the spleen and thymus of SCID mice injected with I-125-labeled anti-Tac MoAb (22.5 +/- 6.9 and 22.8 +/- 9.6 %ID/g, respectively) were significantly higher than those in the corresponding organs of SCID mice injected with I-125-labeled RPC5 MoAb (12.0 +/- 5.1 and 7.5 +/- 4.6 %ID/g, respectively). Similar results were obtained with In-111-labeled anti-Tac MoAb. These results were consistent with the histological findings of SCID mice bearing ATL-43T cells, indicating that ATL-43T cells infiltrated preferentially into the lymphoid organs, such as the spleen and thymus, and proliferated there. Thus, the radiometric techniques employed in this study were very useful to evaluate the proliferation sites of ATL-43T cells in SCID mice. Furthermore, this murine model could give us an opportunity to test the feasibility of therapeutic application of radiolabeled anti-Tac MoAb.
  • COMPARISON OF THE CHASE EFFECTS OF AVIDIN, STREPTAVIDIN, NEUTRAVIDIN, AND AVIDIN-FERRITIN ON A RADIOLABELED BIOTINYLATED ANTITUMOR MONOCLONAL-ANTIBODY, H KOBAYASHI, H SAKAHARA, K ENDO, M HOSONO, ZS YAO, S TOYAMA, J KONISHI, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 86(3), 310 - 314, Mar. 1995 , Refereed
    Summary:Injection of avidin can decrease the background radioactivity due to a radiolabeled biotinylated monoclonal antibody. We compared the chase effects of avidin, streptavidin, neutravidin, and avidin-conjugated ferritin on a radiolabeled antitumor monoclonal antibody in tumor-bearing nude mice, A radioiodine-labeled biotinylated monoclonal antibody (OST7) was administered to athymic mice bearing osteogenic sarcomas. After 24 h, an avidin, streptavidin, neutravidin or avidin-conjugated ferritin chaser was intravenously injected into the mice. At 2 h after the chase, the biodistribution of the radiolabeled monoclonal antibody was determined. Clearance from the blood was dose-dependently accelerated by avidin and its effect was 10-fold stronger than that of neutravidin or avidin-ferritin. Streptavidin did not promote clearance of the biotinylated antibody, Avidin was the most effective chasing agent for improving the biodistribution of the radiolabeled biotinylated monoclonal antibody among the four avidin derivatives tested.
  • Bronchodilator and Cardiovascular Effects of NKH477, a Novel Water-Soluble Forskolin Derivative, in Guinea Pigs, Masashi Iida, Naomi Fujita, Makoto Hosono, Yoshikazu Sukenaga, The Japanese Journal of Pharmacology, The Japanese Journal of Pharmacology, 68(3), 245 - 253, 1995 , Refereed
    Summary:The bronchodilator and cardiovascular effects of NKH477 (6-(3-dimethylaminopropionyl)forskolin hydrochloride) were evaluated. In anesthetized guinea pigs, i.v. bolus injections of NKH477 (1–100 µg/kg) inhibited the bronchoconstriction induced by inhaled leukotriene D4, increased the heart rate (HR) and decreased the diastolic arterial blood pressure (DBP) in a dose-dependent manner. The bronchodilator effect of NKH477 was 1500 times more potent than that of aminophylline and 17 times less potent than that of isoproterenol. The selectivity of NKH477 for bronchodilation vs an increase in HR was 15 times higher than that of isoproterenol and similar to that of aminophylline and vs a decrease in DBP, the selectivity was 4 times higher than that of aminophylline and similar to that of isoproterenol. I.v. infusion of NKH477 (0.1–3 µg/kg/min) for 2 hr dose-dependently inhibited the bronchoconstriction induced by i.v. histamine. Isoproterenol (0.1 µg/kg/min, i.v.) enhanced the bronchoconstriction after termination of the infusion, whereas NKH477 did not. In conscious guinea pigs, inhalation of NKH477 (0.1–5 mg/ml) concentrationdependently inhibited the bronchoconstriction induced by inhaled histamine, and a high concentration of NKH477 (35.4 mg/ml) increased the HR. The bronchodilator effect of inhaled NKH477 was 15 times less potent than that of isoproterenol. The selectivity of inhaled NKH477 was similar to that of isoproterenol. These results indicate that NKH477 may be useful as a bronchodilator. © 1995, The Japanese Pharmacological Society. All rights reserved.
  • Kinetics of platelets in dogs with thrombocytopenia induced by antiglycoprotein IIb/IIIa receptor monoclonal antibody, Makoto Hosono, Naoaki Sone, Keigo Endo, Tsuneo Saga, Hisataka Kobayashi, Masako N. Hosono, Harumi Sakahara, Kojiro Yasunaga, Junji Konishi, Nuclear Medicine and Biology, Nuclear Medicine and Biology, 22(1), 71 - 76, 1995 , Refereed
    Summary:To experimentally assess the kinetics of platelets in thrombocytopenia, we constructed a canine model using 111In-oxine labeled autologous platelets and an intact antiplatelet monoclonal antibody (MAb) NNKY2-11 (IgG2a). With the infusion of radiolabeled autologous platelets into dogs, the peripheral platelet count and blood radioactivity level were examined, and the radioactivity in the liver, spleen and heart was determined with scintigraphic analysis. Thereafter, i.v. injection of 100 μg/kg of NNKY2-11 had no effect on platelet counts or the biodistribution of radiolabeled platelets. However, 200 and 300 μg/kg of MAb reduced the platelets, and the radioactivity of the liver and spleen augmented clearly after injection of MAb. Platelet radioactivity in serum, which had decreased after MAb infusion, did not recover, even when peripheral platelet counts returned to the normal levels, indicating that these new platelets might be derived from the platelet-storage pool or new thrombocytogenesis. This model of antiplatelet MAb induced thrombocytopenia seems to be useful for analyzing the kinetics of platelets in thrombocytopenia. © 1995.
  • KINETICS OF PLATELETS IN DOGS WITH THROMBOCYTOPENIA INDUCED BY ANTIGLYCOPROTEIN IIB/IIIA RECEPTOR MONOCLONAL-ANTIBODY, M HOSONO, N SONE, K ENDO, T SAGA, H KOBAYASHI, MN HOSONO, H SAKAHARA, K YASUNAGA, J KONISHI, NUCLEAR MEDICINE AND BIOLOGY, NUCLEAR MEDICINE AND BIOLOGY, 22(1), 71 - 76, Jan. 1995 , Refereed
    Summary:To experimentally assess the kinetics of platelets in thrombocytopenia, we constructed a canine model using In-111-oxine labeled autologous platelets and an intact antiplatelet monoclonal antibody (MAb) NNKY2-11 (IgG2a). With the infusion of radiolabeled autologous platelets into dogs, the peripheral platelet count and blood radioactivity level were examined, and the radioactivity in the liver, spleen and heart was determined with scintigraphic analysis. Thereafter, i.v. injection of 100 mu g/kg of NNKY2-11 had no effect on platelet counts or the biodistribution of radiolabeled platelets. However, 200 and 300 mu g/kg of MAb reduced the platelets, and the radioactivity of the liver and spleen augmented clearly after injection of MAb. Platelet radioactivity in serum, which had decreased after MAb infusion, did not recover, even when peripheral platelet counts returned to the normal levels, indicating that these new platelets might be derived from the platelet-storage pool or new thrombocytogenesis. This model of antiplatelet MAb induced thrombocytopenia seems to be useful for analyzing the kinetics of platelets in thrombocytopenia.
  • CASE-REPORT - UPTAKE OF PENTAVALENT TC-99M DIMERCAPTOSUCCINIC ACID BY PIGMENTED VILLONODULAR SYNOVITIS - COMPARISON WITH COMPUTED-TOMOGRAPHY, MAGNETIC-RESONANCE-IMAGING AND GA-67 SCINTIGRAPHY, H KOBAYASHI, Y KOTOURA, M HOSONO, H SAKAHARA, T YAMAMURO, K ENDO, J KONISHI, BRITISH JOURNAL OF RADIOLOGY, BRITISH JOURNAL OF RADIOLOGY, 67(802), 1030 - 1032, Oct. 1994 , Refereed
    Summary:The scintigraphic findings of a patient with pigmented villonodular synovitis are described and compared with the computed tomography and magnetic resonance imaging data. Intense uptake of pentavalent technetium-99m dimercaptosuccinic acid without gallium-67 citrate uptake indicates that pigmented villonodular synovitis has the features of a hyperplastic or neoplastic lesion rather than an inflammatory lesion from the point of view of nuclear medicine.
  • IMPROVED CLEARANCE OF RADIOLABELED BIOTINYLATED MONOCLONAL-ANTIBODY FOLLOWING THE INFUSION OF AVIDIN AS A CHASE WITHOUT DECREASED ACCUMULATION IN THE TARGET TUMOR, H KOBAYASHI, H SAKAHARA, M HOSONO, ZS YAO, S TOYAMA, K ENDO, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 35(10), 1677 - 1684, Oct. 1994 , Refereed
    Summary:The techniques of radioimmunoimaging and radioimmunotherapy suffer from prolonged high background radioactivity because intravenously injected antibodies remain in the circulation and in the organs far longer than necessary for effective binding to the target. To decrease background and increase radionuclide excretion without decreasing the dose of radioactivity delivered to the target tumor, we used radiolabeled biotinylated antibodies followed by a ''chase'' avidin injection. Methods: A mouse monoclonal antibody, OST7 (IgG1), which reacts with human osteosarcoma, was biotinylated and labeled with I-125, I-131 or Tc-99m. Radiolabeled biotinylated OST7 (10 mu g) was administered intravenously into nude mice bearing human osteosarcomas and 30 mu g of avidin was injected intravenously 6 or 24 hr later. Results: Following avidin injection in mice pretreated with radiolabeled biotinylated antibodies, radioactivity was promptly cleared from the blood and deposited in the liver and spleen, after which radioiodine was rapidly detached from the antibody and excreted in the urine. The tumor-to-blood ratios at 6 and 24 hr after the injection of I-125-labeled biotinylated OST7 increased compared with the values before the avidin chase without any loss of tumor radioactivity. Furthermore, the tumor-to-background radioactivity ratio was improved and better images were obtained more rapidly after the injection of radiolabeled biotinylated antibodies than with conventional immunoscintigraphy. Conclusions: This method may find application in clinical radioimmunoimaging, especially using short half-life radionuclides such as Tc-99m and I-123.
  • INTRAOSSEOUS HEMANGIOMATOSIS - TECHNETIUM-99M(V)DIMERCAPTOSUCCINIC ACID AND TECHNETIUM-99M-HYDROXYMETHYLENE DIPHOSPHONATE IMAGING, H KOBAYASHI, C SHIGENO, H SAKAHARA, M HOSONO, M HOSONO, ZS YAO, K ENDO, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 35(9), 1482 - 1484, Sep. 1994 , Refereed
    Summary:We report a case of histologically proven intraosseous hemangiomatosis in which marked accumulation of pentavalent technetium-99m-dimercaptosuccinic acid (Tc-99m(V)DMSA) and technetium-99m-hydroxymethylene diphosphonate (Tc-99m-HMDP) was observed in the osteolytic hemangiomatous lesions.
  • SCHWANNOMA OF THE EXTREMITIES - COMPARISON OF MRI AND PENTAVALENT TC-99M DIMERCAPTOSUCCINIC ACID AND GALLIUM-67-CITRATE SCINTIGRAPHY, H KOBAYASHI, Y KOTOURA, H SAKAHARA, M HOSONO, M HOSONO, T TSABOYAMA, T YAMAMURO, K ENDO, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 35(7), 1174 - 1178, Jul. 1994 , Refereed
    Summary:The diagnostic value of MRI and scintigraphy was studied in patients with Schwannomas of the upper or lower extremities. MRI (T1- and T2-weighted imaging), pentavalent Tc-99m-dimercaptosuccinic acid and Ga-67-citrate scintigraphy were performed in 11 patients with 12 histologically proven benign Schwannomas. All six tumors with a maximum diameter greater than or equal to 3 cm showed marked accumulation of pentavalent Tc-99m-dimercaptosuccinic acid, whereas they showed no uptake of Ga-67-citrate. MRI detected all of the tumors, and the lesions had a signal intensity equal to or slightly less than that of skeletal muscle on T1-weighted images and hyperintense to that of subcutaneous fat on T2-weighted images. MRI was superior to detect small Schwannomas of the extremities. A positive Tc-99m-dimercaptosuccinic acid scan and a negative Ga-67-citrate scan however is useful to distinguish sarcoma with myxoid change from Schwannoma.
  • 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma, Harumi Sakahara, Keigo Endo, Tsuneo Saga, Makoto Hosono, Hisataka Kobayashi, Junji Konishi, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 8(2), 133 - 137, Jun. 1994 , Refereed
    Summary:131I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1-3 doses of 3.33-4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patient had no symptoms before131I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 weekto 1 month after131I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from131I-MIBG therapy. Thus,131I-MIBG appears to be useful for the palliation of malignant pheochromocytoma. © 1994 Springer-Verlag.
  • SCINTIGRAPHIC DETECTION OF NEURAL-CELL-DERIVED SMALL-CELL LUNG-CANCER USING GLIOMA-SPECIFIC ANTIBODY, H KOBAYASHI, H SAKAHARA, M HOSONO, M SHIRATO, S KONDO, S MIYATAKE, H KIKUCHI, Y NAMBA, K ENDO, J KONISHI, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 120(5), 259 - 262, Mar. 1994 , Refereed
    Summary:Radiolabeled GA-17, a murine monoclonal antibody that reacts specifically with glioma cells, bound to a small-cell lung cancer (SCLC) cell line NCI-H69 derived from neural cells, both in vitro and in vivo. The affinity constant of GA-17 F(ab')(2) fragment binding to NCI-H69 was 1.02x10(8)/M while that to the glioma cell line U87MG was 1.22x10(8)/M. Iodine-l25-labeled GA-17 F(ab')(2) fragments injected i.v. localized well in NCI-H69 cells xenografted in nude mice. The percentage of the injected dose per gram accumulated in the xenografted tumor was 6.87+/-1.34%g(-1) (mean+/-SD, n=5) 24 h after injection. On the other hand, control monoclonal F(ab')(2) fragments accumulated in the xenografted tumor at 0.75+/-0.30%g(-1). The tumor-to-blood ratio was 1.8 for NCI-H69, while that of control F(ab')(2) was 0.60. In conclusion, the radiolabeled GA-17 F(ab')(2) fragment is expected to be useful clinically to visualize the small-cell lung cancer and in radioimmunotherapy.
  • DISSOCIATION IN SERUM CA125 CONCENTRATIONS MEASURED BY DIFFERENT MONOCLONAL-ANTIBODIES, H SAKAHARA, T KOUSAKA, N HATTORI, K TOMIDA, ZS YAO, M HOSONO, H KOBAYASHI, M SHIRATO, K ENDO, J KONISHI, GYNECOLOGIC ONCOLOGY, GYNECOLOGIC ONCOLOGY, 52(3), 301 - 305, Mar. 1994 , Refereed
    Summary:The new immunoradiometric assay for CA125 (CA125II assay) uses the monoclonal antibody M11 as an immunoadsorbent. The epitope recognized by M11 is different from the OC125 epitope. Monoclonal antibodies 130-22 and 145-9 recognize an epitope designated as CA130 on the molecule expressing the OC125 epitope. Similarity of M11 epitope to the epitope of anti-CA130 antibodies and dissociation of antigen levels measured by the original CA125 assay and new CA125II assay were examined. Anti-CA130 antibodies partially competed with M11 for the M11 epitope. Among more than 20,000 serum samples we found 12 patients in whom the serum CA125 concentration measured by the CA125II assay was different from that measured by the original assay. In 11 out of 12 patients the CA125 concentration was moderately or extremely high by the original assay but very low by the CA125II assay. Eight of the 11 patients had benign disease, one had no apparent disease and two had cancer. The antigen level determined by CA130 assay was very low in all the 11 patients. In one patient the CA125II assay showed a higher antigen level than the original assay or CA130 assay. The heterogeneity of the epitope expression could cause the dissociation of CA125 levels measured by the different monoclonal antibodies. (C) 1994 Academic Press, Inc.
  • EFFECT OF HYPERTHERMIA ON TUMOR UPTAKE OF RADIOLABELED ANTI-NEURAL CELL-ADHESION MOLECULE ANTIBODY IN SMALL-CELL LUNG-CANCER XENOGRAFTS, MN HOSONO, M HOSONO, K ENDO, R UEDA, Y ONOYAMA, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 35(3), 504 - 509, Mar. 1994 , Refereed
    Summary:This study was performed to examine the effect of hyperthermia on the intratumor accumulation of a monoclonal antibody (Mab) in an animal model. Mab NE150 (IgG1) recognizes the neural cell adhesion molecule (NCAM) expressed by human small-cell lung cancer (SCLC) cells. Methods: Athymic mice inoculated with NCI-H69, an SCLC cell line, received an intravenous injection of I-125- and In-111-NE150 and the serial changes of the biodistribution were determined. Furthermore, athymic mice bearing NCI-H69 were either sham-treated or treated by a single hyperthermia at 42 degrees C or 43 degrees C for 1 hr, with the tumor-bearing leg in a water bath using pentobarbital anesthesia. Immediately after heating, the mice were given an intravenous injection of radiolabeled NE150, and the biodistribution was examined at 24 and 48 hr. Results: NE150 localized well in the transplanted tumor when compared with a control Mab. In mice treated at 43 degrees C, there was a 1.34- to 1.67-fold increase in the tumor uptake of I-125- and In-111-NE150 compared to sham-treated mice at both 24 and 48 hr. In addition, a 1.84- to 2.22-fold increase of the tumor-to-blood ratio was demonstrated, since radiolabeled NE150 cleared faster from the circulation in the mice given hyperthermia. A histological study demonstrated the infiltration of neutrophils in the perivascular spaces, indicating an increase of tumor vascular permeability, which might be one of the main reasons for the enhancement of Mab uptake. Conclusion: Hyperthermia seems to be a potential method of achieving an increased tumor accumulation of Mab in the radioimmunotargeting of SCLC.
  • TREATMENT OF SMALL-CELL LUNG-CANCER XENOGRAFTS WITH IODINE-131-ANTI-NEURAL CELL-ADHESION MOLECULE MONOCLONAL-ANTIBODY AND EVALUATION OF ABSORBED DOSE IN TISSUE, M HOSONO, K ENDO, MN HOSONO, H KOBAYASHI, M SHIRATO, H SAKAHARA, R UEDA, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 35(2), 296 - 300, Feb. 1994 , Refereed
    Summary:Human small-cell lung cancer (SCLC) is considered a feasible target for immunotherapy using a radiolabeled monoclonal antibody (Mab). A murine Mab, NE150 (IgG1), reacts with the neural cell adhesion molecule, which is identical to cluster 1 antigen of SCLC. Methods: To estimate their therapeutic effects, NE150 and an isotype-matched control Mab were labeled with I-131 and administered intravenously as a single dose into athymic mice inoculated with a NCI-H69 SCLC xenograft. The absorbed dose in organs was also examined based upon a long-term biodistribution study of I-131-NE150. Results: Tumors (initial volume 563.4 +/- 223.5 mm(3)) treated with 11.1 MBq (300 mu Ci) of I-131-NE150 diminished and became invisible at days 30-33, demonstrating a 60-day mean growth delay to reach a tripled initial volume compared with sham-treated tumors. Cumulative absorbed doses were estimated to be 2310, 410, 500, 330, and 790 cGy for the tumor, liver, kidney, spleen and lung, respectively. Conclusion: Iodine-131-NE150 had potent therapeutic effects against SCLC transplants in athymic mice, however, careful assessment of the side effects, improvement of radioiodination and chimerization of the Mab might be necessary to achieve efficient targeting in clinical therapeutic applications.
  • PENTAVALENT TC-99M DIMERCAPTOSUCCINIC ACID SPECT OF METASTATIC RENAL-CELL CARCINOMA IN THE SCALP AND IN THE BRAIN, H KOBAYASHI, H SAKAHARA, M HOSONO, M SHIRATO, J KONISHI, CLINICAL NUCLEAR MEDICINE, CLINICAL NUCLEAR MEDICINE, 19(2), 136 - 137, Feb. 1994 , Refereed
    Summary:The authors report marked accumulation of pentavalent technetium-99m dimercaptosuccinic acid in metastatic tumors from a renal cell carcinoma in the brain and the scalp on brain SPECT images.
  • A newly designed radioimmuno-conjugate releasing a hippurate-like radiometal chelate for enhanced target/non-target radioactivity, Yasushi Arano, Hiroshi Matsushima, Masaaki Tagawa, Tatsuo Inoue, Mitsuru Koizumi, Makoto Hosono, Harumi Sakahara, Keigo Endo, Junji Konishi, Akira Yokoyama, Nuclear Medicine and Biology, Nuclear Medicine and Biology, 21(1), 63 - 69, 1994 , Refereed
    Summary:Target-to-non-target ratio of radioactivity can be enhanced by the injection of monoclonal antibodies (MoAbs) labeled with metallic radionuclides, if some modality to accelerate the urinary excretion of radioactivity accumulated in non-target tissues could be introduced. In this study, a radioimmunoconjugate chemically designed to release a hippurate-like radiometal chelate was synthesized and tested in vivo. A 67Ga chelate of succinyldeferoxamine (SDF) was conjugated with a MoAb against osteogenic sarcoma (OST7, IgG1) through an ester bond using a new metabolizable MESS linker, N-[[4-(maleimidoethoxy)succinyl]oxy]succinimide (67Ga-DFO-MESS-OST7). When injected into normal mice, 67Ga-DFO-MESS-OST7 exhibited faster clearance of radioactivity from circulation with less accumulation in the liver, kidney and spleen than those observed with 67Ga-DFO-EMCS-OST7, which was prepared under identical conditions to 67Ga-DFO-MESS-OST7 except for using a non-metabolizable linker holding no ester bond to release 67Ga-SDF. Size exclusion HPLC analysis of the liver homogenate obtained from mice 24 h after injection of 67Ga-DFO-MESS-OST7 indicated that all the radioactivity was eluted in the high molecular weight fraction with most of it being present as the 67Ga-DFO-MESS-OST7 fraction. Reverse-phase HPLC analysis of urine sample from the same mice showed a single radioactivity peak at the same retention time as that of 67Ga-SDF. In athymic mice bearing osteogenic sarcoma, 67Ga-DFO-MESS-OST7 exhibited higher tumor-to-blood and tumor-to-organ ratio of radioactivity when compared with 67Ga-DFO-EMCS-OST7. These results indicated that 67Ga-DFO-MESS-OST7 achieved enhanced target-to-non-target ratio of the radioactivity, due to preferential cleavage of the ester bond in non-target tissues, followed by rapid urinary excretion of the resulting chelate (probably as 67Ga-SDF). These results also suggest that the present design would become an applicable modality for enhancing the target-to-non-target ratio of radioactivity by MoAbs. © 1994.
  • A NEWLY DESIGNED RADIOIMMUNOCONJUGATE RELEASING A HIPPURATE-LIKE RADIOMETAL CHELATE FOR ENHANCED TARGET/NON-TARGET RADIOACTIVITY, Y ARANO, H MATSUSHIMA, M TAGAWA, T INOUE, M KOIZUMI, M HOSONO, H SAKAHARA, K ENDO, J KONISHI, A YOKOYAMA, NUCLEAR MEDICINE AND BIOLOGY, NUCLEAR MEDICINE AND BIOLOGY, 21(1), 63 - 69, Jan. 1994
    Summary:Target-to-non-target ratio of radioactivity can be enhanced by the injection of monoclonal antibodies (MoAbs) labeled with metallic radionuclides, if some modality to accelerate the urinary excretion of radioactivity accumulated in non-target tissues could be introduced. In this study, a radioimmunoconjugate chemically designed to release a hippurate-like radiometal chelate was synthesized and tested in vivo. A Ga-67 chelate of succinyldeferoxamine (SDF) was conjugated with a MoAb against osteogenic sarcoma (OST7, IgG(1)) through an ester bond using a new metabolizable MESS linker, N-[[4-(maleimidoethoxy)succinyl]oxy]succinimide (Ga-67-DFO-MESS-OST7). When injected into normal mice, Ga-67-DFOMESS-OST7 exhibited faster clearance of radioactivity from circulation with less accumulation in the liver, kidney and spleen than those observed with Ga-67-DFO-EMCS-OST7, which was prepared under identical conditions to Ga-67-DFO-MESS-OST7 except for using a non-metabolizable linker holding no ester bond to release (GaSDF)-Ga-67. Size exclusion HPLC analysis of the liver homogenate obtained from mice 24 h after injection of Ga-67-DFO-MESS-OST7 indicated that all the radioactivity was eluted in the high molecular weight fraction with most of it being present as the Ga-67-DFO-MESS-OST7 fraction. Reverse-phase HPLC analysis of urine sample from the same mice showed a single radioactivity peak at the same retention time as that of Ga-67-SDF. In athymic mice bearing osteogenic sarcoma, Ga-67-DFOMESS-OST7 exhibited higher tumor-to-blood and tumor-to-organ ratio of radioactivity when compared with Ga-67-DFO-EMCS-OST7. These results indicated that Ga-67-DFO-MESS-OST7 achieved enhanced target-to-non-target ratio of the radioactivity, due to preferential cleavage of the ester bond in non-target tissues, followed by rapid urinary excretion of the resulting chelate (probably as Ga-67-SDF). These results also suggest that the present design would become an applicable modality for enhancing the target-to-nontarget ratio of radioactivity by MoAbs.
  • SOFT-TISSUE TUMORS - DIAGNOSIS WITH TC-99M (V) DIMERCAPTOSUCCINIC ACID SCINTIGRAPHY, H KOBAYASHI, H SAKAHARA, M HOSONO, M SHIRATO, K ENDO, Y KOTOURA, T YAMAMURO, J KONISHI, RADIOLOGY, RADIOLOGY, 190(1), 277 - 280, Jan. 1994 , Refereed
    Summary:PURPOSE: to assess the potential of technetium-99m (V) dimercaptosuccinic acid (DMSA) scintigraphy for diagnosis of soft-tissue tumors. MATERIALS AND METHODS: Tc-99m (V) DMSA scintigraphy was performed in 76 patients with histologic proof of soft-tissue tumors. In 57 of these patients, gallium-67 citrate scintigraphy was performed within 2 weeks after Tc-99m (V) DMSA scin-tigraphy. RESULTS: Uptake of Tc-99m (V) DMSA was clearly detected in almost all sarcomas, metastatic carcinomas, highly recurrent benign tumors (ie, extraabdominal desmoids and teno-synovial giant cell tumors), superficial and deep hemangiomas, and granulomatous soft-tissue lesions but was not found in other benign solid tumors of soft tissue. Uptake of Ga-67 citrate was clearly detected in all inflammatory lesions and metastatic carcinomas, eight of 14 sarcomas (57%), and two of 10 highly recurrent benign tumors (20%) but was not found in hemangiomas or benign soft-tissue tumors. CONCLUSION: Low-grade malignant and highly recurrent benign lesions, which often recur after surgery, were detected more accurately with Tc-99m (V) DMSA scintigraphy than with Ga-67 citrate scintigraphy.
  • SIMILARITY AND COEXPRESSION OF TUMOR-ASSOCIATED ANTIGENS RECOGNIZED BY DIFFERENT MONOCLONAL-ANTIBODIES, H SAKAHARA, T SAGA, K ENDO, T KOUSAKA, M HOSONO, H KOBAYASHI, M SHIRATO, J KONISHI, BRITISH JOURNAL OF CANCER, BRITISH JOURNAL OF CANCER, 68(5), 920 - 925, Nov. 1993 , Refereed
    Summary:The concentration of carcinoembryonic antigen (CEA), CA130, CA125, SLX, CA19-9, SPan1, and tumour-associated glycoprotein 72 (TAG-72) in the culture supernatant of 15 cancer cell lines and in the sera of 58 cancer patients was measured, and the co-expression of these antigens was examined by double determinant immunoradiometric assays. The high correlation coefficient of the concentrations and significant binding in the double determinant assays indicated a close relationship between CA125 and CA130 and between CA19-9 and SPan1. There was variable binding of the I-125-labelled anti-SLX, anti-CA19-9, and anti-SPan1 antibodies to anti-CA130 beads that had been pre-incubated with the culture supernatants, suggesting the presence of the epitopes of SLX, CA19-9, and SPan1 on the molecule expressing CA130. Similarly, the epitopes of SLX, CA19-9, and SPan1 could be present on the molecule expressing CEA. I-125-labelled anti-CA19-9, anti-SLX, and anti-TAG-72 antibodies were bound in variable proportions to anti-CA130 beads or to anti-CEA beads that had been pre-incubated with patients' sera. However, CEA and CA130 were not expressed on the same molecule, either in the culture supernatant, or in patients' sera. In conclusion, the carbohydrate epitopes of CA19-9, SPan1, SLX, and TAG-72 could be present on the molecule recognised by the anti-CA130 or anti-CEA antibody; however, the epitopes of CA130 and CEA did not co-exist on the same molecule.
  • SCINTIGRAPHIC DETECTION OF XENOGRAFTED TUMORS PRODUCING HUMAN BASIC FIBROBLAST GROWTH-FACTOR, H KOBAYASHI, H SAKAHARA, M HOSONO, M SHIRATO, J KONISHI, JA TAKAHASHI, Y ODA, H KIKUCHI, K ENDO, Y KOZAI, M HATANAKA, CANCER IMMUNOLOGY IMMUNOTHERAPY, CANCER IMMUNOLOGY IMMUNOTHERAPY, 37(5), 281 - 285, Oct. 1993 , Refereed
    Summary:A murine monoclonal antibody 3H3 recognizes the basic fibroblast growth factor (FGF) and inhibits the growth of human glioblastoma cells both in vitro and in vivo. We studied the potential of a scintigraphic technique using the 3H3 antibody to detect tumors that produce basic FGF. I-125- and In-111-labeled 3H3 bound to U87MG human glioblastoma cells in vitro. U87MG cells were inoculated subcutaneously into nude mice. After development of the tumor, radiolabeled 3H3 was injected into the subcutaneous space surrounding the tumor. A high level of radioactivity from 3H3 was retained at the tumor, whereas an irrelevant antibody cleared rapidly from the injected site. Radiolabeled 3H3 was not retained in tumors that did not produce basic FGF. Scintigraphic detection of tumors expressing basic FGF would be valuable for the therapeutic application of the antibody.
  • SCINTIGRAPHIC EVALUATION OF TENOSYNOVIAL GIANT-CELL TUMOR USING TECHNETIUM-99M(V)-DIMERCAPTOSUCCINIC ACID, H KOBAYASHI, H SAKAHARA, M HOSONO, M SHIRATO, J KONISHI, Y KOTOURA, T YAMAMURO, K ENDO, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 34(10), 1745 - 1747, Oct. 1993 , Refereed
    Summary:Technetium-99m(V) dimercaptosuccinic acid (DMSA) and Ga-67-citrate scintigraphy were performed in three patients with primary and recurrent tenosynovial giant-cell tumor (one localized type and two diffuse type). In all cases, Tc-99m(V)DMSA showed marked accumulation in all primary and recurrent tumors; however, Ga-67-citrate showed no accumulation in any of the tumors. Technetium-99m(V)-DMSA scintigraphy was useful in detecting tenosynovial giant-cell tumor and in diagnosing recurrence of this tumor.
  • Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells, Toshiharu Nakai, Harumi Sakahara, Keigo Endo, Makoto Shirato, Hisataka Kobayashi, Makoto Hosono, Tsuneo Saga, Masaru Sakamoto, Junji Konishi, Annals of Nuclear Medicine, Annals of Nuclear Medicine, 7(3), 133 - 139, Sep. 1993 , Refereed
    Summary:The effect of drugs on the release of CA125 antigen and the binding of anti-CA125 mono-clonal antibody (MoAb) to malignant cells was evaluated in vitro. TMCC-1, uterine cervical adenocarcinoma cells, were exposed to dexamethasone (DEX), sodium n-butyrate (NaB), dibutyryl cyclic AMP (dbcAMP), retinoic acid (RA), calcitriol (VD3), and interferon-γ (IFN-γ). NaB, RA and VD3 increased CA125 release per cell and125I-labeled anti-CA125 MoAb binding to the cells. DEX also increased the125I-labeled anti-CA125 MoAb binding to the cells, and CA125 antigen release per cell was also slightly increased. IFN-γ suppressed both CA125 release and125I-labeled MoAb binding. A combination of DEX, VD3 and RA and increased the binding of MoAb to TMCC-1 cells, but the amount of bound MoAb was not significantly different from that obtained by single drug treatment. DbcAMP had no significant effect on enhancing MoAb binding. Drugs can increase the binding of anti-CA125 MoAb to malignant cells and they may be applied to increase the tumor uptake of radiolabeled MoAbs in vivo. © 1993 Springer-Verlag.
  • A HUMAN MOUSE CHIMERIC MONOCLONAL-ANTIBODY AGAINST CA-125 FOR RADIOIMMUNOIMAGING OF OVARIAN-CANCER, H KOBAYASHI, H SAKAHARA, T SAGA, M HOSONO, M SHIRATO, H KANDA, K ISHIBASHI, T WATANABE, K ENDO, ISHIWATA, I, J KONISHI, CANCER IMMUNOLOGY IMMUNOTHERAPY, CANCER IMMUNOLOGY IMMUNOTHERAPY, 37(3), 143 - 149, Aug. 1993 , Refereed
    Summary:Murine monoclonal antibody 196-14 recognizes the ovarian-cancer-associated antigen CA125, but the epitope it recognizes is different from that of monoclonal antibody OC 125. We developed a human/mouse chimeric 196-14 using the variable regions of the murine 196-14 and human heavy-chain (gamma1) and light-chain (kappa) constant regions. Cell binding and competitive inhibition assays using chimeric 196-14 labeled with I-125, In-111 or Tc-99m demonstrated that the in vitro immunoreactivity of the chimeric antibody was identical to that of the parental murine monoclonal antibody. However, in mice bearing human ovarian cancer xenografts, the clearance from blood was faster and absolute levels of accumulation in the tumor were lower for the I-125-labeled or Tc-99m-labeled chimeric antibody than for the murine antibody labeled with the corresponding radionuclides. The tumor-to-blood radioactivity ratio was not significantly different between the chimeric antibody and the murine antibody, regardless of the radionuclide used for labeling. Chimeric antibody 196-14 labeled with I-131, In-111 or Tc-99m is promising for the radioimmunoimaging of ovarian cancer.
  • IN-VIVO INSTABILITY OF REDUCTION-MEDIATED TC-99M-LABELED MONOCLONAL-ANTIBODY, H SAKAHARA, T SAGA, K ENDO, N HATTORI, M HOSONO, H KOBAYASHI, M SHIRATO, T YAMAMURO, S TOYAMA, Y ARANO, A YOKOYAMA, J KONISHI, NUCLEAR MEDICINE AND BIOLOGY, NUCLEAR MEDICINE AND BIOLOGY, 20(5), 617 - 623, Jul. 1993 , Refereed
    Summary:A murine monoclonal antibody that reacts with human osteogenic sarcoma (OST7) was reduced and directly labeled with Tc-99m without any loss of immunoreactivity. No fragmentation of the antibody was detected by high performance liquid chromatography after the labeling. However, SDS PAGE analysis of the labeled antibody demonstrated the presence of low molecular weight species. Although more than 95% of the radioactivity remained bound at the antibody after incubation with human serum for 24 h, Tc-99m-labeled OST7 was cleared faster from the circulation than I-125-labeled OST7 or In-111-labeled OST7 in mice. Urinary and fecal excretion of Tc-99m were higher than those of I-125. When the I-125-labeled antibody was dual-labeled with Tc-99m, the blood clearance of Tc-99m was faster than that of I-125, suggesting release of Tc-99m from the antibody in vivo. Tc-99m-labeled OST7, however, gave a higher tumor-to-blood ratio than I-125- or In-111-labeled OST7 in mice bearing human osteogenic sarcoma. The Tc-99m-labeled antibody prepared by the direct method was unstable in vivo, but retained a good tumor targeting ability.
  • TECHNETIUM-99M(V)DIMERCAPTOSUCCINIC ACID UPTAKE IN INTRAABDOMINAL MASSIVE DEPOSIT OF AMYLOID PROTEIN, H KOBAYASHI, H SAKAHARA, T ITOH, T KUDOH, T TAKAGI, K SHIBUYA, S NOMURA, M HOSONO, K ENDO, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, JOURNAL OF NUCLEAR MEDICINE, 34(5), 815 - 817, May 1993 , Refereed
    Summary:Technetium-99m(V)dimercaptosuccinic acid (DMSA) scintigraphy was performed in two patients with pathologically confirmed primary amyloidosis. Both patients had tumor-like deposits of AL-type amyloid in the abdomen. Marked uptake of the tracer by the amyloid deposits was noted. Technetium-99m-(V)DMSA scintigraphy appears to be useful in detecting the distribution of amyloid deposits and in determining the appropriate site for biopsy.
  • CONSTRUCTION OF IMMUNORADIOMETRIC ASSAY FOR CIRCULATING C-ERBB-2 PROTOONCOGENE PRODUCT IN ADVANCED BREAST-CANCER PATIENTS, M HOSONO, T SAGA, H SAKAHARA, H KOBAYASHI, M SHIRATO, K ENDO, T YAMAMOTO, T AKIYAMA, K TOYOSHIMA, J KONISHI, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 84(2), 147 - 152, Feb. 1993 , Refereed
    Summary:The human c-erbB-2 protooncogene product (erbB-2 protein) is a 185 kilodalton glycoprotein closely related to epidermal growth factor receptor protein. In this study, we measured the concentration of circulating erbB-2 protein in cancer patients by means of a new immunoradiometric assay (IRMA). Two monoclonal antibodies (MoAbs), SV2-61gamma and 6G10, recognize erbB-2 protein but bind to separate epitopes. SV2-61gamma was used as an immunoadsorbent and 6G10 as an I-125-labeled probe. A serum was considered positive for erbB-2 protein if the percent binding exceeded the mean of the normal group by more than 3 standard deviations. Eleven of 21 patients with advanced breast cancer and 1 of 15 with advanced gastric cancer were positive. Serum erbB-2 protein levels correlated well with the therapy and the status of the patients with breast cancer. On the contrary, all patients with advanced colon, ovarian, or pancreatic cancers, showed levels below the cut-off value. These results suggest that circulating erbB-2 protein can be measured using the newly constructed IRMA. Since c-erbB-2 protooncogene amplification and overexpression are accepted as a good marker of aggressiveness, relapsing potency, and poor prognosis, this IRMA should be a promising tool with which to help manage breast cancer patients.
  • Evaluation of a cytokeratin 19 assay kit 'BALL ELSA CYFRA21-1', H. Sakahara, T. Kousaka, N. Hattori, M. Hosono, H. Kobayashi, M. Shirato, Z. Yao, J. Konishi, Kakuigaku, Kakuigaku, 30(12), 1475 - 1479, 1993 , Refereed
    Summary:We evaluated 'BALL ELSA CYFRA21-1' kit, an immunoradiometric assay kit for cytokeratin 19. Monoclonal antibodies KS19-1 and BM19-21 are used for immunoadsorbent and indicator, respectively. There was no problems in reproducibility, dilution test and recovery test. Minimum detectable concentration was 0.42 ng/ml. The antigen measured by this kit was immunologically cross-reactive with tissue polypeptide antigen (TPA) and CYFRA21-1 concentration was closely correlated with TPA concentration in patient's serum. One of twenty-six healthy subjects showed serum concentration over a cut-off value of 2.0 ng/ml. Serum CYFRA21-1 concentration elevated in 5 of 10 esophageal cancer patients, 5 of 10 gastric cancer patients, 7 of 10 colorectal cancer patients and 6 of 10 pancreatic cancer patients. Positive rate in patients with benign disease including hepatopathy was low. BALL ELSA CYFRA21-1 kit is reliable and CYFRA21-1 could be a useful tumor marker in gastrointestinal cancer.
  • In vivo instability of reduction-mediated 99mTc-labeled monoclonal antibody, Harumi Sakahara, Tsuneo Saga, Keigo Endo, Noriko Hattori, Makoto Hosono, Hisataka Kobayashi, Makoto Shirato, Takao Yamamuro, Sakuji Toyama, Yasuo Arano, Akira Yokoyama, Junji Konishi, Nuclear Medicine and Biology, Nuclear Medicine and Biology, 20(5), 617 - 623, 1993 , Refereed
    Summary:A murine monoclonal antibody that reacts with human osteogenic sarcoma (OST7) was reduced and directly labeled with 99mTc without any loss of immunoreactivity. No fragmentation of the antibody was detected by high performance liquid chromatography after the labeling. However, SDS-PAGE analysis of the labeled antibody demonstrated the presence of low molecular weight species. Although more than 95% of the radioactivity remained bound at the antibody after incubation with human serum for 24 h, 99mTc-labeled OST7 was cleared faster from the circulation than 125I-labeled OST7 or 111In-labeled OST7 in mice. Urinary and fecal excretion of 99mTc were higher than those of 125I. When the 125I-labeled antibody was dual-labeled with 99mTc, the blood clearance of 99mTc was faster than that of 125I, suggesting release of 99mTc from the antibody in vivo. 99mTc-labeled OST7, however, gave a higher tumor-to-blood ratio than 125I- or 111In-labeled OST7 in mice bearing human osteogenic sarcoma. The 99mTc-labeled antibody prepared by the direct method was unstable in vivo, but retained a good tumor targeting ability. © 1993.
  • DIFFERENT ANTIGENIC NATURE IN APPARENTLY HEALTHY WOMEN WITH HIGH SERUM CA-125 LEVELS COMPARED WITH TYPICAL PATIENTS WITH OVARIAN-CANCER, MN HOSONO, K ENDO, H SAKAHARA, Y WATANABE, T SAGA, T NAKAI, M HOSONO, T NAKAJIMA, Y ONOYAMA, J KONISHI, CANCER, CANCER, 70(12), 2851 - 2856, Dec. 1992 , Refereed
    Summary:Background. CA 125 is a representative ovarian cancer-associated antigen defined by monoclonal antibody OC125. Recently, monoclonal antibodies were produced (designated 130-22 and 145-9) that were reactive with CA 125 but bound to a separate epitope named CA 130. There was a close correlation between serum CA 125 and CA 130 values in most instances. However, among more than 8000 serum samples, 5 apparently normal women had high serum CA 125 values, despite having normal CA 130 values. In this study, the antigenic nature of these five women was investigated. Methods. Using gel chromatography, the molecular masses of CA 125 and CA 130 were estimated that were found in the five women with false-positive CA 125 values. The sera were examined using double-determinant assays combining iodine-125-labeled OC125 or iodine-125-labeled 130-22 with OC125-coated or 145-9-coated beads. Results. The molecular masses of both CA 125 and CA 130 were estimated as greater than 1000 kilodaltons (KD); the CA 130 mass from one of the five women with an abnormal CA 125 level was approximately 200 KD using gel chromatography. Using the double-determinant assays that combined iodine-125-labeled OC125 or iodine-125-labeled 130-22 with OC125-coated or 145-9-coated beads, high radioactivity was found only in the homologous assay using iodine-125-labeled OC125 with OC125-coated heads. These results suggest that the antigenic nature of CA 125 found in apparently healthy women differs from that found in patients with ovarian cancer and that CA 130 epitopes are not present. Conclusions. Measurement of serum CA 130 concentrations may be useful for excluding women with falsely elevated CA 125 values.
  • HUMAN MOUSE CHIMERIC ANTIBODIES SHOW LOW REACTIVITY WITH HUMAN ANTIMURINE ANTIBODIES (HAMA), M HOSONO, K ENDO, H SAKAHARA, Y WATANABE, T SAGA, T NAKAI, C KAWAI, A MATSUMORI, T YAMADA, T WATANABE, J KONISHI, BRITISH JOURNAL OF CANCER, BRITISH JOURNAL OF CANCER, 65(2), 197 - 200, Feb. 1992 , Refereed
    Summary:Human anti-murine antibody (HAMA) response is a serious problem in the repeated infusion of murine monoclonal antibodies (MoAbs). HAMA positive sera were obtained from seven patients with colorectal cancer, pancreas cancer, malignant melanoma or myocardial infarction who had previously received radiolabelled MoAbs. The nature of HAMA was analysed using size exclusion high performance liquid chromatography (HPLC) after incubating with radiolabelled MoAbs including IgG, Fab or human mouse chimeric Abs. Immune complexes composed of HAMA and MoAbs were formed. The percentage of radioactivity with a high molecular weight was related to HAMA levels determined by enzyme linked immunosorbent assay. Most radioactivity present in immune complex shifted to the antibody fraction after the addition of normal murine serum. All of seven sera were reactive with all four murine IgGs and this suggests that HAMA in these patients recognised the constant region of MoAbs. In one patient, HAMA was considered to recognise the variable region and to be anti-idiotypic. There was no significant binding with human/mouse chimeric Abs in any HAMA positive serum, although five out of seven patients were reactive with murine MoAb Fab, indicating that HAMA was composed of Abs responsive to the CH1 or CL region of murine IgG. These results suggest that (1) HAMA was composed of Ab responsive to Fe portion and or CH1 or CL region of murine IgG, and (2) human mouse chimeric Abs look promising in the repeated infusion of MoAb in HAMA positive patients.
  • Improvement of Drug-Induced Cardiac Failure by NKH477, a Novel Forskolin Derivative, in the Dog Heart-Lung Preparation, Akira Fujita, Takashi Takahira, Makoto Hosono, Keita Nakamura, The Japanese Journal of Pharmacology, The Japanese Journal of Pharmacology, 58(4), 375 - 381, 1992 , Refereed
    Summary:The efficacy of NKH477, a novel water-soluble forskolin derivative, in improving cardiac failure was assessed in dog heart-lung preparations. Cardiac functions depressed by pentobarbital, propranolol or verapamil so that cardiac output had been reduced by about 40-50% of the respective control were all improved by NKH477 (10-100 μg) in a dose-dependent manner. With 100 μg NKH477, almost complete restoration of cardiac performance was attained in the respective cardiac failures. In the combination of NKH477 with ouabain (30 μg), 30 μg of NKH477 completely restored the cardiac function depressed by pentobarbital, associated with a slight but not significant increase in heart rate. No arrhythmias were induced by any of the NKH477 doses used in the experiments. These results suggest that NKH477 should be subjected to clinical trials in the treatment of cardiac failure. © 1992, The Japanese Pharmacological Society. All rights reserved.
  • DRUG EFFECTS ON CA125 ANTIGEN EXPRESSION AND ANTIBODY-BINDING TO CANCER-CELLS, T NAKAI, K ENDO, M HOSONO, T SAGA, Y WATANABE, H SAKAHARA, K IMAI, A YACHI, Y KIYOZUKA, ISHIWATA, I, J KONISHI, INTERNATIONAL JOURNAL OF CANCER, INTERNATIONAL JOURNAL OF CANCER, 48(3), 463 - 467, May 1991 , Refereed
    Summary:CA125 is a high-molecular weight glycoprotein expressed on most serous-type ovarian cancer and some lung adenocarcinoma tissues. The effects of various drugs on the release of CA125 antigen into culture medium and on monoclonal antibody (MAb) binding to cancer cells were studied using 8 human cancer cell lines, all of which expressed CA125 on their cell surfaces. The effect of dexamethasone was seen at as low a concentration as 10(-9) m dexamethasone, and the release of CA125 and the binding of radiolabelled anti-CA125 antibody were completely inhibited after exposure to 10(-7) m dexamethasone. The number of antibody binding sites markedly decreased. In contrast, sodium butyrate increased CA125 expression. These findings were clearly detected in only 3 cancer cell lines and a significant effect was not seen in the 5 other cancer cell lines. Interferon-gamma, examined in 3 cell lines, suppressed in a dose-dependent manner in 2 CA125 expression cell lines, but enhanced it in one line. No apparent effects were seen after exposure to tissue necrosis factor or interleukin-2. These results suggest that drugs may regulate the CA125 antigen expression in some, but not all, cancer cells and may affect the biodistribution of radiolabelled MAbs.
  • SCINTIGRAPHIC DETECTION OF OVEREXPRESSED C-ERBB-2 PROTOONCOGENE PRODUCTS BY A CLASS-SWITCHED MURINE ANTI-C-ERBB-2 PROTEIN MONOCLONAL-ANTIBODY, T SAGA, K ENDO, T AKIYAMA, H SAKAHARA, M KOIZUMI, Y WATANABE, T NAKAI, M HOSONO, T YAMAMOTO, K TOYOSHIMA, J KONISHI, CANCER RESEARCH, CANCER RESEARCH, 51(3), 990 - 994, Feb. 1991 , Refereed
    Summary:Class-switched monoclonal antibody SV2-61r recognizes the extracellular domain of c-erbB-2 protooncogene products separate from the epidermal growth factor receptor. We studied the potential of SV2-61r for evaluating the amplification of c-erbB-1 protooncogene on cancer cells, which has been reported to have prognostic value in adenocarcinoma patients. Radiolabeled SV2-61r specifically bound to various adenocarcinoma cells in addition to c-erbB-1-transfected NIH-3T3 cells (A4) with the affinity constant of 4.4 X 10(8) M-1. SV2-61r injected i.v. localized well to A4 cells xenografted in nude mice. Tumor uptake and localization index of radioiodinated SV2-61r, probably due to the internalization and dehalogenation of formed antibody-antigen complexes. Biodistribution and specificity of targeting were assessed by comparison among three cells, A4, lung cancer SBC-3 (c=erbB-2 weakly positive) and B-lymphoblastoid Manca cells (c-erbB-2 negative). Tumor:blood ratios, obtained 48 h after injection, were 5.63, 1.45, and 0.68, respectively, indicating the potential of In-111-labeled SV2-61r for evaluating the amplification of c-erbB-2 protooncogene on cancer cells. Because of its close relationship with carcinogenesis and the uniform expression, c-erbB-2 protooncogene products seem to be the optimal target of imaging and therapy of adenocarcinoma patients.
  • Detection of human anti-mouse antibody in patients receiving 111In-antimyosin Fab: Multicenter clinical study in Japan, C. Kawai, K. Endo, A. Matsumori, T. Nishimura, M. Hosono, Kakuigaku, Kakuigaku, 28(11), 1289 - 1300, 1991 , Refereed
    Summary:In the multicenter clinical study of 111In-Antimyosin Fab (74 MBq, 0.5 mg), human anti-mouse antibody (HAMA) titers have been evaluated in serum from 456 patients using the sensitive enzyme-linked immunosorbent assay. Presence of HAMA was confirmed by the neutralization test or using the size exclusion high performance liquid chromatography (HPLC) analysis in 11 of 393 patients (2.8%). HAMA was still detectable in 2 patients even 40 weeks after injection. None of 7 patients judged as positive for the intradermal test, a patient with vascular pain or 3 patients with fever or flare and itching with fever, developed detectable levels HAMA in their serum. These results suggest that patients may develop HAMA response after infusion of 111In-Antimyosin Fab, but pathogenic role of HAMA in these patients remains to be studied.
  • AN ANTIBODY-TUMOR MODEL FOR THE TARGETING OF CA125-PRODUCING GYNECOLOGIC MALIGNANCIES, T SAGA, ISHIWATA, I, K ENDO, H SAKAHARA, M KOIZUMI, Y WATANABE, T NAKAI, M HOSONO, H ISHIKAWA, M SAWADA, J KONISHI, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 81(11), 1141 - 1148, Nov. 1990 , Refereed
  • INFLUENCE OF COCKTAILS OF LABELED MONOCLONAL-ANTIBODIES ON THE LOCALIZATION OF ANTIBODIES IN HUMAN TUMOR XENOGRAFTS, Y WATANABE, K ENDO, T SAGA, M KOIZUMI, H SAKAHARA, T NAKAI, M HOSONO, ZS YAO, M KUROKI, Y MATSUOKA, J KONISHI, JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE JOURNAL OF CANCER RESEARCH, 81(3), 266 - 271, Mar. 1990 , Refereed
  • CT MANIFESTATIONS OF A RUPTURED HEPATIC TUMOR AFTER TRANSCATHETER ARTERIAL EMBOLIZATION, Y NAGATA, S KOHNO, T SAGA, K OKAJIMA, M HOSONO, M TAMAKI, T KANATA, A TAKABAYASHI, S MATSUDA, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, COMPUTERIZED MEDICAL IMAGING AND GRAPHICS, 13(5), 419 - 422, Sep. 1989 , Refereed
  • BILIO-ENTERIC ANASTOMOSIS AS A RISK FACTOR FOR POSTEMBOLIC HEPATIC-ABSCESSES, K OKAJIMA, S KOHNO, M TAMAKI, M HOSONO, M KAWAMOTO, Y NISHIYAMA, M SUGANO, T MIYAOKA, CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 12(3), 128 - 130, May 1989 , Refereed
  • Improvement of Pentobarbital-Induced Heart Failure by MCI-154, a Novel and Potent Cardiotonic Agent, in the Dog Heart-Lung Preparation, Keisuke Satoh, Kazuo Nunoki, Toshikazu Goto, Makoto Hosono, Hiroo Hashimoto, Yoshinori Sato, Norio Taira, The Japanese Journal of Pharmacology, The Japanese Journal of Pharmacology, 47(2), 189 - 195, 1988 , Refereed
    Summary:The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10–100 μg improved the cardiac function curve and restored it to the control level at 100 μg. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective β1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure. © 1988, The Japanese Pharmacological Society. All rights reserved.
  • Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations, Makoto Hosono, Norio Taira, Journal of Cardiovascular Pharmacology, Journal of Cardiovascular Pharmacology, 10(6), 692 - 698, 1987 , Refereed
    Summary:MCI-154 is a potent nonglycoside and non-sympathomimetic cardiotonic agent with a pyridazinone structure. We assessed its cardiac and coronary vasodilator effects by use of isolated, blood-perfused papillary muscle, sinoatrial (SA) node, and atrioventricular (AV) node preparations of dogs. The drug (I-100 nmol) was injected intraarterially. MCI-154 increased the force of contraction of paced and unpaced papillary muscles but failed to affect the rate of automaticity of the latter. It increased sinus rate and shortened AV conduction time by accelerating AV nodal conduction, but in all doses examined it produced no arrhythmias. In all preparations, it increased blood flow. All the effects were long-lasting (1-2 h). MCI-154, however, was not homogeneously effective on these cardiovascular variables. The drug was nearly equieffective in producing a positive inotropic effect and coronary vasodilatation, but less effective in producing positive chronotropic and dromotropic effects. In having such a cardiovascular profile, MCI-154 most resembles milrinone among new cardiotonic agents, although unlike milrinone, its main mechanism of cardiotonic action is believed to be the sensitization of the contractile proteins to Ca2+. Whatever mechanisms are involved, the revealed cardiovascular profile of MCI-154 justifies its clinical trial in the treatment of heart failure. © 1987 Raven Press, Ltd., New York.
  • Coronary vasodilator versus cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in the dog heart, Makoto Hosono, Norio Taira, Journal of Cardiovascular Pharmacology, Journal of Cardiovascular Pharmacology, 9(6), 633 - 640, 1987 , Refereed
    Summary:We compared the coronary vasodilator and cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in isolated, blood-perfused sinoatrial (SA) node, atrioventricular (AV) node, and papillary muscle preparations of dogs. The drug was administered intraarterially. In SA node preparations MCI-176 reduced sinus rate and produced atrial standstill in large doses. In AV node preparations MCI-176 prolonged AV conduction time and produced second-or third-degree AV block in large doses only when administered into the artery supplying the AV node, but failed to affect AV conduction when administered into the artery supplying the His-Purkinje-ventricular system. In paced papillary muscle preparations MCI-176 reduced the force of contraction. In spontaneously beating papillary muscles MCI-I76 failed to change the beating rate. MCI-176 increased blood flow in all preparations. The dose that doubled blood flow was slightly larger than the dose that produced a 15% increase in AV conduction time, but about one-third the dose that produced a 15% decrease in sinus rate. The dose estimated to reduce the force of contraction by half was more than 10 times the dose that doubled blood flow. The results indicate that MCI-176 can be classified as a nonvasoselective calcium antagonist but that it differs from others. © 1987 Raven Press, New York.
  • Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs, Norio Taira, Kenzo Takahashi, Makoto Hosono, Journal of Cardiovascular Pharmacology, Journal of Cardiovascular Pharmacology, 10(3), 274 - 279, 1987 , Refereed
    Summary:The effect of DHP-218, a dihydropyridine phosphonate Ca2+ channel blocker, on atrioventricular (AV) nodal conductivity was compared with its vascular effect in dogs. In isolated, blood-perfused AV node preparations, a long-lasting increase in AV conduction time which culminated in second- or third-degree AV block at large doses occurred when DHP-218 was injected into the AV node artery, but not when injected into the artery that supplies the His-Purkinje-ventricular system. However, with DHP-218, a far longer-lasting increase in blood flow through both arteries occurred, and at smaller doses it occurred with little effect on AV conduction. In anesthetized, open-chest dogs of which heart rate was controlled at 150 beats/min, intravenous DHP-218 produced an initially rather quick and later very slowly developing and long-lasting fall in blood pressure. AV conduction time was prolonged only after the largest dose. The functional refractory period of the AV conduction system was rather shortened in all doses examined except for the largest dose. A marked increase in AV conduction time which culminated in third-degree AV block was seen in one of six dogs, only under conditions in which the heart was deprived of central neural control. These results indicate appreciable selectivity of DHP-218 for vasculature versus the AV node. © 1987 Raven Press. Ltd., New York.
  • Effective I-131 therapy for metastasis of thyroid cancer to cervical vertebrae. A case report, K. Fujiwara, K. Endo, Y. Iwasaki, M. Hosono, J. Konishi, K. Torizuka, M. Seki, Japanese Journal of Clinical Radiology, Japanese Journal of Clinical Radiology, 31(9), 1045 - 1048, 1986 , Refereed
  • Distinctive effect of angiotensin II on prostaglandin production in dog renal and femoral arteries, Hiroyuki Satoh, Makoto Hosono, Susumu Satoh, Prostaglandins, Prostaglandins, 27(6), 807 - 820, 1984 , Refereed
    Summary:The effect of angiotensin II (Ang II) on prostaglandin (PG) production in dog renal and femoral vasculature was examined in vivo and in vitro. In pentobarbital anesthetized dogs, the reduction of blood flow induced by intraarterial infusion of Ang II was potentiated by pre-treatment with indomethacin (5 mg/kg) in the renal but not the femoral vasculature. Isolated renal and femoral arterial strips were incubated and the release of PGE2 and PGI2 (as 6-keto-PGF1α) into the medium was measured by radioimmunoassay. Basal PGE2 and PGI2 production by renal and femoral arterial strips was approximately the same. PGI2 production was predominant for both strips. Ang II stimulated PG production in renal but not femoral arteries. In the renal artery, Ang II-induced PG production was inhibited by indomethacin (10-6 M), mepacrine (10-4 M) and saralasin (10-6 M). These results suggest that Ang II stimulates PG production by the renal artery per se and the Ang II receptor is linked to phospholipase A2 in the renal but not the femoral artery. © 1984.

Books etc

  • Survey report on the actual situation of exposure and reduction of exposure in radiation work in the medical field(190701-02), Hosono M, Mikami Y, Watanabe H, Takenaka M, Koba Y, Joint author, Survey and research on actual conditions of exposure and reduction of exposure in radiation work in the medical field,   2020 03 31
  • Study on the method of radiation dose survey in radiation work in the medical field, Hosono M, Kanda R, Akahane K, Torisu K, Yamamoto K, Sakamoto H, Yamada T, Sakaguchi K, Tochio M, Kato M, Kurosawa T, Joint author, Survey and research on actual conditions of exposure and reduction of exposure in radiation work in the medical field(190701-02),   2020 03 31
  • Perspectives in Nuclear Medicine Technology (Clinical), HOSONO Makoto, Contributor, What is Theranostics?, Yamashiro Printing Co. Ltd.,   2020 03 15
  • Health and labor science research grant aid research fiscal year 2016-2018 Research on medical radiation protection corresponding to new treatment method general research report, HOSONO Makoto, YAMAGUCHI Ichiro, TAKAHASHI Takeo, AKAHANE Masaaki, Joint author,   2019 03
  • Health and Labor Science Research Grants Subsidy Research 2018 "Research on medical radiation protection corresponding to new treatment methods general research report, HOSONO Makoto, YAMAGUCHI Ichiro, TAKAHASHI Takeo, AKAHANE Masaaki, Joint author,   2019 03
  • Heterogeneity of intratumoral antibody distribution, HANAOKA Kohei, HOSONO Makoto, Joint author, Springer International Publishing,   2018 04 , 9783319782379
  • Features of ibritumomab as radionuclide therapy. Resistance to ibritumomab in lymphoma, HOSONO Makoto, Joint author, Resistance to ibritumomab in lymphoma, Springer International Publishing,   2018 04 , 9783319782386
  • Gamut of FDG-PET, HOSONO Makoto, Joint author, JSNM,   2012 10
  • Safety and Efficient Use of Radiation in Medicine, HOSONO Makoto, Joint author, Comprehensive Report,   2012 03
  • Comparison of functions of CT, MRI, and PET, Joint author,   2005 10

Conference Activities & Talks

  • Present status and revision works of DRLs, HOSONO Makoto, 55th Autumn Meeting of Japan Radiological Society,   2019 10 20 , 招待有り, TOYAMA Hiroshi
  • Recent updates on radionuclide therapy -focusing on Ra-223-, HOSONO Makoto, 19th Kinki Radiology Forum,   2019 10 05 , 招待有り
  • Basics of radiation therapy, HOSONO Makoto, 84th Annual Meeting of Eastern Section of Japanese Urological Association,   2019 10 03 , 招待有り, ASANO Tomohiko
  • Outline of research on radiation protection in medicine for novel therapeutic procedures by grant of MHLW for fiscal years 2016-2018, HOSONO Makoto, TAKAHASHI Takeo, YAMAGUCH Ichiro, AKAHANE Masaaki, IKEBUCHI Hideharu, YANAGIDA Sachiko, NAKAMURA Yoshihide, 36th Meeting of Japanese Society of Hyperthermia,   2019 09 07 , TAKAHASHI Takeo
  • Trends in safe utilization of medical radiation, HOSONO Makoto, 37th Meeting of Southern Osaka Imaging Study Consortium,   2019 08 28 , 招待有り
  • Optimization of respiratory gated 18F-FDG PET/CT scan protocol for cardiac sarcoidosis, Hanaoka K, Watanabe S, Kaida H, Hosono M, Ishii K, Annual Meeting of Society of Nuclear Medicine Molecular Imaging,   2019 06 22 , Society of Nuclear Medicine Molecular Imaging
  • Comparison among 18F-FDG uptake parameters for assessing the prognosis of esophageal squamous cell carcinoma, Kaida H, Shiraishi O, Iwama M, Kimura Y, Kitajima K, Hosono M, Yasuda T, Ishii K, Annual Meeting of Society of Nuclear Medicine Molecular Imaging,   2019 06 22 , Society of Nuclear Medicine Molecular Imaging
  • Evaluation of respiratory motion-corrected PET/CT in oncological patients, Otani T, Hosono M, Nakamoto Y, Kidera K, Kitaguchi K, Watanabe M, Miyake K, Annual Meeting of Society of Nuclear Medicine Molecular Imaging,   2019 06 22 , Society of Nuclear Medicine Molecular Imaging
  • Examination of actual radiation exposure dose of the patients who performed EUS-guided dranage (EUS-BD/EUS-PD/EUS-CD), Takenaka M, Hayashi S, Nishida T, Hosono M, Yoshikawa T, Ishikawa Rei, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Kamata K, Yamao K, Kudo M, DDW 2019,   2019 05 18 , DDW 2019
  • Radiation protection standards in novel radionuclide therapy, HOSONO Makoto, The 13th Asia Oceania Congress of Nuclear Medicine and Biology,   2019 05 10 , 招待有り, Asia Oceania Federation of Nuclear Medicine and Biology
  • Guidelines in radionuclide therapy, HOSONO Makoto, 19th Spring Meeting of Japanese Society of Nuclear Medicine,   2019 04 28
  • Perspectives on radionuclide therapy, HOSONO Makoto, 19th Spring Meeting of Japanese Society of Nuclear Medicine,   2019 04 27 , 招待有り
  • ICRP perspectives for individualized radionuclide therapy, HOSONO Makoto, Theranostics World Congress 2019 (TWC2019),   2019 03 02 , 招待有り
  • Radiation protection for patients and practitioner in fluoroscopy-guided procedures, HOSONO Makoto, 9th Meeting of FIGHT-Japan,   2019 02 24 , 招待有り
  • Contribution to PET and RNT as Pharmacist, ASAMI Keita, HOSONO Makoto, Japanese Society of Hospital Pharmacists,   2019 01 20 , 招待有り
  • ICRP C3, HOSONO Makoto, Radiation Effect Association,   2018 12 26 , 招待有り
  • Management of radiation control in short-lived radionuclides including alpha emitters, HOSONO Makoto, Japanese Society of Radiation Safety Management,   2018 12 06 , 招待有り
  • Nuclear Medicine in Oncology, HOSONO Makoto, 62nd Meeting of Fukuoka RI Conference,   2018 10 27 , 招待有り, Fukuoka RI Conference
  • Domestic Situations of Nuclear Medicine Therapy and Future Prospects, HOSONO Makoto, 56th Annual Meeting of Japanese Society of Clinical Oncology,   2018 10 19 , 招待有り, Japanese Society of Clinical Oncology
  • Radionuclide Therapy, HOSONO Makoto, 31st Annual Meeting of Japanese Society of Radiation Oncology,   2018 10 11 , 招待有り, Japanese Society of Radiation Oncology
  • Interpretation and determination of images, HOSONO Makoto, 36th Safety handling course of radioimmunotherapy using Yttrium-90 labeled anti-CD20 antibody,   2018 09 29 , 招待有り
  • Significance and application of diagnostic reference levels in ICRP recommendation (Explanation of Pub.135), HOSONO Makoto, Course held by Radiation Effect Association (ICRP Seminar),   2018 09 26 , 招待有り
  • Medical use and reasonable safety management of radionuclides (including alpha emitting radionuclides), HOSONO Makoto, 平成30年度秋期放射線安全管理研修会 放射線障害防止中央協議会,   2018 09 20 , 招待有り
  • Radiological Protection for Innovative Targeted Therapy, HOSONO Makoto, Annual Meeting of Society of Nuclear Medicine and Molecular Imaging 2018,   2018 06 26 , 招待有り, Society of Nuclear Medicine and Molecular Imaging
  • Effectiveness of targeted alpha therapy, HOSONO Makoto, 14th Workshop on safety handling of Ra-223,   2018 05 26 , 招待有り
  • Guidelines in radionuclide therapy, HOSONO Makoto, !8th Spring Meeting of JSNM,   2018 05 13 , 招待有り
  • From Molecular Imaging to Molecular Radiotherapy, HOSONO Makoto, 18th Spring Meeting of JSNM,   2018 05 12 , 招待有り
  • Perspectives of radionuclide therapy, HOSONO Makoto, 18th Spring Meeting of JSNM,   2018 05 12 , 招待有り
  • Individualized treatment planning in radionuclide therapy, HOSONO Makoto, 12th Congress of the World Federation of Nuclear Medicine and Biology,   2018 04 20 , 招待有り, 12nd Congress of the World Federation of Nuclear Medicine and Biology
  • Radiation Protection in Therapy with Radiopharmaceuticals, HOSONO Makoto, International Workshop on the Biological Effects on Radiation 2018,   2018 03 21 , 招待有り
  • Development and clinical application of targeted alpha therapy, HOSONO Makoto, Seminar at ARRONAX,   2018 01 15 , 招待有り, ARRONAX, Nantes University
  • Impact of new technology on patient radiation protection in nuclear medicine-including hybrid systems, low dose PET, HOSONO Makoto, International Conference on Radiation Protection in Medicine: Achieving Change in Practice,   2017 12 13 , 招待有り, IAEA
  • Efficacy of Targeted Alpha Therapy, HOSONO Makoto,   2017 11 25 , 招待有り, Japan Radioisotope Association
  • Targeted Alpha Therapy in Japan, HOSONO Makoto, Seminar at Salgrenska Hospital, University Göteborg,   2017 11 08 , 招待有り, Salgrenska Hospital, University Göteborg
  • Current Status on Radionuclide Therapy, HOSONO Makoto, Joint FMU-ICRP Workshop on Radiological Protection in Medicine,   2017 10 03 , 招待有り, Fukushima Medical University and ICRP
  • Prognostic impact of 18F-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients, HOSONO Makoto, Kaida H, Azuma K, Kawahara A, Sadashima E, Hattori S, Akiba J, Rominger A, Takamori A, Fujimoto K, Hosono M, Ishii K, Murakami T, Ishibashi M,   2017 06 10
  • Clinical evaluation and optimization of Q.Clear; a new PET reconstruction algorithm, Otani T, Hosono M, Kanagaki M, Fukumoto G, Onishi Y, Matsubara N, Kimura H, Annual Meeting of Society of Nuclear Medicine and Molecular Imaging,   2017 06 10
  • Methods of survey and decontamination of radium-223 dichloride for radionuclide therapy in clinical facilities, Hosono M, Hohara S, Inagaki M, Sakaguchi K, Yoshida S, Yamanishi H, Wakabayashi G, Matsuda T, Ito T, 10th International Symposium on Targeted Alpha Therapy,   2017 05 30
  • α線内用療法の有効性(臨床応用に関する基礎的事項), HOSONO Makoto,   2017 05 27 , 招待有り
  • 4D-CTを用いた呼吸同期撮像法の有用性, 藤井 康司, 白髭 賢也, 竹中 達明, 細野 眞, 日本放射線技術学会総会学術大会予稿集,   2017 03
  • アルファ線核種の臨床利用における法令と指針, 細野 眞, 日本放射線技術学会総会学術大会予稿集,   2017 03
  • FDG-PET/CTで集積を認めた異所性甲状腺癌の一例, 甲斐田 勇人, 石井 一成, 細川 知紗, 仁 誠雲, 細野 眞, 村上 卓道, 花岡 宏平, 乾 浩己, 核医学,   2017 02 , (一社)日本核医学会
  • センチネルリンパ節SPECT/CTで肺野に集積を認めた1例, 小西達郎, 坂口健太, 細野眞, 核医学症例検討会症例集,   2017 02
  • 甲状腺乳頭癌術後のフォローのPET/CTにて皮膚に多発集積を認めた1例, 尾谷知亮, 細野眞, 金柿光憲, 乘本周平, 木村弘之, 核医学症例検討会症例集,   2017 02
  • 上顎洞術後変化としての眼窩下管拡大, 福井 秀行, 柏木 伸夫, 任 誠雲, 甲斐田 勇人, 柳生 行伸, 小塚 健倫, 細川 知紗, 熊野 正士, 鶴崎 正勝, 松木 充, 今岡 いずみ, 石井 一成, 細野 眞, 村上 卓道, Japanese Journal of Radiology,   2017 02
  • PET/CTにおける新しい再構成法Q.Clearの検討, 尾谷 知亮, 金柿 光憲, 乗本 周平, 木村 弘之, 細野 眞, Japanese Journal of Radiology,   2017 02
  • 前立腺小線源療法後1年以内死亡の3例, 横川 正樹, 中松 清志, 稲田 正浩, 福田 浩平, 建部 仁志, 石川 一樹, 立花 和泉, 門前 一, 金森 修一, 西村 恭昌, 細野 眞, Japanese Journal of Radiology,   2017 02
  • Survey on radionuclide therapy facilities in Japan with grants by Ministry of Health, Labour, and Welfare, Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yanagida S, Kitaoka A, Annual Congress of European Association of Nuclear Medicine,   2016 10 15
  • Estimation of administered fluorodeoxyglucose activity in patients on the basis of dose equivalent rate on head by multiple regression analysis, Hosono M, Sakaguchi K, Imamura T, Takahara N, Hayashi M, Hosokawa C, Yamada M, Ishii K, Annual Congress of European Association of Nuclear Medicine,   2016 10 15
  • Survey and decontamination of radium-223 dichloride for alpha- particle radionuclide therapy in clinical facilities, Hosono M, Hohara S, Inagaki M, Yamanishi H, Wakabayashi G, Matsuda T, Sakaguchi K, Hanaoka K, Ito T, Annual Congress of European Association of Nuclear Medicine,   2016 10 15
  • 認知症患者における線条体アミロイド沈着の検討, 細川 知紗, 石井 一成, Sauerbeck Julia, Sheiwein Franziska, 甲斐田 勇人, 兵頭 朋子, 山田 穣, 細野 眞, 花岡 宏平, 村上 卓道, 核医学,   2016 10 , (一社)日本核医学会
  • 前立腺 前立腺がん診療の新技術 骨転移のある日本人の症候性去勢抵抗性前立腺癌患者への塩化ラジウム-223の第II相試験, 永森 聡, 上村 博司, 和久本 芳彰, 植村 天受, 木村 剛, 横溝 晃, 菊川 浩明, 絹谷 清剛, 細野 眞, 山口 郁, 筒井 弘一, 松永 瑛典, 松原 伸晃, 日本癌治療学会学術集会抄録集,   2016 10
  • Pretherapeutic FDG heterogeneity in tumors can predict local control in oropharyngeal cancer patients undergoing intensity-modulated radiation therapy, Hanaoka K, Hosono M, Tatebe H, Ishikawa K, Monzen H, Ishii K, Nishimura Y, Annual Meeting of Society of Nuclear Medicine Molecular Imaging,   2016 06 11
  • Texture analysis for FMISO PET/CT in oncology patients receiving extra-beam radiation therapy, Hosono M, Tachibana I, Nishimura Y, Hanaoka K, Sakaguchi K, Ishikawa K, Nakamatsu K, Kanamori S, Annual Meeting of Society of Nuclear Medicine and Molecular Imaging,   2016 06 11
  • JSNM Education, Accreditation, and Multidisciplinary Team Practice, HOSONO Makoto, Annual Meeting of Society of Nuclear Medicine,   2016 06 11 , 招待有り
  • Dose evaluation and control for Nuclear Medicine. Joint Symposium 2: Dose evaluation and control for medical radiation exposure, HOSONO Makoto, Japan Radiology Congress,   2016 04 14 , 招待有り
  • Clinical evaluation and optimization of a new PET reconstruction algorithm Q.Clear in lung cancer, Otani T, Hosono M, Kanagaki M, Fukumoto G, Onishi Y, Matsubara N, Kimura H, ECR 2017,   2016 02 28
  • 11C-PiB PET陽性認知症の線条体集積の検討, 細川 知紗, 石井 一成, Sauerbeck Julia, Scheiwein Franziska, 甲斐田 勇人, 山田 穣, 兵頭 朋子, 細野 眞, 花岡 宏平, 村上 卓道, 核医学,   2016 02 , (一社)日本核医学会
  • ゼヴァリン療法におけるIn‐111抗体とFDGの腫瘍内不均一性解析, 花岡宏平, 細野眞, 核医学(Web),   2016
  • 認知症患者における線条体アミロイド沈着の検討, 細川知紗, 石井一成, SAUERBECK Julia, SHEIWEIN Franziska, 甲斐田勇人, 兵頭朋子, 山田穣, 細野眞, 花岡宏平, 村上卓道, 核医学(Web),   2016
  • α核種による治療の現状と将来, HOSONO Makoto, 第132回関西Cancer Therapistの会,   2015 12 02 , 招待有り
  • Tumor hypoxia detected by 18F-misonidazole (F-MISO) PET/CT as a prediction of initial tumor response of radiation therapy (RT), Tachibana I, Hosono M, Inada M, Fukuda K, Tatebe H, Ishikawa K, Yokokawa M, Nakamatsu K, Kanamori S, Nishimura Y, ASTRO 2015, 57th annual meeting,   2015 10 18
  • Occupational radiation exposure of nursing staff in PET facility in association with performance status of patients, Hosono M, Takahara N, Yakushiji Y, Sakaguchi K, Yamada Y, Hosokawa C, Ishii K, Annual Congress of European Association of Nuclear Medicine,   2015 10 10
  • Therapy planning and dose prescription in radioiodine-131 therapy for hyperthyroidism using radioiodine-123 SPECT/CT imaging, Hanaoka K, Hosono M, Otsuka M, Asai Y, Okumura M, Ishii K, Murakami T, Annual Congress of European Association of Nuclear Medicine,   2015 10 10
  • Texture analysis for tumor hypoxia visualized by FMISO PET/CT during radiation therapy, Hosono M, Tachibana I, Nishimura Y, Hanaoka K, Kanamori S, Nakamatsu K, Ishikawa K, Sakaguchi K, Annual Congress of European Association of Nuclear Medicine,   2015 10 10
  • Assessment of heart injury induced by radiation therapy for esophageal cancer using FDG-PET/CT, Hanaoka k, Hosono M, Inada M, Sakaguchi K, Shimomura K, Tamura M, Matsumoto K, Monzen H, Nishimura Y, Annual Congress of European Association of Nuclear Medicine,   2015 10 10
  • Radiation exposure of nursing staff in PET practices in correlation to performance status of patients, Hosono M, Takahara N, Yakushiji Y, Sakaguchi K, Ishii K, SNMMI 2015 Annual Meeting,   2015 06 06
  • Updates and Prospects of Alpha-emitters in Targeted Radionuclide Therapy, HOSONO Makoto, 15th International Conference of Radiation Research,   2015 05 25 , 招待有り
  • Predictive values of 111In-ibritumomab tiuxetan SPECT/CT and 18F-FDG PET/CT in radioimmunotherapy for B-cell non-Hodgkin's lymphoma, Hanaoka K, Hosono M, Ishii K, Sakaguchi K, Tatsumi Y, Nishimura Y, 15th International Conference of Radiation Research,   2015 05 25
  • Tumor hypoxia imaging with 18F-misonidazole (F-MISO) positron emission tomography (PET) during radiation therapy (RT), Tachibana I, Hosono M, Ishikawa K, Nakamatsu K, Matsuura T, Tatebe H, Inada M, Fukuda K, Kanamori S, Nishimura Y, International Conference of Radiation Research,   2015 05 25
  • Myocardial changes on FDG‐PET/CT after radiation therapy for esophageal cancer, INADA Masahiro, FUKUDA Kohei, TATEBE Hitoshi, ISHIKAWA Kazuki, TACHIBANA Izumi, YOKOKAWA Masaki, NAKAMATSU Kiyoshi, KANAMORI Shuichi, NISHIMURA Yasumasa, HOSONO Makoto, 日本医学放射線学会総会抄録集,   2015 02 28
  • Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition, Ishii K, Hosokawa C, Hyodo T, Wakabayashi Y, Yamada M, Kozuka T, Hosono M, Murakami T, Annual Congress of European Association of Nuclear Medicine,   2014 10 18
  • Texture analysis of intratumoral hypoxia on FMISO PET/CT in radiation therapy, Hosono M, Tachibana I, Nishimura Y, Hanaoka K, Kanamori S, Nakamatsu K, Ishikawa K, Annual Congress of European Association of Nuclear Medicine,   2014 10 18
  • Predictive value of heterogeneity of intratumoral In-111-Zevalin and FDG distributions for tumor response in Zevalin therapy, Hosono M, Hanaoka K, Ishii K, Sakaguchi K, Yamada M, Komeya Y, Tsuchiya N, Im SW, Tatsumi Y, Matsumura I, Annual Congress of European Association of Nuclear Medicine,   2014 10 18
  • Measurement and parameters of α-emitting radium-223 for radionuclide therapy in accordance with radiation protection standards, Hosono M, Hohara S, Yamanishi H, Inagaki M, Wakabayashi G, Matsuda T, Sakaguchi K, Hanaoka K, Itoh T, Annual Congress of European Association of Nuclear Medicine,   2014 10 18
  • Heterogeneity of intratumoral hypoxia on FMISO PET/CT in association with local control in radiation therapy, Hosono M, Tachibana I, Nishimura Y, Hanaoka K, Kanamori S, Nakamatsu K, Shibata T, Ishikawa K, Tamura M, ASTRO 2014, 56th annual meeting,   2014 09 14
  • Comparison between SUV and BP images acquired using 11C-PIB PET: Questionable PIB accumulation in SUV images, Hosokawa C, Ishii K, Kimura Y, Sakaguchi K, Hosono M, Murakami T, SNMMI 2014 Annual Meeting,   2014 06 07
  • Heterogeneity of intratumoral In-111-Zevalin and FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell lymphoma, Hosono M, Hanaoka K, Ishii K, Sakaguchi K, Im SW, Tsuchiya N, Yoshihiro K, Tatsumi Y, Matsumura I, SNMMI 2014 Annual Meeting,   2014 06 07
  • Measurement and radiation control of α-emitting radium-223 in radionuclide therapy for prostate cancer with bone metastases, Hosono M, Hohara S, Yamanishi H, Inagaki M, Wakabayashi G, Sakaguchi K, Hanaoka K, Itoh T, SNMMI 2014 Annual Meeting,   2014 06 07
  • Present status and future of radionuclide therapy, HOSONO Makoto, Applied physics meeting,   2013 12 14 , 招待有り
  • Therapy planning and dose prescription in radioiodine therapy for hyperthyroidism using SPECT/CT, Hosono M, Hanaoka K, Ishii K, Im S, Sakaguchi K, Yagyu Y, Matsukubo Y, Ohno Y, Ikegami H, Annual Congress of European Association of Nuclear Medicine,   2013 10 19
  • Association among heterogeneity of intratumoral anti-CD20 antibody distribution, glucose metabolism and therapeutic response in radioimmunotherapy for B-cell lymphoma, Hosono M, Hanaoka K, Ishii K, Im S, Sakaguchi K, Yagyu Y, Komeya Y, Tsuchiya N, Tatsumi Y, Matsumura I, Annual Congress of European Association of Nuclear Medicine,   2013 10 19
  • Application of NM imaging to radiation therapy, HOSONO Makoto, Tokai nuclear medicine meeting,   2013 09 28 , 招待有り
  • Present status and future of radionuclide therapy, HOSONO Makoto, Imaging meeting of South Osaka,   2013 08 21 , 招待有り
  • PET ans Radiation Safety, HOSONO Makoto, PET and nuclear medicine nurse seminar,   2013 06 22 , 招待有り
  • Therapy planning and dose prescription in radioiodine therapy for hyperthyroidism using SPECT/CT, Therapy planning, dose prescription in, radioiodine therapy for hyperthyroidism using, SPECT/CT, SNMMI 2013 Annual Meeting,   2013 06 08
  • Heterogeneity of CD20 antigen expression and glucose metabolism in correlation with therapeutic response in radioimmunotherapy for B-cell lymphoma, Hosono M, Hanaoka K, Ishii K, Im SW, Sakaguchi K, Yagyu Y, Komeya Y, Tsuchiya N, Tatsumi Y, Matsumura I,   2013 06 08
  • Guidelines in nuclear medicine, HOSONO Makoto, JSNM Spring Meeting,   2013 04 28 , 招待有り
  • Review on radionuclide therapy, HOSONO Makoto, JSNM Spring Meeting,   2013 04 27 , 招待有り
  • Overview of Radiation Protection in Radionuclide Therapy, HOSONO Makoto, international conference on radiation protection in medicine - setting the scene for the next decade,   2012 12
  • Radiation Protection in PET/CT, HOSONO Makoto, international conference on radiation protection in medicine - setting the scene for the next decade,   2012 12 , 招待有り
  • Three dimensional planning of radioiodine therapy for hyperthyroidism by iodine-123 SPECT/CT, Hanaoka K, Hosono M, Kurokawa T, Sakaguchi K, Yoshida S, Inoue R, Ishii K, Murakami T, Annual Congress of European Association of Nuclear Medicine,   2012 10 27
  • Prediction of tumor response by Indium-111-Zevalin SPECT/CT and FDG-PET/CT in radioimmunotherapy for B-cell non-Hodgkin lymphoma, HOSONO Makoto, Annual Congress of European Association of Nuclear Medicine,   2012 10 27
  • Radiation safety in Nuclear Medicine, HOSONO Makoto, 11th Annual General Meeting of Asian Regional Cooperative Council for Nuclear Medicine,   2012 10 24
  • 脳血管性認知症のcilostazol投与前後における脳血流変化の検討, 花田 一志, 細野 眞, 辻井 農亜, 船津 浩二, 明石 浩幸, 原田 毅, 三川 和歌子, 池田 真優子, 白川 治, 村上 卓道, 日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集,   2012 10 , 日本臨床精神神経薬理学会・日本神経精神薬理学会
  • Infrastructure for Radionuclide Therapy, HOSONO Makoto, 52nd Annual Meeting of Japanese Society of Nuclear Medicine,   2012 10 , 招待有り
  • PET and Radiation RIsk Communication, HOSONO Makoto, PET Summer Seminar 2012 in Shinshu,   2012 09 , 招待有り
  • Chronological Documents on the Fukushima Accident-Nuclear Emergency at the Fukushima Nuclear Reactor Accident in March 2011, HOSONO Makoto, Annual Meeting of Society of Nuclear Medicine,   2012 06 09 , 招待有り
  • Continuing Education for Certified Doctor "Guidelines", HOSONO Makoto, 12th Spring Congress of Japanese Society of Nuclear Medicine,   2012 04 28 , 招待有り
  • Seminar for Young Specialists "Radionuclide Therapy", HOSONO Makoto, 12th Spring Congress of Japanese Society of Nuclear Medicine,   2012 04 27 , 招待有り
  • Indium-111-Zevalin-SPECT/CT and FDG-PET/CT as quantitative evaluation in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma, Annual Congress of the European Association of Nuclear Medicine,   2011 10 15 , Annual Congress of the European Association of Nuclear Medicine
  • Measurement of functional thyroid weight using I-123 SPECT/CT as planning for radioiodine therapy, Hanaoka K, Hosono M, Shimosegawa E, Hatazawa J, EANM’11 annual congress of European Society of Nuclear Medicine,   2011 10 15
  • A prospective Clinical Trial on Tumor Hypoxia Imaging with 18F-misonidazole (F-MISO) positron Emission Tomography (PET), Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Tamura M, Koike R, Nishikawa T, Ishikawa K, Hosono M, 53rd annual meeting of ASTRO,   2011 10 02
  • Clinical impact of CT attenuation correction by SPECT/CT in brain perfusion images, Ishii K, Hanaoka K, Okada M, Kumano S, Komeya Y, Tsuchiya N, Hosono M, Murakami T, SNM 2011 Annual Meeting,   2011 06 04
  • The iliac wing sign: The feasibility for diagnosis of bone and/or soft-tissue injury of the pelvis and hips, Kakigi T, Hosono M, Shimono T, Hiraoka T, Nishimura K, ECR 2011,   2011 03 03
  • FDG and F-MISO PET-CT in the treatment planning for radiation therapy., the First International Conference on Real-time Tumor-tracking Radiation Therapy with 4D Molecular,   2011 02 , the First International Conference on Real-time Tumor-tracking Radiation Therapy with 4D Molecular
  • A Prospective Clinical Trial of Tumor Hypoxia Imaging with 18F-misonidazole (F-MISO) Positron Emission Tomography (PET), American Society for Radiation Oncology 53rd Annual Meeting,   2011 , American Society for Radiation Oncology 53rd Annual Meeting
  • Definition of target volumes by PET/CT for radiation therapy planning using moving phantom, Hanaoka K, Hosono M, Okubo M, Usami K, Okumura M, Sumita M, Nishimura Y, Murakami T, EANM'10,   2010 10 09
  • PET/CTシミュレーションにおける転移リンパ節の評価, 大久保充, 中松清志, 柴田徹, 金森修一, 西川龍之, 小池竜太, 立花和泉, 奥村雅彦, 西村恭昌, 細野眞, Japanese Journal of Radiology,   2010 07 25
  • Measurement of regional cerebral blood flow associated with cilostazol tehrapy in vascular dementia., SNM2009 Annual Meeting,   2009 06 13 , ISM 2009 Annual Meeting
  • Assessment of lymph node metastasis in esophageal cancer with SUV correction based on count recovery on 18F-FDG PET/CT., SNM2009 Annual Meeting,   2009 06 13 , SNM2009 Annual Meeting
  • Malignant Lymphoma Post Therapy:Usefulness and Pitfalls Using FDG-PET/CT Compared to CT, MRI, and Ga Sxintigraphy., 94rd Radiological Society of North America,   2008 12 , 94rd Radiological Society of North America
  • CT appearance of post OOKP procedure.,   2008 10
  • Adrenal masses: The additional value of FDG-PET/CT for cancer patients, Okada M, Hosono M, Shimono T, Kumano S, Usami K, Yamazoe Y, Komeya Y, Kagawa Y, Tsuchiya N, Murakami T, 55th annual meeting of Society of Nuclear Medicine,   2008 06 14 , 55th annual meeting of Society of Nuclear Medicine
  • Utility of partial volume correction based on count recovery on FDG PET/CT in lymph node metastasis of lung cancer, 55th annual meeting of Society of Nuclear Medicine,   2008 06 , 55th annual meeting of Society of Nuclear Medicine
  • New insight into the pathogenesis of malignant lymphoma by integrated FDG-PET/CT, 55th annual meeting of Society of Nuclear Medicine,   2008 06 , 55th annual meeting of Society of Nuclear Medicine
  • Evaluation of lymph node metastases in esophageal cancer with SUV correction for partial volume effect on FDG PET/CT, 55th annual meeting of Society of Nuclear Medicine,   2008 06 , 55th annual meeting of Society of Nuclear Medicine
  • Static and moving phantom studies for treatment planning in an integrated PET/CT system., the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology,   2007 10 , the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
  • Effect of attenuation correction on wall motion quantification in Tl-201 ECG-gated myocardial SPECT. Assessment of lymph node metastasis in lung cancer with SUV correction based on count recovery in FDG PET/CT., 54th Annual Meeting of Society of Nuclear Medicine.,   2007 06 , 54th Annual Meeting of Society of Nuclear Medicine.
  • Assessment of lymph node metastasis in lung cancer with SUV correction based on count recovery in FDG PET/CT., 54th Annual Meeting of Society of Nuclear Medicine.,   2007 06 , 54th Annual Meeting of Society of Nuclear Medicine.
  • Abdominal calcifications: Pictorial review of liver, spleen, gallbladder, kidney, peritoneum, and vascular structure lesions, Im S, Okada M, Yoh T, Tsuchiya N, Hosono M, Murakami T, 92nd Scientific Assembly and Annual Meeting RSNA,   2006 11 26
  • MR imaging, CT, and PET in patients with cancer of peritoneum and abdominal wall, Komeya Y, Okada M, Hosono M, Takeuchi R, Matsumura K, Murakami T, 92nd Scientific Assembly and Annual Meeting RSNA,   2006 11 26
  • Biliary obstruction: Value of imaging for choledocholithiasis, pancreas, and bile duct cancer, Okada M, Im S, Yagyu Y, Shimono T, Murakami T, Hosono M, 92nd Scientific Assembly and Annual Meeting RSNA,   2006 11 26
  • Hepatocellular carcinoma, cholangiocarcinoma, and liver metastasis by multimodality imaging: MSCT, US, MRI, and PET, Okada M, Yagyu Y, Murakami T, Numata K, Takeuchi R, Hosono M, 92nd Scientific Assembly and Annual Meeting RSNA,   2006 11 26
  • PET first : Malignant Lymphoma., 92nd Radiological Society of North America.,   2006 11 , 92nd Radiological Society of North America.
  • Early cancer diagnosis in healthy population, an epidemiological dilemma, Takeuchi R, Sengoku T, Okada M, Hosono M, Ohta H, Matsumura K, Annual Congress of EANM 2006,   2006 10 01
  • Comparison of adrenal cortical scintigraphy, CT and chemical-shift MRI for differential diagnosis of adrenal cortical functioning adenoma, Yoh T, Hosono M, Tsuchiya N, Komeya Y, Hanada K, Im SW, Ashikaga R, Shimono T, Yagyu Y, Hiroi K, 53rd annual meeting of Society of Nuclear Medicine,   2006 06 03
  • Difference of brain surface images between with and without attenuation correction for application to 3D-SSP technique, Hanada K, Hosono M, Hitomi Y, Yagyu Y, Komeya Y, Funatsu K, Takahashi E, Kudo T, Hitomi K, Nishimura Y, 53rd annual meeting of Society of Nuclear Medicine,   2006 06 03
  • Quantitative assessment of wall motion and thickening on TL-201 stress myocardial gated SPECT for detecting ischemia, Komeya Y, Hosono M, Yoh T, Tsuchiya N, Hanada K, Ashikaga R, Yagyu Y, Koike R, Hiroi K, Kudo K, 53rd annual meeting of Society of Nuclear Medicine,   2006 06 03
  • Quantification of left ventricular systolic and diastolic function using TL-201 gated SPECT and derivative analysis for detecting ischemia, Komeya Y, Hosono M, Yoh T, Tsuchiya N, Hanada K, Im SW, Ashikaga R, Yagyu Y, Okada M, Shimono T, 53rd annual meeting of Society of Nuclear Medicine,   2006 06 03
  • Statistical image analysis of regional cerebral blood flow in patients of mild cognitive impairment and relation of MMSE subgroups, Hanada K, Hosono M, Hitomi Y, Yagyu Y, Komeya Y, Kitahata D, Ohga Y, Kudo T, Hitomi K, Nishimura Y, 53rd annual meeting of Society of Nuclear Medicine,   2006 06 03
  • A case of granular cell carcinoma of the kidney,   2006 05
  • Management of acute reactions to contrast media in kinki univ. medical hospital,   2006 04
  • Management of acute reactions to contrast media in kinki univ. medical hospital,   2006 04
  • Management of acute reactions to contrast media in kinki univ. medical hospital,   2005 10
  • Correlation of regional cerebral blood flow and MMSE subgroups in patients of mild cognitive impairment, Hanada K, Hosono M, Hitomi Y, Yagyu Y, Kirime E, Komeya Y, Koike R, Kitahata D, Kudo T, Hitomi K, Nishimura Y, 52nd annual meeting of Society of Nuclear Medicine,   2005 06 18 , Society of Nuclear Medicine 52nd Annual Meeting
  • Wall motion and thickening measurement on Tl-201 stress myocardial gated SPECT for detecting ischemia, Komeya Y, Hosono M, Kudo T, Koike R, Hiroi K, Yagyu Y, Hanada K, Nishimura Y, 52nd annual meeting of Society of Nuclear Medicine,   2005 06 18
  • Assessment of left ventricular systolic and diastolic function using Tl-201 gated SPECT for detectiong ischemia, Komeya Y, Hosono M, Kudo T, Koike R, Hiroi K, Yagyu Y, Nin Seiun, Hanada K, Nishimura Y, 52nd annual meeting of Society of Nuclear Medicine,   2005 06 18
  • Quantification of attenuation correction in Tl-201 myocardial SPECT,   2005 04
  • Diagnostic effectiveness of Alzheiwer disease by 3D-SRT,   2004 11
  • A trial to make a normal database of 99mTc-HMPAO SPECT in Kinki University Hospital,   2004 07
  • Different regional cerebral blood flow patterns in chronic schizophrenia with and without delusion, SNM,   2004 06 , SNM
  • Wall motion quantification on Tl-201 gated SPECT for detecting ischemia, SNM,   2004 06 , SNM
  • Regional CBF change and detection of vasospasm in subarachnoid hemorrhage, SNM,   2004 06 , SNM
  • Disease severity and diagnostic performance of nuclear medicine physicians are not related in brain perfusion SPECT inpection for Alzheimer's disease,   2004 06
  • Investigation of a diagnosis of Alzheimer disease by VOI classic,   2004 06
  • Utility of 3D-SRT in a diagnosis of Alzheimer disease,   2004 04
  • Alzheimer型痴呆の診断における3D-SRTの有用性, 花田 一志, 細野 眞, 柳生 行伸, 中松 清志, 小池 竜太, 米矢 吉宏, 西村 恭昌, 切目 栄司, 辻井 農亜, 人見 一彦, 日本医学放射線学会雑誌,   2004 02 , (公社)日本医学放射線学会
  • Regional cerebral blood flow in assessment of major depression and Alzheimer's disease in early elderly., Society of Nuclear Medicine 51nd Annual Meeting,   2004 , Society of Nuclear Medicine 51nd Annual Meeting
  • Different regional cerebral blood flow patterns in chronic schizophrenia with and without delusion., Society of Nuclear Medicine 51nd Annual Meeting,   2004 , Society of Nuclear Medicine 51nd Annual Meeting
  • 幻覚妄想状態時の脳血流変化に対する検討, 花田 一志, 細野 眞, 中松 清志, 小池 竜太, 米矢 吉宏, 杉本 美和, 東 睦広, 辻井 農亜, 核医学,   2003 11 , (一社)日本核医学会
  • Three-dimensional stereotacitc surface projection of brain perfusion SPET enhances diagnosis of Alzheimer’s disease,   2003 08
  • Diagnostic performance of brain perfusion SPECT for Alzheimer's disease: comparison between visual interpretation and three-dimensional sterotactic surface display, SNM,   2003 06 , SNM
  • Evaluation of regional CBF in subarachnoid hemorrhage using 99mTc-ECD, SNM,   2003 06 , SNM
  • Isothiocyanato-dioxo-carboxymethyl-tetraazacyclotridecane as a new chelate to label antibody with technetium-99m, SNM,   2003 06 , SNM
  • 201Tl SPECT and CT fusion in thoracic malignancy, SNM,   2003 06 , SNM
  • Global cerebral blood flow changes measured by brain perfusion SPECT immediately after whole brain irradiation, ECNM,   2003 06 , ECNM
  • Cerebral blood flow measurements by Tc-99m ECD and phase contrast MR, ECNM,   2002 09 , ECNM
  • Brain perfusion SPET in Alzheimer’s disease has equivalent diagnostic power as MRI, ECNM,   2002 09 , ECNM
  • Multiple marker image histogram analyses optimized for diagnostic performance: demonstration for SPECT lung V/Q, SNM,   2002 06 , SNM
  • Detection of esophageal cancer and prediction of response to chemoradiotherapy, SNM,   2002 06 , SNM
  • Quantitative measurement of regional pulmonary blood flow in normal volunteers, SNM,   2002 06 , SNM
  • Comparison of cine phase contrast MR and 99mTc-ECD for quantification of cerebral blood flow, RSNA,   2001 11 , RSNA
  • Regional cerebral blood flow quantification SPECT in aneurysmal subarachnoid hemorrhage, RSNA,   2001 11 , RSNA
  • Accuracy of left ventricular ejection fraction determined by pFAST, PC-based software different from Germano’s method, for quantitative EKG-gated myocardial perfusion SPECT (QGS), RSNA,   2001 11 , RSNA
  • Diagnostic performance of nuclear medicine physicians interpreting brain perfusion SPECT in Alzheimer’s disease and other dementias, RSNA,   2001 11 , RSNA
  • Regional CBF quantification in aneurysmal subarachnoid hemorrhage, Hosono M, Machida K, Matsui T, Honda N, Takahashi T, Kashimada A, Shimizu Y, Osada H, Dei S, Ohmichi M, Asano T, ECNM,   2001 08 25 , ECNM
  • Value of cerebral blood flow spet in dementia compared with magnetic resonance imaging, Machida K, Honda N, Hosono M, Shimizu Y, Kosuda S, Matsuda H, Ohshima M, Momose T, Koizumi K, Matsumoto H, Hashimoto J, Congress 2001 of European Association of Nuclear Medicine,   2001 08 25
  • Detection of changes in regional CBF in subarachnoid hemorrhage using 99mTc-ECD, Hosono M, Machida K, Matsui T, Honda N, Takahashi T, Kashimada K, Shimizu Y, Osada H, Dei S, Ohmichi M, Ootawa N, Okada T, Nishimura K, Asano, T, 48th annual meeting of Society of Nuclear Medicine,   2001 06 23
  • Fractal analysis for ventilation/perfusion ratio map in differentiating lung diseases, Dei S, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Shimizu Y, Osada H, Ohmichi M, Ohtawa N, Takahashi M, Tanaka A, Thie JA, 48th annual meeting of Society of Nuclear Medicine,   2001 06 23
  • Relationship between 99mTc-GSA scintigraphy and portal circulation in patients with hepatocellular carcinoma complicated by liver cirrhosis, Osada H, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Shimizu Y, Watanabe W, Ohmichi M, 48th annual meeting of Society of Nuclear Medicine,   2001 06 23
  • Creation of quantitative regional pulmonary blood flow map by concurrent use of MR angiograpy and perfusion SPECT, Honda N, Machida K, Osada H, Hosono M, Takahashi T, Kamano T, Kashimada A, Shimizu Y, Watanabe W, Dei S, Oomichi M, Usui Y, Hondo M, Okada T, Nishimura K, Ootawa N, Tanaka A, Takahashi M, 48th annual meeting of Society of Nuclear Medicine,   2001 06 23
  • Inexpensive tool for quantification of left ventricular ejection fraction from gated-myocardial perfusion SPET, Machida K, Honda N, Hosono M, Shimizu Y, Nishimura K, Congress 2000 of European Association of Nuclear Medicine,   2000 09 02
  • Changes of blood flow measured with Tc-99m ethyl cysteinate dimer in detection of vasospasm, Hosono M, Machida K, Matsui T, Honda N, Takahashi T, Kashimada A, Shimizu Y, Dei S, Ohmichi M, Asano T, Congress 2000 of European Association of Nuclear Medicine,   2000 09 02
  • Quantification of cerebral blood flow with 99mTc ethyl cysteinate dimer for detecting vasospasm in aneurysmal subarachnoid hemorrhage, Hosono M, Machida K, Matsui T, Honda N, Takahashi T, Kashimada A, Shimizu Y, Osada H, Dei S, Toyoda H, Ohmichi M, Asano T, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Interobsever variation in differential diagnosis of dementia by cerebral blood flow SPECT, Honda N, Machida K, Matsuda H, Ohshima M, Momose T, Matsumoto T, Hosono M, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Myocardial wall thickening idex on 99mTc tetrofosmin gated SPECT for quantitative evaluation of regional wall motion, himizu Y, Machida K, Honda N, Hosono M, Takahashi T, Osada H, Toyoda H, Ohmichi M, Kato T, Maruyama Y, Tanaka S, Yoshimoto N, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • 99mTc-Pyrophosphate SPECT is more sensitive for functional recovery after acute myocardial infarction than rest/redistribution 201Tl SPECT, Shimizu Y, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Osada H, Toyoda H, Watanabe W, Dei S, Ohmichi M, Ootawa N, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Quantitative gated SPECT with 99mTc tetrofosmin is more accurate than echocardiography in determining left ventricular ejection fraction, Nishimura K, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Shimizu Y, Osada H, Toyoda H, Watanabe W, Dei S, Ohmichi M, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Detection of intrapulmonary shunting in liver cirrhosis by quantitative 99mTc MAA scintigraphy, Hosono M, Machida K, Honda N, Takahashi T, Kashimada A, Shimizu Y, Osada H, Dei S, Toyoda H, Ohmichi M, Ochiai K, Hondo M, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Quantification of regional lung perfusion using 99mTc-MAA SPECT and cine phase contrast MR angiography, Osada H, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Shimizu Y, Watanabe W, Ohmichi M, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Ventilation/perfusion ratio maps with 99mTc-technegas and 99mTc-MAA in lung diseases, Dei S, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Shimizu Y, Osada H, Toyoda H, Watanabe W, Ohmichi M, Ootawa N, 47th annual meeting of Society of Nuclear Medicine,   2000 06 03
  • Quantitative evaluation of regional wall motion by a wall thickening index of gated Tc-99m-tetrofosmin myocardial perfusion tomography, Shimizu Y, Machida K, Honda N, Hosono M, Takahashi T, Takahashi T, Kamano T, Kashimada A, Osada H, Watanabe W, Dei S, Oomichi M, 46th annual meeting of Society of Nuclear Medicine,   1999 06 06
  • Quantification of regional pulmonary arterial blood flow using Tc-99m-MAA SPECT and cine phase contrast MR angiography, Osada H, Machida K, Honda N, Takahashi T, Hosono M, Takahashi T, Kashimada A, Shimizu Y, 46th annual meeting of Society of Nuclear Medicine,   1999 06 06
  • Ventilation SPECI is superior to CT ventilation map by non-radioactive xenon inhalation, Honda N, Machida K, Hosono M, Takahashi T, Takahashi T, Kamano T, Kashimada K, Osada H, Shimizu Y, Watanabe W, Dei S, Oomichi M, 46th annual meeting of Society of Nuclear Medicine,   1999 06 06
  • mCBF quantification and SPECT for detecting vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH) using Tc-99m ethyl cysteinate dimer (ECD), Hosono M, Machida K, Honda N, Takahashi T, Takahashi T, Kashimada A, Osada H, Shimizu Y, Dei S, Toyoda T, Matsui T, Asano T, 46th annual meeting of Society of Nuclear Medicine,   1999 06 06
  • Quantitative monitoring of cerebral blood flow (CBF) in patients with aneurysmal subarachnoid hemorrhage (SAH) with Tc-99m ethyl cysteinate dimer (ECD), Hosono M, Machida K, Honda N, Takahashi T, Takahashi T, Matsui T, 84th scientific assembly and annual meeting of RSNA,   1998 11 29
  • Localization of small-cell lung cancer xenograft by two-step method with bispecific antibody and bivalent hapten, Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Faivre-Chauvet A, Machida K, Gautherot E, Barbet J, Chatal JF, Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology,   1998 08 30
  • Detection of vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH) by non-invasive cerebral blood flow quantification, Hosono M, Machida K, Honda N, Takahashi T, Takahashi T, Dei S, Shimizu Y, Kamano T, Kashimada A, Osada H, Matsui T, Asano T, Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology,   1998 08 30
  • Assessment of regional wall motion by gated myocardial perfusion tomography with 99mTc-tetrofosmin, Machida K, Honda N, Takahashi T, Hosono M, Takahashi T, Kamano T, Kashimada A, Osada H, Shimizu Y, Iwase T, Toyoda H, Ogawa K, Watanabe W, Dei S, Ohmichi M, Ohiai K, Takishima T, Joint Congress of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology,   1998 08 30
  • Diagnostic abilities of high resolution CT, dynamic CT, and Tl-201 SPECT for evaluation of pulmonary masses, Kashimada A, Machida K, Honda N, Hosono M, Takahashi T, Takahashi T, Kamano T, Shimizu Y, Osada H, Iwase S, Toyoda H, Ogawa K, Watanabe W, Ohmichi M, Dei S, Ochiai T, 45th annual meeting of Society of Nuclear Medicine,   1998 06 01
  • Utility of thallium-201 SPECT in determining site of image-guide biopsy for patients with thoracic tumor, Ogawa K, Machida K, Honda N, Takahashi T, Hosono M, Kamano T, Kashimada A, Shimizu Y, Osada H, Iwase S, Toyoda H, Watanabe W, Ohmichi M, Dei S, Ochiai T, 45th annual meeting of Society of Nuclear Medicine,   1998 06 01
  • Flow patterns of ascending aorta in aortic regurgitation analysed by velocity-encoding MR imaging, Honda N, Machida K, Takahashi T, Kamano T, Hosono M, Kashimada A, 83rd scientific assembly and annual meeting of RSNA,   1997 11 30
  • Spiral CT of stapes: spectrum of findings in normal and abnormal ears, Osada H, Machida K, Honda N, Takahashi T, Hosono M, Kamano T, 83rd scientific assembly and annual meeting of RSNA,   1997 11 30
  • Transient hypersecretion of catecholamines associated with exacerbation of symptoms after I-131 MIBG therapy in patients, Sakahara H, Saga T, Yao Z, Nakamoto Y, Sato N, Hosono M, Endo K, Konishi J, 44th annual meeting of Society of Nuclear Medicine,   1997 06 01
  • Simultaneous dual-isotope Tc-99m-tetrofosmin and Tl-201 SPECT in evaluation of primary lung cancer, Hosono M, Machida K, Honda N, Takahashi T, Kamano T, Kashimada A, 82nd scientific assembly and annual meeting of RSNA,   1996 12 01
  • Portal flow measurement with velocity-encoding MR imaging in diffuse liver diseases, Honda N, Machida K, Osada H, Takahashi T, Hosono M, Kamano T, 82nd scientific assembly and annual meeting of RSNA,   1996 12 01
  • Two-step targeting of medullary thyroid cancer by bivalent hapten and bispecific antibody in mice, Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thedrez P, Barbet J, Gautherot E, Machida K, Chatal JF, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Evaluation of three-head gamma camera SPECT images in 6 institutes, Hosono M, Machida K, Honda N, Matsumoto T, Togawa T, Yui N, Murata H, Maruno H, Hatano O, Uno K, Ohta M, Oyamada H, Kubo K, Ishii K, Nishimaki H, Horiike S, Matsunaga K, Mori Y, Iinuma T, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Targeting of small-cell lung cancer xenografts by Re-188-labeled monoclonal antibodies, Hosono MN, Hosono M, Mishra AK, Faivre-Chauvet A, Barbet J, Gautherot E, Knapp FF, Yamada R, Chatal JF, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Cinematic display of ECG-gated Tc-99m-tetrofosmin myocardial perfusion SPECT, Shimizu Y, Machida K, Honda N, Hosono M, Takahashi T, Kashimada A, Osada H, Iwase T, Toyoda H, Ogawa K, Watanabe W, Dei S, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Whole body scan by 3-head SPECT system: comparison of 3-projection Tc-99m-MDP bone scan with conventional 2-projection scan, Honda N, Machida K, Hosono M, Shimizu Y, Toyoda H, Sakurai K, Takahashi T, Kamano T, Kashimada A, Osada H, Iwase T, Watanabe W, Ogawa K, Dei S, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Evaluation of I-123 iomazenil SPECT for cerebrovascular disease:comparison with brain perfusion SPECT and brain MRI, Kashimada A, Machida K, Honda N, Hosono M, Takahashi T, Kamano T, Shimizu Y, Osada H, Iwase T, Toyoda H, Ogawa K, Watanabe W, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Preliminary study of measurement of regional pulmonary flow using MRI and Tc-99m-MAA lung perfusion scintigraphy, Osada H, Machida K, Honda N, Mamiya T, Takahashi T, Hosono M, Kamano T, Kashimada A, Shimizu Y, Iwase T, Toyoda H, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Value of Tl-201 and I-123-BMIPP dual energy cardiac SPECT in patients with chronic renal failure on hemodialysis, Toyoda H, Machida K, Honda N, Hosono M, Takahashi T, Kamano T, Shimizu Y, Osada H, Iwase T, Toyoda H, Ogawa K, Watanabe W, S Dei, Kasahara N, The 6th Asia and Oceania Congress of Nuclear Medicine and Biology,   1996 09 30
  • Radioimmunodetection of medullary thyroid cancer by bivalent hapten and bispecific antibody in mice, Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thedrez P, Barbet J, Gautherot E, Machida K, Chatal JF, Congress 1996 of European Association of Nuclear Medicine,   1996 09 14
  • Localization of small-cell lung cancer xenografts by Re-188-labeled monoclonal antibodies, Hosono MN, Hosono M, Mishra AK, Faivre-Chauvet A, Barbet J, Gautherot E, Knapp FF, Yamada R, Machida K, Chatal JF, Congress 1996 of European Association of Nuclear Medicine,   1996 09 14
  • BMIPP and MIBG SPET finding in myotonic dystrophy, Honda N, Machida K, Hosono M, Mamiya T, Takahashi T, Kamano T, Kashimada A, Osaka H, Shimizu Y, Iwase T, Yoyoda H, Kinoshita S, Congress 1996 of European Association of Nuclear Medicine,   1996 09 14
  • Preliminary study of measurement of focal pulmonary flow using MRI and 99mTc-MAA lung perfusion scintigraphy, Osada H, Machida K, Honda N, Mamiya T, Takahashi T, Hosono M, Kamano T, Kashimada A, Shimizu Y, Iwase T, Toyoda H, 43rd annual meeting of Society of Nuclear Medicine,   1996 06 03
  • Targeting of small-cell lung cancer by octreotide labeled with I-125, In-111, and Re-188 in a mouse model, Hosono M, Hosono MN, Haberberger T, Zamora PO, Guhlke S, Bender H, Knapp FF Jr, Biersack HJ, Congress 1995 of European Association of Nuclear Medicine,   1995 08 26
  • Imaging of small-cell lung cancer xenografts with I-125, In-111 and Re-188 octreotides, Hosono M, Hosono MN, Haberberger T, Zamora PO, Guhlke S, Bender H, Knapp FF Jr, Biersack HJ, 42nd annual meeting of Society of Nuclear Medicine,   1995 06 12
  • Immunoscintigraphy of ovarian cancer using a monoclonal antibody to CA125, akahara H, Hosono M, Kobayashi H, Yao Z, Saga T, Yano S, Endo K, Mori T, Konishi J, 42nd annual meeting of Society of Nuclear Medicine,   1995 06 12
  • Scintigraphic detection of colorectal carcinoma xenografts with Re-188 labeled monoclonal antibody, Hosono M, Hosono MN, Bender H, Zamora PO, Guhlke S, Knapp FF Jr, Biersack HJ, 6th World Congress of the World Federation Nuclear Medicine and Biology,   1994 10 23
  • Improved biodistribution of radiolabeled biotinylated monoclonal antibody followed by the injection of avidin as a "chase", Kobayashi H, Sakahara H, Hosono M, Yao Z-S, Yamamuro T, Toyama S, Endo K, Konishi J, 6th World Congress of the World Federation Nuclear Medicine and Biology,   1994 10 23
  • Localization of infiltration of human leukemia cells in SCID mice, osono M, Kondo A, Yao Z, Kobayashi H, Hosono MN, Sakahara H, Imada K, Okuma M, Uchiyama T, Konishi J, ongress 1994 of European Association of Nuclear Medicine,   1994 08 20
  • Radioimmunotargeting with Re-188 labeled monoclonal antibody in mice bearing colorectal carcinoma xenografts, Hosono MN, Hosono M, Zamora PO, Guhlke S, Bender H, Biersack HJ, Onoyama Y, Ochi H, Konishi J, Congress 1994 of European Association of Nuclear Medicine, Düsseldorf,   1994 08 20
  • Detection of proliferation sites of ATL cells in SCID mice, Hosono M, Kondo A, Yao Z, Kobayashi H, Hosono MN, Sakahara H, Imada K, Okuma M, Uchiyama T, Konishi J, 41st annual meeting of Society of Nuclear Medicine,   1994 06 05
  • Ra-223投与患者の呼気に排泄されるRn-219放射能量の定量, 大江 一弘, 渡部 直史, 神谷 貴史, 吉村 崇, 細野 眞, 篠原 厚, 畑澤 順, 核医学,   2019 10 , (一社)日本核医学会
  • Clinical evaluation and optimization of Q.Clear; a new PET reconstruction algorithm, Tomoaki Otani, Makoto Hosono, Mitsunori Kanagaki, JOURNAL OF NUCLEAR MEDICINE,   2017 05 , SOC NUCLEAR MEDICINE INC
  • Prognostic impact of F-18-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients., Hayato Kaida, Koichi Azuma, Akihiko Kawahara, Eiji Sadashima, Satoshi Hattori, Jun Akiba, Axel Rominger, Shinzo Takamori, Kiminori Fujimoto, Makoto Hosono, Kazunari Ishii, Takamichi Murakami, Masatoshi Ishibashi, JOURNAL OF NUCLEAR MEDICINE,   2017 05 , SOC NUCLEAR MEDICINE INC

Misc

  • Texture analysis for tumor hypoxia visualized by FMISO PET/CT during radiation therapy, M. Hosono, I. Tachibana, Y. NIshimura, K. Hanaoka, S. Kanamori, K. Nakamatsu, K. Ishikawa, K. Sakaguchi, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42, S712, S712,   2015 10
  • Tumor Hypoxia Detected by 18F-misonidazole (F-MISO) PET/CT as a Prediction of Initial Tumor Response of Radiation Therapy (RT), I. Tachibana, M. Hosono, M. Inada, K. Fukuda, H. Tatebe, K. Ishikawa, M. Yokokawa, K. Nakamatsu, S. Kanamori, Y. Nishimura, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, S105, S105,   2015 11 , Refereed
  • Assessment of heart injury induced by radiation therapy for esophageal cancer using FDG-PET/CT, K. Hanaoka, M. Hosono, M. Inada, K. Sakaguchi, K. Shimomura, M. Tamura, K. Matsumoto, H. Monzen, Y. Nishimura, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42, S408, S408,   2015 10
  • Measurement and parameters of alpha-emitting radium-223 for radionuclide therapy in accordance with radiation protection standards, M. Hosono, S. Hohara, H. Yamanishi, M. Inagaki, G. Wakabayashi, T. Matsuda, K. Sakaguchi, K. Hanaoka, T. Itoh, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S329, S329,   2014 10
  • Predictive value of heterogeneity of intratumoral In-111-Zevalin and FDG distributions for tumor response in Zevalin therapy, M. Hosono, K. Hanaoka, K. Ishii, K. Sakaguchi, M. Yamada, Y. Komeya, N. Tsuchiya, S. Im, Y. Tatsumi, I. Matsumura, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S174, S174,   2014 10
  • Texture Analysis of Intratumoral Hypoxia on FMISO PET/CT in Radiation Therapy, M. Hosono, I. Tachibana, Y. Nishimura, K. Hanaoka, S. Kanamori, K. Nakamatsu, K. Ishikawa, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S248, S248,   2014 10
  • Heterogeneity of Intratumoral Hypoxia on FMISO PET/CT in Association With Local Control in Radiation Therapy, M. Hosono, I. Tachibana, Y. Nishimura, K. Hanaoka, S. Kanamori, K. Nakamatsu, T. Shibata, K. Ishikawa, M. Tamura, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S792, S792,   2014 09
  • Comparison between SUV and BP images acquired using 11C-PIB PET: Questionable PIB accumulation in SUV images, Chisa Hosokawa, Kazunari Ishii, Yuichi Kimura, Kenta Sakaguchi, Makoto Hosono, Takamichi Murakami, JOURNAL OF NUCLEAR MEDICINE, 55,   2014 05
  • Measurement and radiation control of alpha-emitting radium-223 in radionuclide therapy for prostate cancer with bone metastases, Makoto Hosono, Sin-ya Hohara, Hirokuni Yamanishi, Masayo Inagaki, Genichiro Wakabayashi, Kenta Sakaguchi, Kohei Hanaoka, Tetsuo Itoh, JOURNAL OF NUCLEAR MEDICINE, 55,   2014 05
  • Therapy planning and dose prescription in radioiodine therapy for hyperthyroidism using SPECT/CT, M. Hosono, K. Hanaoka, K. Ishii, S. Im, K. Sakaguchi, Y. Yagyu, Y. Matsukubo, Y. Ohno, H. Ikegami, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 40, S231, S232,   2013 10
  • Prediction of tumor response by Indium-111-Zevalin SPECT/CT and FDG-PET/CT in radioimmunotherapy for B-cell non-Hodgkin lymphoma, M. Hosono, K. Hanaoka, K. Ishii, K. Sakaguchi, S. Im, N. Tsuchiya, Y. Komeya, Y. Yagyu, Y. Tatsumi, I. Matsumura, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 39, S372, S372,   2012 10
  • Indium-111-Zevalin-SPECT/CT and FDG-PET/CT as quantitative evaluation in radioimmunotherapy for B-cell non-Hodgkin's lymphoma, K. Hanaoka, M. Hosono, Y. Yamazoe, Y. Tatsumi, Y. Komeya, N. Tsuchiya, K. Ishii, K. Usami, T. Murakami, T. Uto, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S426, S426,   2011 10
  • A Prospective Clinical Trial on Tumor Hypoxia Imaging with 18F-misonidazole (F-MISO) Positron Emission Tomography (PET), I. Tachibana, Y. Nishimura, T. Shibata, S. Kanamori, K. Nakamatsu, M. Tamura, R. Koike, T. Nishikawa, K. Ishikawa, M. Hosono, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2, S731, S732,   2011
  • Static and moving phantom studies for treatment planning in an integrated PET/CT system, Y. Nishimura, M. Okubo, K. Nakamatsu, M. Okumura, T. Shibata, S. Kanamori, R. Koike, K. Hiroi, T. Nishikawa, M. Hosono, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69, 3, S694, S695,   2007
  • Assessment of early therapeutic effects on VX2 rabbit carcinoma using FDG-microPET, K Ishii, M Hosono, Y Wada, S Kondo, Y Takada, T Tada, T Okamura, M Maeda, Y Watanabe, Y Inoue, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63, 2, S483, S484,   2005
  • Diagnostic performance of brain perfusion SPECT for Alzheimer's disease: Comparison between visual interpretation and three-dimensional stereotactic surface display., N Honda, K Machida, T Matsumoto, H Matsuda, E Imabayashi, M Hosono, JOURNAL OF NUCLEAR MEDICINE, 44, 5, 12P, 12P,   2003 05
  • Evaluation of regional CBF in subarachnoid hemorrhage using Tc-99m-ECD., M Hosono, K Machida, T Matsui, N Honda, T Takahashi, A Kashimada, O Murata, H Osada, N Ohtawa, T Asano, JOURNAL OF NUCLEAR MEDICINE, 44, 5, 232P, 232P,   2003 05
  • Tl-201 SPECT and CT fusion in thoracic malignancy., N Honda, K Machida, M Hosono, A Kashimada, T Takahashi, H Osada, W Watanabe, O Murata, T Okada, JOURNAL OF NUCLEAR MEDICINE, 44, 5, 376P, 376P,   2003 05
  • Isothiocyanato-dioxo-carboxymethyl-tet-raazacyclotridecane as a new chelate to label antibody with technetium-99m., AK Mishra, M Hosono, K Chuttani, P Mishra, RK Sharma, JF Chatal, JOURNAL OF NUCLEAR MEDICINE, 44, 5, 301P, 301P,   2003 05
  • Quantitative measurement of regional pulmonary blood flow in normal volunteers., Y Usui, K Machida, N Honda, M Hosono, H Osada, T Takahashi, A Kashimada, W Watanabe, O Murata, M Omichi, T Okada, M Takahashi, JOURNAL OF NUCLEAR MEDICINE, 43, 5, 348P, 349P,   2002 05
  • Multiple marker image histogram analyses optimized for diagnostic performance: Demonstration for SPECT lung V/Q., JA Thie, K Machida, N Honda, M Hosono, S Dei, M Takahashi, JOURNAL OF NUCLEAR MEDICINE, 43, 5, 145P, 145P,   2002 05
  • Detection of esophageal cancer and prediction of response to chemoradiotherapy using (201)T1 SPECT., M Omichi, K Machida, N Honda, M Hosono, T Takahashi, A Kashimada, H Osada, K Ochiai, N Ohtawa, M Hondo, N Usui, T Okada, K Nishimura, H Ohno, JOURNAL OF NUCLEAR MEDICINE, 43, 5, 297P, 298P,   2002 05
  • Evaluation of QOL in cancer patients during radiation therapy, T Takahashi, K Machida, N Honda, M Hosono, A Kashimada, O Murata, H Osada, M Omichi, M Hondo, INTERNATIONAL JOURNAL OF CANCER, 486, 487,   2002
  • Comparison of cine phase contrast MR and 99mTc-ECD for quantification of cerebral blood flow, M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, H Osada, RADIOLOGY, 221, 480, 480,   2001 11
  • Regional cerebral blood flow quantification SPECT in aneurysmal subarachnoid hemorrhage, M Hosono, K Machida, T Matsui, N Honda, T Takahashi, T Asano, RADIOLOGY, 221, 237, 237,   2001 11
  • Accuracy of left ventricular ejection fraction determined by p-FAST, PC-based software different from Germano's method, for quantitative EKG-gated myocardial perfusion SPECT (QGS), K Nishimura, K Machida, N Honda, M Hosono, A Kashimada, T Takahashi, RADIOLOGY, 221, 129, 129,   2001 11
  • Diagnostic performance of nuclear medicine physicians interpreting brain perfusion SPECT in Alzheimer's disease and other dementias, N Honda, K Machida, T Matsumoto, H Matsuda, M Hosono, M Oshima, RADIOLOGY, 221, 238, 238,   2001 11
  • Value of cerebral blood flow SPET in dementia compared with magnetic resonance imaging, K Machida, N Honda, M Hosono, Y Shimizu, S Kosuda, H Matsuda, M Ohshima, T Momose, K Koizumi, T Matsumoto, J Hashimoto, EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 28, 8, 1019, 1019,   2001 08
  • Regional CBF quantification in aneurysmal subarachnoid hemorrhage, M Hosono, K Machida, T Matsui, N Honda, T Takahashi, A Kashimada, H Osada, Y Shimizu, M Ohmichi, S Dei, T Asano, EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 28, 8, 1222, 1222,   2001 08
  • Creation of quantitative regional pulmonary blood flow map by concurrent use of MR angiography and perfusion SPECT., N Honda, K Machida, H Osada, M Hosono, T Takahashi, A Kashimada, Y Shimizu, W Watanabe, M O'Michi, S Dei, Y Usui, M Hondo, T Okada, K Nishimura, N Otawa, A Tanaka, M Takahashi, JOURNAL OF NUCLEAR MEDICINE, 42, 5, 346P, 346P,   2001 05
  • Detection of changes in regional CBF in subarachnoid hemorrhage using Tc-99m-ECD., M Hosono, K Machida, T Matsui, N Honda, T Takahashi, K Kashimada, Y Shimizu, H Osada, S Dei, M Ohmichi, N Ootawa, T Okada, K Nishimura, T Asano, JOURNAL OF NUCLEAR MEDICINE, 42, 5, 232P, 232P,   2001 05
  • Relationship between Tc-99m-GSA scintigraphy and portal circulation in patients with hepatocellular carcinoma complicated by liver cirrhosis., H Osada, K Machida, N Honda, M Hosono, T Takahashi, A Kashimada, Y Shimizu, W Watanabe, H Oomichi, JOURNAL OF NUCLEAR MEDICINE, 42, 5, 329P, 329P,   2001 05
  • Fractal analysis for ventilation/perfusion ratio map in differentiating lung diseases., S Dei, K Machida, N Honda, M Hosono, T Takahashi, K Kashimada, Y Shimizu, H Osada, N Ohtawa, M Ohmichi, M Takahashi, A Tanaka, JA Thie, JOURNAL OF NUCLEAR MEDICINE, 42, 5, 191P, 191P,   2001 05
  • Detection of intrapulmonary shunting in liver cirrhosis by quatitative Tc-99m MAA scintigraphy., M Hosono, K Machida, N Honda, T Takahashi, A Kashimada, Y Shimizu, H Osada, S Dei, H Toyoda, M Ohmichi, K Ochiai, M Hondo, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 320P, 320P,   2000 05
  • Myocardial wall thickening index on Tc-99m tetrofosmin gated SPECT for quantitative evaluation of regional wall motion., Y Shimizu, K Machida, N Honda, M Hosono, T Takahashi, H Osada, H Toyoda, M Ohmichi, T Kato, K Maruyama, S Tanaka, N Yoshimoto, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 162P, 162P,   2000 05
  • Tc-99m-pyrophosphate SPECT is more sensitive for functional recovery after Acute Myocardial Infarction than rest/redistribution (201)T1 SPECT., Y Shimizu, K Machida, N Honda, M Hosono, T Takahashi, A Kashimada, H Osada, H Toyoda, W Watanabe, S Dei, M Ohmichi, N Ootawa, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 164P, 164P,   2000 05
  • Interobserver variation in differential diagnosis of dementia by cerebral blood flow SPECT., N Honda, K Machida, H Matsuda, M Ohshima, T Momose, T Matsumoto, M Hosono, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 107P, 107P,   2000 05
  • Ventilation/perfusion ratio maps with Tc-99m-Technegas and Tc-99m-MAA in lung disease., S Dei, K Machida, N Honda, M Hosono, T Takahashi, A Kashimada, Y Shimizu, H Osada, H Toyoda, W Watanabe, M Ohmichi, N Ootawa, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 324P, 324P,   2000 05
  • Quantification of regional lung perfusion using Tc-99m-MAA SPECT and cine phase contrast MR angiography., H Osada, K Machida, N Honda, M Hosono, T Takahashi, A Kashimada, Y Shimizu, W Watanabe, M Oumichi, JOURNAL OF NUCLEAR MEDICINE, 41, 5, 323P, 323P,   2000 05
  • Tumor perfusion studies using fast magnetic resonance imaging in head and neck cancer treated with radiotherapy, T Takahashi, K Machida, N Honda, T Takahashi, M Hosono, A Kashimada, Y Shimizu, H Osada, W Watanabe, M Omichi, EUROPEAN JOURNAL OF CANCER, 35, S175, S175,   1999 09
  • MCBF quantification and spect for detecting vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH) using Tc-99m ethyl cysteinate dimer (ECD)., M Hosono, K Machida, N Honda, T Takahashi, T Takahashi, A Kashimada, H Osada, Y Shimizu, S Dei, H Toyoda, T Matsui, T Asano, JOURNAL OF NUCLEAR MEDICINE, 40, 5, 268P, 268P,   1999 05
  • Ventilation SPECT is superior to CT ventilation map by non-radioactive xenon inhalation., N Honda, K Machida, M Hosono, T Takahashi, T Takahashi, T Kamano, A Kashimada, H Osada, Y Shimizu, N Watanabe, S Dei, M Oomichi, JOURNAL OF NUCLEAR MEDICINE, 40, 5, 197P, 197P,   1999 05
  • Quantification of regional pulmonary arterial blood flow using Tc-99m-MAA spect and cine phase contrast MR angiography., H Osada, K Machida, N Honda, T Takahashi, M Hosono, T Takahashi, A Kashimada, Y Shimizu, JOURNAL OF NUCLEAR MEDICINE, 40, 5, 195P, 196P,   1999 05
  • Quantitative evaluation of regional wall motion by a wall thickening index of gated Tc-99m-tetrofosmin myocardial perfusion tomography., Y Shimizu, K Machida, N Honda, M Hosono, T Takahashi, T Kamano, A Kashimada, H Osada, W Watanabe, S Dei, M Oomichi, JOURNAL OF NUCLEAR MEDICINE, 40, 5, 177P, 177P,   1999 05
  • Quantitative monitoring of cerebral blood flow (CBF) in patients with aneurysmal subarachnoid hemorrhage (SAH) with Tc-99m ethyl cysteinate dimer (ECD), M Hosono, K Machida, N Honda, T Takahashi, T Takahashi, T Matsui, RADIOLOGY, 209P, 250, 250,   1998 11
  • Utility of thallium-201SPECT in determining site of image-guided biopsy for patients with thoracic tumor., K Ogawa, K Machida, N Honda, T Takahashi, T Takahashi, M Hosono, T Kamano, A Kashimada, Y Shimizu, H Osada, S Iwase, H Toyoda, W Watanabe, M Ohmichi, S Dei, T Ochiai, JOURNAL OF NUCLEAR MEDICINE, 39, 5, 193P, 193P,   1998 05
  • Diagnostic abilities of high resolution CT, dynamic CT, and TL-201 SPECT for evaluation of pulmonary masses., A Kashimada, K Machida, N Honda, M Hosono, T Takahashi, T Takahashi, T Kamano, Y Shimizu, H Osada, S Iwase, H Toyoda, K Ogawa, W Watanabe, M Ohmichi, S Dei, T Ochiai, JOURNAL OF NUCLEAR MEDICINE, 39, 5, 45P, 45P,   1998 05
  • Flow patterns of ascending aorta in aortic regurgitation analyzed by velocity-encoding MR imaging, N Honda, K Machida, T Takahashi, T Kamano, M Hosono, A Kashimada, RADIOLOGY, 205, 1014, 1014,   1997 11
  • Transient hypersecretion of catecholamines associated with exacerbation of symptoms after I-131 MIBG therapy in patients with pheochromocytoma., H Sakahara, T Saga, Z Yao, Y Nakamoto, N Sato, M Hosono, K Endo, J Konishi, JOURNAL OF NUCLEAR MEDICINE, 38, 5, 1108, 1108,   1997 05
  • Simultaneous dual-isotope Tc-99m tetrofosmin and Tl-201 SPECT in evaluation of primary lung cancer, M Hosono, K Machida, N Honda, T Takahashi, T Kamano, A Kashimada, RADIOLOGY, 201, 1658, 1658,   1996 11
  • Portal flow measurement with velocity-encoding MR imaging in diffuse liver diseases, N Honda, K Machida, H Osada, T Takahashi, M Hosono, T Kamano, RADIOLOGY, 201, 70, 70,   1996 11
  • Preliminary study of measurement of focal pulmonary flow using MRI and Tc-99m-MAA lung perfusion scintigraphy, H Osada, K Machida, N Honda, T Mamiya, T Takahashi, M Hosono, T Kamano, A Kashimada, Y Shimizu, T Iwase, H Toyoda, JOURNAL OF NUCLEAR MEDICINE, 37, 5, 1414, 1414,   1996 05
  • TUMORAL CALCINOSIS-LIKE METASTATIC CALCIFICATION IN A PATIENT WITH RENAL OSTEODYSTROPHY - CT AND SCINTIGRAPHIC APPEARANCES, H KOBAYASHI, M HOSONO, R FUJIMOTO, J KONISHI, CLINICAL NUCLEAR MEDICINE, 20, 12, 1112, 1114,   1995 12
  • INCIDENTAL DETECTION OF PAPILLARY CARCINOMA OF THE THYROID BY TC-99M-(V)-DMSA TUMOR SCINTIGRAPHY, H KOBAYASHI, Y KOTOURA, T TSUBOYAMA, M HOSONO, H SAKAHARA, J KONISHI, CLINICAL NUCLEAR MEDICINE, 20, 7, 638, 638,   1995 07
  • A CASE OF MELORHEOSTOSIS WITH A 14-YEAR FOLLOW-UP, H KOBAYASHI, Y KOTOURA, M HOSONO, T TSUBOYAMA, C SHIGENO, EUROPEAN RADIOLOGY, 5, 6, 651, 653,   1995
    Summary:Melorheostosis is a benign sclerosing dysplasia with a very unusual and characteristic roentgenographic appearance. We reported a patient with melorheostosis in the left lower extremity followed up for 14 years. Although the extraosseous lesions only slightly enlarged, the bone scintigraphy showed the activity of the metabolism to be still high.
  • DETECTION OF PROLIFERATION SITES OF ATL CELLS IN SCID MICE, M HOSONO, A KONDO, Z YAO, H KOBAYASHI, MN HOSONO, H SAKAHARA, K IMADA, M OKUMA, T UCHIYAMA, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, 35, 5, P56, P56,   1994 05
  • BIODISTRIBUTION OF IN-111 OXIDE LABELED PLATELET IN DOG INJECTED WITH ANTI-THROMBOCYTIC MONOCLONAL-ANTIBODY, M HOSONO, N SONE, H SAKAHARA, H KOBAYASHI, M SHIRATO, K ENDO, K YASUNAGA, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, 34, 5, P119, P119,   1993 05
  • CHEMICAL MODIFICATION OF AN ANTIBODY TO AFFORD DISCRIMINATED RELEASE OF HIPPURATE-LIKE CHELATE IN NONTARGET FOR TARGET-SELECTIVE RADIOACTIVITY DELIVERY, Y ARANO, T INOUE, T MUKAI, M HOSONO, H SAKAHARA, J KONISHI, A YOKOYAMA, JOURNAL OF NUCLEAR MEDICINE, 34, 5, P29, P29,   1993 05
  • EFFECT OF HYPERTHERMIA ON UPTAKE OF MONOCLONAL-ANTIBODY IN SMALL-CELL LUNG-CANCER XENOGRAFTS, MN HOSONO, M HOSONO, H KOBAYASHI, M SHIRATO, H SAKAHARA, T NAKAJIMA, K ENDO, R UEDA, J KONISHI, Y ONOYAMA, JOURNAL OF NUCLEAR MEDICINE, 34, 5, P215, P215,   1993 05
  • RADIOTHERAPY IN MICE WITH I-131-LABELED ANTI-SMALL CELL LUNG-CANCER MONOCLONAL-ANTIBODY, M HOSONO, MN HOSONO, H KOBAYASHI, M SHIRATO, H SAKAHARA, K ENDO, R UEDA, J KONISHI, JOURNAL OF NUCLEAR MEDICINE, 34, 5, P215, P215,   1993 05
  • STAGING OF BILE-DUCT CANCER - COMPARATIVE-STUDY OF US, CT, AND MR IMAGING, K ITOH, M HOSONO, Y NAKANO, J KONISHI, RADIOLOGY, 185, 257, 257,   1992 11

Awards & Honors

  •   2020 08 , Kindai University Faculty of Medicine, Best Teacher Award (FY2019), Medical Education
  •   2020 04 , Kindai University Faculty of Medicine, Best Teacher Award (FY2018), Medical Education
  •   2019 11 , ICRP, Award to authors: ICRP Publication 140, Radiological protection in therapy with radiopharmaceuticals
  •   2009 10 , Japanese Society of Nuclear Medicine, 48th Japanese Society of Nuclear Medicine Award
  •   2008 12 , RSNA, Certificate of Merit, Malignant lymphoma post therapy: usefulness and pitfalls using FDG-PET/CT compared to CT, MRI, and Ga scintigraphy
  •   2007 11 , RSNA, Certificate of Merit, Wide spectrum of malignant lymphoma: new insight into the pathogenesis of lymphoid malignancies in PET-CT and MRI
  •   2006 12 , RSNA, Certificate of Merit, MR imaging, CT, and PET in patients with cancer of peritoneum and abdominal wall
  •   1997 10 , Atomic Energy Research Foundation in Medicine, Award, Atomic Energy Research Foundation in Medicine

Research Grants & Projects

  • Ministry of Health, Labour and Welfare, Workers' illnessclinical research project, Survey and research on the actual conditions of radiation exposure and reduction in radiation work in medicine
  • Ministry of Health, Labour and Welfare, Health and Labour Sciences Research Grants, Research on standards for radiation protection in conventional and innovative radiological practices
  • Ministry of Education, Culture, Sports, Science and Technology, Grant-in-Aid for Scientific Research (C), Dosimetry and personalized therapy in radionuclide therapy using novel nuclides
  • Nuclear Regulatory Agency, Project for promotion of radiation safety regulations, Research on reasonable radiation management for short-lived alpha emitters
  • Ministry of Health, Labour and Welfare, Ministry of Health, Labour and Welfare: Health and Labour Sciences Research Grants, Research on radiation protection for novel therapeutic procedures
  • Ministry of Education,Culuture,Sports,Science and Technology, Grant-in-Aid for Scientific Research, Treatment of metastatic bone diseases by alpha-emitter Ra-223
  • Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), Imaging of proliferative ability and hypoxia of tumor in radioimmunotherapy, In patients with CD20 positive B-cell non-Hodgkin lymphoma who underwent yttrium-90 labeled anti-CD20 ibritumomab tiuxetan therapy, glucose metabolism by FDG and hypoxia by FMISO were evaluated with PET/CT before and after therapy, and changes were analyzed over time. Antigen expression of CD20 was also evaluated by SPECT/CT using indium-111 labeled anti-CD20 antibody. Association of glucose metabolism, hypoxia, and CD20 expression with therapeutic response was analyzed.
  • Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), Optimization of radioimmunotherapy with radiolabeled anti-HER2 antibody, Molecular targeting concept and technology have recently been established and applied to disease entities, and have proved efficient and indispensable in some pathological status. As one of molecular targeting applications, radioimmunoscintigraphy and radioimmunotherapy which use radiolabeled monoclonal antibodies recognizing malignancy have successfully been undertaken in laboratory studies and clinical applications. The purpose of this study was to develop tumor imaging and therapy using molecular targeting techniques. To conduct radioimmunotherapy with radiolabeled anti-HER2 antibody in patients, we investigated conditions of radiolabeling techniques of potentially therapeutic radionuclides and tumor-directed antibodies. Chelating agents having macrocycle structures are suitable for radioimmunotherapy because of conjugation stability. Parameters of radiolabeling for chelates have been determined and optimized in animal models with human cancers. Distributions of malignant cells were studied in animal models using radiolabeling of cancer cells. A liver metastasis model was constructed by injecting radiolabeled cancer cells into the portal vein or spleen. Biodistribution of cancer cells was determined by tracer studies using radiolabeled antibodies. The obtained data were used for analyzing parameters in forthcoming radioimmunotherapy. Basic safety standards in radiological protection were considered for prospects of radionuclide therapy in clinical facilities. In conclusion, our study demonstrates significant findings of basic investigation as molecular imaging and therapy are increasingly applied to clinical practices.
  • Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), Radio immunotherapy of malignant tumors by pretargeting, The "affinity enhancement system", a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for the targeting of carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody.Antineural cell adhesion molecule/antihistamine bispecific anti-body NKI NBLIJ79 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NC1-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later 1251-labeled bivalent histamine hapten. 1251-labeled in tact NKINBLI was injected into other groups of mice. Biodisributions were examined as a function of time.In mice of the two-step targeting, tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 ± 1.1, 10.8 ± 13.2 and 4.6 ± 4.7, respectively, at 5 h, whereas 1251-labeled NK1NBL1 showed tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 ± 0.1, 1.1 ± 0.2 and 0.9 ± 0.1, respectively, at 5 h. Dosimetry showed that tumor-to-liver and -to-bone marrow ratios of absorbed irradiation doses were 14.3 and 16.8 for the two-step method and 4.2 and 2.6 for the one-step method. This suggested that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1.This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer by giving enhanced tumor-to-normal tissue contrast.
  • Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), Clinical efficacy of brain blood flow SPECT in the diagnosis of pochiatric disorders in the aged, Brain perfusion SPECT (BP-SPECT) has characteristic patterns of abnormality enabling differential diagnosis of dementia. The purpose was to measure inter-obserYer variations in diagnosis of dementia using BP-SPECT. BP-SPECT images of 57 cases, 19 of Alzheimer s Disease (AD) eight of multi-infarct dementia (MID), three of Pick's disease, five of other dementias and 22 normal controls, were interpreted by ten nuclear medicine physicians of variable experience before and after the addition of MRl. The physicians independently rated diagnoses that were listed beforehand according to a 5-point s...
  • Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research(基盤研究(C)), EVALUATION OF ACCURACY OF SPECT IN THE DIAGNOSIS OF BRAIN TUMOR, Fifteen-four studies of ^<20l>T1 brain tumor SPECT were independently interpreted by 9 nuclear medicine physicians with and without reference magnetic resonance images in 2 separate sessions to define an effect of referring images, and inter-observer variations. The physicians were requested to detect foci of abnormal deposits, and to discriminate whether they were malignant or not according to 5-grade scaling of subjective diagnostic confidence. Receiver-operating characteristics (ROC) analysis was performed. Mean sensitivity for presence of lesions (SFP), and sensitivity and specifcity fo...
  • Grant-in-Aid for Scientific Research, Radioimmunotherapy